Excluded: Patients whose use of alcohol or drugs is sufficient to impair compliance with protocol requirements.
Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results
Subjects who consume >14 alcoholic drinks per week.
Excessive consumption of xanthine-based beverages
History of drug abuse or use of illegal drugs: use of soft drugs (marijuana  pot) within 3 months of the screening visit or hard drugs (cocaine  PCP  crack)within 1 year of the screening visit
Non-smokers.
Smokers may participate  but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules
Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [ 1 Unit = 150mL of wine  360 mL of beer  or 45mL of 40% alcohol])
Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine  phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug at screening.
Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months
subjects who have discontinued smoking or the use of nicotine/nicotine containing products for at least approximately 3 months may be enrolled in the study at the discretion of the investigator
Current use of tobacco products including cigarettes  cigars  pipes  or chewing tobacco  current participation in a smoking cessation program  or discontinuation of smoking within 3 months prior to screening
Exclusion Criteria: Consumption greater than 14 alcoholic drinks per week
alcoholism  drug addiction  acute withdrawal from chemical dependency  psychiatric disease)
Be current smokers of cigarettes (past 7 days)
History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week
History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day
Inebriated
or abstinence
Patients who are currently cigarette smokers.
Smokes at least 20 cigarettes per day (1 pack per day)
Smoking
Smoking  alcohol intake (more than 2 drinks/week)
Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help them quit smoking
Subjects who are  appear to be  or are known  current or former drug addicts or alcoholics.
History of drug abuse during prior twelve months
History of smoking  alcoholism  and use of illicit drugs
Patient has a history of substance abuse within the past year.
Have been a smoker in the past 12 months
Have smoked an average of at least 10 cigarettes/day in the preceding year  with < 3 month total abstinence period
Subject is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start
Existing Substance abuse
Use of any tobacco products in the 6 months proceeding drug administration.
Abuse alcohol or drugs.
Abuse alcohol or require drugs which  in the opinion of the investigator  may increase the risk of pancreatitis.
Abuse drugs or alcohol.
abusive drug or alcohol consumption.
alcohol high consumption
Alcohol or drug abuse
Are known to have had a substance abuse (drug or alcohol) problem within the previous 3 years
Self-reported level of motivation to stop smoking >=  7  on a scale of 1-to-10
Subjects who consume > 14 alcoholic drinks per week
Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
has a history of alcohol or drug abuse within the past year
Have had at least one HIV risk behavior (unprotected sexual activity  sharing injection drug needles without following CDC guidelines for needle-cleaning  sexual activity while under the influence of drugs or alcohol) during the three-month period prior t
History of alcoholism or drug abuse within 12 months of the study.
History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
Patients with excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.
Subjects who have a history of alcohol or drug abuse within 1 year of study entry
The presence of alcoholism or drug abuse within the past year
history of smoking within 2 years of surgery  or
alcohol consumption > 14 drinks per week
Exclusion Criteria: Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month
Chronic alcohol or illicit drug use
Drug or alcohol abuse within 12 months of enrollment.
had a history of alcohol or substance abuse within 12 months of enrolment
History of drug or alcohol abuse or dependence
Ingestion of alcohol within 1 week of the first dose of study medication.
Recent history of drug and/or alcohol abuse
Recent history of drug or alcohol abuse.
Subject consumes more than 3 alcoholic beverages per day
Subject consumes more than 6 caffeinated beverages per day
Active substance abuse or dependence
Active substance abuse or illegal drug use.
Active substance abuse.
Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)
Substance abuse
Substance abuse or dependence within the past 3 months  except for nicotine
Have a history of drug abuse in the past 2 years and/or positive finding on urinary drug screening  other than prescribed medication.
History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine  PCP  crack) within 1 year prior to the screening visit or positive urine drug screen at screening
Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana  pot) use within 3 months of the screening visit and hard drugs (cocaine  PCP  crack) use within 1 year of the screening visit
Residing in Bandiagara for the duration of the study
Residence in skilled nursing facility
Subjects living too far from participating center or unable to return for follow-up visits
All patients presenting to Mayo Clinic  Jacksonville  Florida for a screening  surveillance colonoscopy  and/or a diagnostic and surveillance upper endoscopy  will be eligible based on inclusion and exclusion criteria
Live within 10 miles of UCLA
Patient who live and can be located in the Kintampo District.
Reside within zip codes corresponding to the lowest performing schools in the broad Miami area
Residing in Lambarene for the duration of the study
Living in an area where Arthritis Foundation aquatic programs were offered
A rural population in the middle belt of Ghana
Eligible patients will be offered entry into the study on the day of the procedure in the hospital GI or Mayo Clinic Jacksonville endoscopy suites.
Inclusion Criteria: Inborn at Brigham and Women's Hospital  Boston
Inclusion Criteria: Healthy men or women 18 years of age or older
Inclusion Criteria: Male & Females aged 65 and older
Inclusion Criteria: Male and female outpatients 18 years of age or older.
Inclusion criteria: Male and female patients aged above ten years.
Inclusion Criteria: Male and female subjects must be at least 45 years old at the time of consent.
Inclusion Criteria: Male or female 12-70 years of age (inclusive).
Inclusion Criteria: Men and women >= 18 years of age
Inclusion Criteria: Men or women aged 60-85  inclusive
Key Inclusion Criteria: Female and male subjects must be 18 to 65 years of age
Men or women ages greater than or equal to 55 years
Inclusion Criteria: all patients above 18 years
Inclusion Criteria: Male or female subjects 18 to 65 years inclusive.
Age group 6-25 years.
Inclusion Criteria: 18 and 45 years
Must be 18 or over
Any subject over 18 years of age 
18- 45 years old
18 years of age and older
18 years of age or older
18 years of age.
18 years or older
18-80 years of age
Patients must be in the age range of 40 to 80 years.
age < 18 years
age < 21
Age <18 years or >80 years
age = or > than 70 years
Age > 18 years
Age > 18 years.
Age > 60 years
Age >18years
Age >4.0 to <10.0 years
Age >= 18 years
Age  >= 6 years.
Age 18 - 80 Years
age 18 to 65 years
age 18-65 years
Age 21 to 60 years (inclusive).
Age  >= 18 years.
Age between 35 and 75 years.
Age less than 18
Age limits (see below)
Age of at least 18 years and 75 years or less
Age older then 18 years of age.
Age over 18 years
Age over 50 years
Aged 55 to 75
Ages 18 - 60 years old
Ages 18-80
Ages Eligible for Study: 1 Month to 18 Years
Ages Eligible for Study: 1 Year and older
Ages Eligible for Study: 1 Year to 18 Years
Ages Eligible for Study: 10 Years and older
Ages Eligible for Study: 11 Months to 14 Months
Ages Eligible for Study: 11 Years to 16 Years
Ages Eligible for Study: 11 Years to 18 Years
Ages Eligible for Study: 12 Years and older
Ages Eligible for Study: 12 Years to 70 Years
Ages Eligible for Study: 13 Years and older
Ages Eligible for Study: 13 Years to 17 Years
Ages Eligible for Study: 13 Years to 18 Years
Ages Eligible for Study: 15 Years to 18 Years
Ages Eligible for Study: 15 Years to 45 Years
Ages Eligible for Study: 16 Years and older
Ages Eligible for Study: 16 Years to 70 Years
Ages Eligible for Study: 18 Years and older
Ages Eligible for Study: 18 Years to 24 Years
Ages Eligible for Study: 18 Years to 25 Years
Ages Eligible for Study: 18 Years to 26 Years
Ages Eligible for Study: 18 Years to 35 Years
Ages Eligible for Study: 18 Years to 40 Years
Ages Eligible for Study: 18 Years to 45 Years
Ages Eligible for Study: 18 Years to 50 Years
Ages Eligible for Study: 18 Years to 55 Years
Ages Eligible for Study: 18 Years to 60 Years
Ages Eligible for Study: 18 Years to 65 Years
Ages Eligible for Study: 18 Years to 70 Years
Ages Eligible for Study: 18 Years to 75 Years
Ages Eligible for Study: 18 Years to 76 Years
Ages Eligible for Study: 18 Years to 80 Years
Ages Eligible for Study: 18 Years to 85 Years
Ages Eligible for Study: 18 Years to 90 Years
Ages Eligible for Study: 18 Years to 95 Years
Ages Eligible for Study: 19 Years and older
Ages Eligible for Study: 19 Years to 39 Years
Ages Eligible for Study: 19 Years to 50 Years
Ages Eligible for Study: 19 Years to 90 Years
Ages Eligible for Study: 2 Years to 10 Years
Ages Eligible for Study: 20 Years and older
Ages Eligible for Study: 20 Years to 30 Years
Ages Eligible for Study: 20 Years to 60 Years
Ages Eligible for Study: 20 Years to 64 Years
Ages Eligible for Study: 20 Years to 80 Years
Ages Eligible for Study: 21 Years and older
Ages Eligible for Study: 21 Years to 50 Years
Ages Eligible for Study: 21 Years to 60 Years
Ages Eligible for Study: 21 Years to 75 Years
Ages Eligible for Study: 21 Years to 89 Years
Ages Eligible for Study: 25 Years to 65 Years
Ages Eligible for Study: 28 Weeks to 33 Weeks
Ages Eligible for Study: 3 Months to 12 Years
Ages Eligible for Study: 3 Months to 18 Years
Ages Eligible for Study: 3 Years and older
Ages Eligible for Study: 30 Years and older
Ages Eligible for Study: 30 Years to 70 Years
Ages Eligible for Study: 35 Years to 75 Years
Ages Eligible for Study: 4 Years to 9 Years
Ages Eligible for Study: 40 Years and older
Ages Eligible for Study: 40 Years to 80 Years
Ages Eligible for Study: 45 Years and older
Ages Eligible for Study: 45 Years to 60 Years
Ages Eligible for Study: 5 Years to 65 Years
Ages Eligible for Study: 50 Years and older
Ages Eligible for Study: 50 Years to 80 Years
Ages Eligible for Study: 55 Years and older
Ages Eligible for Study: 55 Years to 75 Years
Ages Eligible for Study: 55 Years to 85 Years
Ages Eligible for Study: 6 Weeks to 14 Weeks
Ages Eligible for Study: 6 Years to 13 Years
Ages Eligible for Study: 6 Years to 18 Years
Ages Eligible for Study: 6 Years to 20 Years
Ages Eligible for Study: 6 Years to 25 Years
Ages Eligible for Study: 60 Years and older
Ages Eligible for Study: 60 Years to 80 Years
Ages Eligible for Study: 60 Years to 85 Years
Ages Eligible for Study: 60 Years to 89 Years
Ages Eligible for Study: 65 Years and older
Ages Eligible for Study: 75 Years and older
Ages Eligible for Study: 9 Years to 15 Years
Ages Eligible for Study: up to 21 Years
Ages Eligible for Study: up to 24 Hours
Ages Eligible for Study: up to 3 Months
Ages Eligible for Study: up to 3 Years
Ages Eligible for Study: up to 59 Months
Ages Eligible for Study: up to 6 Years
All patients must be aged 18 years and older.
Are at least 13 years old 
Are at least 16 years old 
Are between the ages of 18 and 70 years of age  inclusive.
Be 18 years of age or older.
Be 18 years old or older.
Be a male or female at least 18 years of age 
Be at least 18 years of age
Be between the ages of 18 and 45 years old  inclusive
Between 18 and 55 years of age
Boys and girls between the ages of 9-15.
Children ten years and below (to be catered for in the child antimalarial efficacy studies mentioned above).
Criteria for children 15 months to 12 years of age
Exclusion Criteria: < 18 years of age
Exclusion Criteria: Age <21 years*
Exclusion Criteria: age > 75 years
Exclusion Criteria: Age less than 18 years
Exclusion Criteria: Individuals younger than 11 years and older than 18 years
Exclusion Criteria: Patient is less than 18 years of age
Exclusion Criteria: Patient less than 18 years of age
For all: Age 15-18
In addition  they must meet all of the following criteria: be at least 18 years of age
Inclusion Criteria: 10 years or older
Inclusion Criteria: 18 to 85 years of age
Inclusion Criteria: 18 years of age and older
Inclusion Criteria: 18 years to 75 years of age
Inclusion Criteria: 18-65 years of age
Inclusion Criteria: age <= 75 years
Inclusion Criteria: Age > 1 year
Inclusion Criteria: Age > 18
Inclusion Criteria: age > 18 years
Inclusion Criteria: Age > 60 years
Inclusion Criteria: Age >= 18 years
Inclusion Criteria: Age 1 to 5 years old
Inclusion Criteria: Age 18-45 years
Inclusion Criteria: Age 18-55 years inclusive at the time of screening
Inclusion Criteria: Age 19 and older
Inclusion Criteria: Age 21-89
Inclusion Criteria: Age 40 to 80 years  inclusive.
Inclusion Criteria: Age greater than 18
Inclusion Criteria: Age greater than 18 and less than 90
Inclusion Criteria: Age is 18 and older.
Inclusion Criteria: Age over 18 years
Inclusion Criteria: Age: 18-80 
Inclusion Criteria: aged 65 years or older
Inclusion Criteria: Ages 18 to 100
Inclusion Criteria: Are aged 55-85 years  inclusive
Inclusion Criteria: Boys and girls ages 9-15
Inclusion Criteria: Children between 6 and 18 years
Inclusion Criteria: Must be between 21 and 50 years of age
Inclusion Criteria: patients >18 years old
Inclusion Criteria: patients aged 75 years old or more
Inclusion Criteria: Subject is between 18 and 55 years of age
Patient greater than or equal to 18 years of age
Patient must be > 18 years of age.
Patients must be >=  18 years of age.
Patients must be older than one year of age
Patients who are younger than 18 years of age
Subject is >=  18 years old.
Subject may be of any age
Subjects must be >= 18 years and <= 75 years of age.
Subjects must be >=18 years and <=75 years of age.
Subjects up to 65 years of age may be enrolled in Panels B and C
Under 18 years of age
Under the age of 19
Exclusion Criteria: Under 18
Had a history or presence of dermal hypersensitivity
A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to Exelon or to other cholinergic compounds  .  pilocarpine  bethanechol  tacrine  velnacrine  donepezil  metrifonate  or physostigmine)
Exclusion Criteria: Hypersensitivity to the active ingredient or one of the components of the drug
Exclusion Criteria: Sensitivity to immune globulin preparations or any benzodiazepine
History of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines.
history of hypersensitivity to active or inactive excipients of tamoxifen and Zoladex
History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)
History of hypersensitivity to the investigational products or to drugs with similar chemical structures
History of hypersensitivity to zolpidem  eszopiclone  or flurazepam.
Hypersensitivity or idiosyncratic reaction to buspirone HCl
Hypersensitivity to any component of ZYFLO CR
Hypersensitivity to didanosine (ddI).
Hypersensitivity to Irbesartan.
Hypersensitivity towards any component of degarelix or mannitol
hypersensitivity or idiosyncratic reaction to buspirone HCl.
Known history of sensitivity to cyclogyl and/or proparacaine HCL 0.5%
Known hypersensitivity to alfuzosin
Known hypersensitivity to any study drug component.
Known hypersensitivity to Argatroban or related compounds.
Known hypersensitivity to AZT.
Known hypersensitivity to estrogens  progestins  or other ingredients of Totelle
Known hypersensitivity to IV or oral ganciclovir.
Known hypersensitivity to murine or chimeric antibodies.
Known hypersensitivity to the study drugs.
No hypersensitivity to trastuzumab (Herceptin??)
Patient has hypersensitivity to gabapentin.
Patients who are sensitive or allergic to aspirin.
Patients with the following are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
Polyene hypersensitivity 
Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.
Patients with the following conditions or symptoms are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
Intolerance to Losartan therapy
Allergic to insulin
Allergy against niacin oder other ingredient of niaspan
Allergy to DHA (Omega 3) or Vitamin D
Allergy to fluorescein
Allergy to lactose.
Allergy to trial required medications
Are allergic to study drugs or any ingredient in them.
Exclusion Criteria: allergy to dairy proteins
Food allergies to the study food
Have an allergy to soybean oil and/or eggs
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
History of allergic reactions or anaphylaxis to immunizations or to any vaccine component
History of allergic reactions to cabergoline or ergot derivatives
History of allergic reactions to heparin
History of allergic reactions to heparin  doxycycline  or other related drugs
History of allergic reactions to heparin  propranolol  or other related drugs.
history of allergies to lidocaine
History of allergy to any of the proposed treatment or its alternatives  i.e
History of allergy to vaccines components
History of drug allergy of clinical significance in the opinion of the investigator.
History of serious allergic reaction to any substance  requiring hospitalization or emergent medical care  
History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care
History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care or history of allergy to vaccines components
Known allergies to aspirin  clopidogrel bisulphate (Plavix??) and ticlopidine (Ticlid??)  heparin  or stainless steel
Known allergies to the same class of drug and/or allergies to eggs
Known allergy to tetracycline.
No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
Patient with known allergy to iodine  iodine containing drugs or contrast agent
Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib  boron or mannitol.
Patients with a history of allergic reaction to an intra-articular injection or avian products.
Patients with known allergies to acetaminophen  lidocaine  hyaluronans  or avian products.
Reported allergy to egg proteins  chicken proteins or any other constituent of the vaccine.
Subject has a documented allergy to radiographic contrast that cannot be pre-treated.
Subject has a documented allergy to the device materials.
Subject has multiple and/or severe allergies to drugs or food
Subjects who have a clinically significant history of food or drug allergy.
You are allergic to amitriptyline or duloxetine.
Known previous intolerance to zidovudine (AZT) at 500 mg/day.
Subject has documented intolerance to BOTH heparin and Angiomax.
History of grade 3 or worse intolerance to 500-600 mg/day AZT.
Known intolerance or inefficacy to either drug.
Usual bedtime between 21:00 and 01:00
habitual bedtime between 9:00 pm and 1:00 am. 
reports habitual bedtime earlier than 9 pm or later than 1 am > 2 times per week 
regular sleep habits  including bedtime between 9 pm and midnight. 
self-report bedtimes that do not vary by > two hours on five nights per week 
sleep onset latency and / or bedtime resistance 
over the last three months for >= 5 nights per week  must have a normal bedtime of between 9 pm and 1 am and a time in bed of >= 7 hours 
patient's bedtime is between 9 pm and 1 am 
habitual bedtime should be determined by sleep history as between 9:00 pm and 12:00 am as determined by sleep history prior to randomization
have regular bedtime (within 1 hour) for 1 week prior to travel. 
usual bedtimes between 9:00 pm and midnight. 
patients who experience rls symptoms requiring treatment after 17:00 but prior to bedtime.
the subject has a history of the following sleep characteristics during the past three months or more at visit 1: bedtime between 22:00-00:00 h on >= five nights per week 
the patient has a habitual bedtime between 2100 and 2400. 
patient's usual bedtime is between 9 p. m 
their sleep schedule will include a typical bedtime of between 9:00 p. m
Anticipated availability for blood draw 4-6 weeks following 3rd vaccine dose
Ability to tolerate oral therapy.
Are unable to take medications by mouth.
Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Inability to communicate or cooperate with the investigator because of a language problem  poor mental status  or impaired cerebral status.
Available for the duration of the study.
Available to participate in follow-up for the duration of study (13 months)
Available to start intervention within 6 weeks
Available for 12 months of follow-up and able to complete study assessments as per clinician judgment
Parent/legal representative able to attend all scheduled visits and comply with all trial procedures.
Subject is unable to refrain from or anticipates the use of any medication (with the exception of metformin or sulfonylurea agents)  including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks until the post-study v
Are available for at least 8 weeks.
Must be able to adhere to the study visit schedule and other protocol requirements
Patients who are able to tolerate ICD programming as specifically prescribed in the study protocol
Clinically significant disorder including excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator
Mental incapacity or language barrier precluding adequate understanding or cooperation
Adequate vision and hearing to participate in study assessments.
Can communicate verbally or with assistive device
Available to participate in follow-up for the duration of study (14 months)
Any reason which  in the opinion of the medical subinvestigator  would prevent the subject from participating in the study
Exclusion Criteria: can not answer a written questionaire
Patients who are unable to complete quality of life questionnaires
Patients who can perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes
Patients who cannot perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes
Able to follow 3-stage commands
Able to recall 2/3 objects after 30 minutes
Can swallow capsules
Difficulty to swallow study medication.
Patients will be excluded from this study for the following reasons: If they are unable to walk several blocks for whatever reason
Capable of completing a 3-day food intake diary with instruction
Difficulty to swallow study medication
Must be able to swallow pills
Able to understand the nature of the study and what will be required of them.
Ability to walk 30 feet without assistance (cane and leg bracing is permitted).
Exclusion Criteria: Patient not being able to walk
Subjects must understand the dosing schedule.
Able to perform 6 minute hall walk
Able to self-administer study medication by subcutaneous injection or caregiver available to administer study medication.
Able to take oral medications
Exclusion Criteria: Patients who are unable to walk several blocks regardless of the reason will be excluded from all the trials  .  arthritis  stroke  claudication).
Patients unable to or with any psychiatric illness that would prevent them to legally comprehend the details and nature of the study.
Caregiver available to assist with the device every day (unless subject capable of using it independently
Diaphragmatic weakness such that patients are unable to tolerate supine position  or swallowing impairment such that patients are unable to maintain nutrition without use of gastrostomy.
Subject is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand.
The participant must also be able to correctly rank the following three levels of pain from highest to lowest: 1) falling from a 2-story building and breaking both ankles  2) stubbing one's toe and 3) getting bitten by a mosquito.
Unable to take oral medication reliably.
Patient or family inability to understand or cooperate with study procedures
Patient must be able to attend all required follow-up visits at the study center.
You must be able to visit the doctor's office once a week for ten (10) weeks.
Exclusion Criteria: Patients who are unable to walk several blocks for any reason.
patients who  for whatever reason(eg  confusion  infirmity alcoholism) are unlikely to comply with trial requirements
Ability to comply with the requirements of the entire study
Intellectual  emotional  and physical ability to comply with oral medication.
Capability of complying with study protocol.
Patient must be able to comply with treatment regimen.
Patients must be able to comply and understand the use of a diary
Be able to comply with all study procedures
Able to comply with all required study procedures and schedule
The subject  in the opinion of the principal investigator  is unlikely to comply with the study protocol or is unsuitable for any other reason.
Unlikely to comply with follow-up protocol
Unlikely to comply with the study protocol and prescribed treatment or is unsuitable for any other reason in the opinion of the investigator
Patient must complete the pre-treatment quality of life questionnaires.
Will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker
Subject cannot stop taking any of their current prescription or non-prescription medications during the study
Inclusion Criteria: Adherence to prior or current HAART was or is being compromised  or HAART was discontinued/interrupted due to nausea/vomiting
Inability to comply with study and follow-up procedures.
Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
No serious medical or psychiatric illness preventing informed consent or intensive treatment  
Ability to provide written informed consent and/or assent.
Ability to voluntarily provide written informed consent prior to treatment.
Able to provide consent
Be able to give informed consent.
Be capable of reading and understanding patient information materials and giving written informed consent.
Capable of consent
Exclusion Criteria: Inability to give written informed consent.
Exclusion Criteria: Inability to provide informed consent
If they are unable to provide informed consent because of cognitive deficits
Inability to provide consent
Patient must be able to provide informed consent.
Patients must be able to provide informed consent
Patients must be able to provide informed consent within the one week after the procedure.
Patients who are able to give informed consent
Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study
Patients who are unable to provide consent.
Patients who are unable to provide informed consent.
Unable to provide consent
Women able to consent for themselves
Women unable to consent for themselves
Exclusion Criteria: Failure to provide an informed consent
Informed consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the procedure to be followed  the experimental nature of the therapy  alternatives  potential benefits
Parent or guardian willing to provide informed consent
Parental non-consent
Patient or guardian available to give written informed consent.
Patients must have the following: Parent or guardian available to give written informed consent.
Patients must sign study-specific informed consent prior to study entry.
Unable to obtain or refusal to consent prior to surgery
(2) Ability and willingness to provide signed  witnessed informed consent.
Any reason which  in the opinion of the Medical Sub- Investigator  would prevent the subject from participating in the study.
Patients who in the judgment of the clinician are likely to violate the protocol regulations or unlikely to complete the study for any reason.
If under legal age  must have legal guardian who is able to give consent
Exclusion Criteria: unable to provide informed consent
Inability to provide informed consent signed.
Inability to provide informed consent.
Must be able to give written informed consent
Persons lacking consent capacity
Consent of parent or guardian if less than 18 years of age.
Consent of patient and parent or guardian if less than 18 years of age.
An informed consent obtained from the patient or his/her guardian and assent for children
Consent of patient and/or care giver (in the case of children)
Subject (or legal representative) understands the nature of the procedure and provides informed consent  prior to enrollment in the study.
Evidence of signed and dated informed consent document (by the patient or a legal guardian) indicating that the patient and/or the legal guardian has been informed of all pertinent aspects of the trial.
Meets the eligibility requirements for registration  .  within certain time windows from annual visits  having signed informed consent for Respiratory Ancillary Study [RAS]  at a site which has concurrent Institutional Review Board [IRB] approval for RAS)
Signed ICF
Signed  informed parental consent if patient is less than 18.
Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year
Absence of informed consent 
All patients must have given signed  informed consent prior to registration to the study.
Confirmed written informed consent
Consent not signed
Consent obtained before first dose of PCV-7 is given
Exclusion Criteria: Informed consent not obtained
Exclusion Criteria: No provision of informed consent
Inability to obtain signed informed consent from a parent or legal guardian.
Inclusion Criteria: Patient has provided informed consent.
Inclusion Criteria: Patient has provided IRB-approved written informed consent prior to conducting any study-related procedures
Inclusion Criteria: Patients having given their written informed consent  prior to participating in the trial.
Inclusion Criteria: provision of informed consent
Inclusion Criteria: Written informed consent
Inclusion Criteria: Written informed consent prior to any study related procedures
Inform consent
informed consent
Informed consent from the patients or authorized representatives must be obtained in writing enrollment into the study
Informed consent must be obtained from all subjects prior to beginning therapy
informed consent signed
Informed consent signed by the parent
Must sign an informed consent form
Patient must have given informed consent
Patient or patient's legally authorized representative has provided written informed consent
Patient signs informed consent
Patients who sign and date a Patient Informed Consent form prior to the implant visit
Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study.
Provide informed consent
provide Informed Consent.
Provide written informed consent signed by patient or legal guardian prior to entering the study or undergoing any study procedures.
provision of informed consent
Separate written informed consent obtained before screening and study start respectively
Separate written informed consent obtained before screening and study start  respectively
Signed consent form
Signed informed consent
Signed informed consent obtained from the subjects (if possible) and their parents
Signed informed consent.
Signed written informed consent
Subject or parent/legally authorized representative has provided written informed consent
Subjects should read  sign and date an Informed Consent Form prior to any study procedures
Will provide written informed consent prior to their participation in the study.
Written informed consent
Written informed consent obtained before inclusion and randomization.
Written informed consent obtained from the parent or guardian of the subjects.
Written informed consent prior to entry into the study.
Written informed consent signed
Written  voluntary informed consent.
Exclusion Criteria: Implanted investigational drug eluting stents
intrauterine device (IUD)
Subject has a cardiac pacemaker or other implanted electro medical devices.
Patients requiring specialized endotracheal tubes
Have an active implantable device
Any implanted device or prosthesis or intrauterine IUD type of device
Condom or diaphragm
double barrier  .  condom  diaphragm with spermicide)
If patient uses a cane routinely in daily activities  then they can use it for their assessments
Admitted to the NICU
Have received intravascular contrast material within the preceding 14 days
Any patient undergoing screening and/or surveillance colonoscopy and/or upper endoscopy with possible biopsy or removal of tissue by polypectomy
A positive zidovudine (AZT) detection assay performed 7 days prior to drug dosing will exclude patients from study participation.
Exclusion Criteria: Screening clinical laboratory values
[Note: If one of the two values is < 400 the patient will be excluded
Abnormal nasal epithelial TEPD total chloride conductance (a more electrically negative value than 5 mV for >= ???€chloride-free+isoproterenol).
Must have a negative urine test for substances of abuse including marijuana  cocaine  cocaine derivatives  opiates and methadone
2 positive Hepatitis B surface antigen results 6 months apart
Exclude if B12 less than 100 pg/ml (normal range greater than 200)
Expired breath CO level > 10 ppm and cotinine level > 210 ng/ml at the baseline measurement
Positive results of urine drug screen testing (amphetamines  benzodiazepines  cannabis  barbiturates  cocaine  opiates  antidepressants).
Positivity for HHV-8 antibodies and plasmaviremia (volunteers will be screened for anti-HHV-8 antibodies and positivity confirmed by PCR  only the individuals confirmed positive by PCR will be excluded)
Subjects who have experienced elevations in liver function test parameters on other cholinesterase inhibitors are still eligible.
triglyceride (TG) levels above 150 mg/dl 
>= >= 5.0 ULN 
1.5 x ULN
(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)
Abnormal age adjusted immunoglobulin levels (IgG or IgA)
Note: creatinine clearance need not be determined if the baseline serum creatinine is within normal limits
All available prior computed tomography (CT) or magnetic resonance imaging (MRI) scans should be reviewed and noted  and measurements showing progression of disease should be documented whenever possible
> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).
Concurrent Medication: Required for patients whose CD4 count falls below 200 cells/mm3:
Calcium less than the ULN
Exclude if folate less than 1.7 ng/ml (normal range greater than 1.9)
Subject exhibits viral strains that are resistant to lopinavir.
Patients with known positivity for human immunodeficiency virus (HIV) will be excluded due to possible pharmacokinetic interactions with bortezomib
They must also have a negative serum beta-human chorionic gonadotropin (B-hCG) at Screening
Documented to be HBsAg positive for > 6 months OR HBsAg positive and IgM anti-HBc negative and anti-HBs negative
Referring Pap smear was ASCUS  + HPV or LGSIL
Refraction with a spherical equivalent less than 5 Dp.
Stable hemodynamic condition: systolic blood pressure on arrival higher than 80 mmHg in the absence of continuous vasopressive drugs administration.
Wechsler Adult Intelligence Scale-Revised score < 70
A score of greater than 4 on the Modified Hachinski Ischemic Scale.
Any focal abnormality on neurologic exam.
Any subject with a screening resting systolic blood pressure >180 mmHg and/or resting diastolic blood pressure of >100 mmHg unless  in the opinion of the principal investigator  the blood pressures would not endanger the subject while participating in thi
AST and ALT >2.5 x ULN (AST and ALT >5 >=  ULN for subjects with liver metastasis)
Be immunosuppressed defined as having: CD4+(T4) lymphocytes = or < 400 cells/mm3.
Clinical laboratory tests (CBC  blood chemistries  urinalysis) taken at Visit 1 must have been within normal limits or clinically acceptable to the Investigator
Clinical laboratory tests (CBC  blood chemistries  urinalysis)must be within normal limits or clinically acceptable to the Investigator/Sponsor.
Clinically significant laboratory abnormalities.
Diagnosis and Criteria for Inclusion: Diagnosis: This study was designed for untreated subjects with primary hypercholesterolemia with plasma LDL-C concentrations between >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) and triglyceride concentrations
Do not have a positive test for HIV virus  hepatitis C virus  or hepatitis B surface antigen
Exclude if T3 uptake is less than 19%
free T4 index is less than 0.8
HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive with positive HBsAg for the previous 6 months
If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.
If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.
If the patient fails this criterion  the Investigator may decide to conduct a 24-hour creatinine clearance test
Inclusion Criteria: >=18 years and <= 75 years of age with LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit) and triglyceride concent
Inclusion Criteria: >=18 years of age and treated with simvastatin 10 mg or 20 mg for at least 6 weeks and LDL-C levels of > 2.5 mmol/L to <=4.20 mmol/L (97 mg/dL to 160 mg/dL) at Visit 1.
Inclusion Criteria: Age 18-80 years  protein concentration in ascitic fluid < 15 g/L and at least one of the following: serum creatinine >=  1.2 mg/dl or BUN >=  25 mg/dl  serum sodium >= 130 mEq/L or severe liver failure as defined by a Child-Pugh s
Inclusion Criteria: Clinical diagnosis of ALS
Inclusion Criteria: Eligible subjects included men or women   passage of 3 or more unformed stools in the preceding 24 hours accompanied by one or more
Inclusion Criteria: Patients must meet all of the following conditions to be eligible for enrollment into the study: Diagnosis of CF based on conclusively abnormal sweat test (sweat chloride >35 mEq/liter.
Laboratory tests within the normal range of the laboratory (hematology  biochemistry  urinalysis) or within the acceptable range per agreement between investigator and sponsor.
Less than 5th percentile in birthweight and head circumference for gestational age
LVEF normal
Mini-Mental State Examination score at screening visit greater than 14
Modified Hachinski Ischemic Index less than or equal to 4
Must have coagulation parameters within the limits of normal for the testing facility
Must have serum chemistry values and urinalysis values within the limits of normal for the testing facility
OR more than 3 mutations from the other points of the LPV mutation score:10 20 24 46 53 54 63 71
Oxygen saturation >= 92% on room air.
Patient has any abnormal chemistry or hematology results that are deemed by the Investigator to be clinically significant.
Patient has pain intensity score of at least 4 on the 11-point Likert numerical rating scale at screening
Patients may be HBeAg positive  and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive.
Patients must have: Positive HIV antibody test results by ELISA.
Patients with contra-indications for multiple biopsies
Positive hepatitis B surface antigen  hepatitis C antibody test  or HIV test.
Satisfactory medical assessment with no clinically significant or relevant
Score of >= 11/14 on Section C (hand) of UE portion of Fugl Meyer Assessment (FMA)
Subjects must have normal or clinically acceptable physical exam and ECG intervals (PR  QRS  QT and QTc) on 12-lead ECG (recorded at 25 mm/s).
Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure >= 128/78 mmHg from non-dominated arm
T4 less than 2.9 ((g/dL)
Weighing at least 60 kg  who are within 10% of their ideal weights 
Weighing at least 60 kg  who are within 10% of their ideal weights 
(If the patient awakens with a deficit  time of onset is considered the time the patient was last seen functioning normally.)
[Note: If one of the two values is < 400 the patient will be excluded
<12 months post-partum*>= 
> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).
>= 5.0 ULN 
>=  21 days since completion of prior chemotherapy  >= 6 weeks since prior Mitomycin-C
>=  50% stenosis for symptomatic subjects
>=  80% stenosis for asymptomatic subjects or
1.5 x ULN
20 000/mL
50 copies/ml for the last 6 months on HAART therapy.
500 cells/mL
500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios
50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..
50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..
5x Upper Limit of Normal (ULN)
8.0 g/dL
A CD4+ count between 200 and 500 cells/mm3.
A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).
A minimum time period of 3 weeks should elapse between the completion of extensive radiation therapy for recurrent/metastatic disease and enrollment in the study.
A Positive and Negative Syndrome Scale (PANSS) total score between 60 (included) and 120 (excluded)
A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure  unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit
A significant (> 50%) stenosis proximal or distal to the target lesion
Abnormal liver function (serum total bilirubin > the upper limit of normal  or serum ALT  AST  or GGT >2.0 times the upper limit of normal).
Abnormal renal function (serum creatinine >1.5 times upper limit of normal).
Abnormal thyroid function tests within the last 6 months
Absolute granulocyte count >=  1 500/mm??
Absolute neutrophil count (ANC) > 1 500/mm3  platelets > 100 000/mm3  and hemoglobin > 9 g/dl
Absolute neutrophil count<750 cells/ul
Acceptable hematologic status: Absolute neutrophil count (ANC) >=  1500 cells/mm(3) (1.5 >= 10(9)/L)
Acceptable liver function: Bilirubin >= 1.5 times upper limit of normal (ULN)
Acceptable renal function: For all patients serum creatinine within normal limits  OR calculated creatinine clearance >=  60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.
Activated partial thromboplastin time (aPTT) >1.5 >=  ULN
Active malignancy of cervix  uterus  fallopian tube(s) or ovary > Stage I  or bladder of any Stage
Adequate bone marrow reserve: (Haemoglobin >=  12g/l  Absolute Neutrophil Count (ANC) >=  2.0x 10^9  Platelets >= 100 000)
Adequate organ function that has been determined within 7 days prior to enrollment  defined as:Leucocyte count > 3 000/uL
All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H
All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H
Allowed: PCP prophylaxis (required for patients with CD4 count < 200 cells/mm3).
ALT greater than 3xULN.
ALT or AST > 5x Upper Limit of Normal (ULN)
ALT/AST < 5 times x UNL  bilirubin < 1.5times x UNL  creatinine < 1.25 times x UNL  normal calcium level
Ambulatory performance score of = or > 70 Karnofsky.
An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size  or a recent history of unintentional weight loss of 10% from the subjects baseline
Anatomic criteria :length of aortic proximal neck >10 mm  diameter of aortic proximal neck < 32 mm  Absence of aortic neck angulation > 90>=  and patent iliac without important stenosis or tortuosity.
ANC > 1 500/ul
ANC > 500/mm^3
ANC ?? 1500/ul  platelet count ?? 100 000/ul
And modifications of ST-T (no persistent ST elevation) on 12-lead EKG 
And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
and systolic blood pressure consistently < 90 mmHg
Anemia (hemoglobin < 8.5 g/dl)
Anemia defined as a hematocrit of < 30 and hemoglobin < 10g/dL.
Angiographic exclusion criteria (as determined >= 30 days prior to procedure): The target carotid artery is completely occluded.
Angiographic exclusion criteria: Unprotected left main coronary artery disease with >=  50% stenosis
Angiographic inclusion criteria (as determined >= 30 days prior to procedure): Target lesion stenosis (% stenosis = (1-N/D) X 100)1  documented by selective angiography pre-intervention  is 1.1
Any one of the following criteria: Diabetes  CRP >= 2 mg/L  or metabolic syndrome
Any patient who has a platelet count < 100 000 cells/mm3 or > 700 000 cells/mm3 or a WBC of < 3 000 cells/mm3
Are (1)NYHA Class IV or (2)NYHA Class III with highest calculated CrCl  60mL/min within the previous 30 days
Are of 40 kg (88 pounds) of weight or more.
AST (SGOT)  ALT (SGPT) and alkaline phosphatase >= 2.5 times ULN (if liver metastases are present  then >= 5 >=  ULN is allowed).
AST and ALT levels which are less than or equal to 10 times the upper limit of normal.
AST or ALT < 2 times ULN (unless related to primary disease)
AST or ALT < 5 times upper limit of normal
Asymptomatic patients with a stenosis greater than 80% by ultrasound or angiography performed in previous 30 days
At least 1 measurable target lesion in accordance with RECIST criteria to assess clinical response (tumors within a previously irradiated field are designated as non-target).
At least moderately concerned about gaining weight after quitting smoking
At least one bidimensionally measurable lesion with clearly defined margins documented by: medical photograph for skin and oral lesions  plain X-ray with at least one diameter 0.5 cm or greater  CT  MRI  or palpation with both diameters 2 cm or greater
At the time of inclusion (>=  1 day post PCI) patient does no longer require i.v
Average of CD4+ cell count at 60 and at 21 days prior to study beginning = or < 400 cells/mm3.
Axillary temperature >= 37.5oC but less than 40 oC or history of fever in preceding 24 hr.
Baseline NIHSS score at least 2 points  not more than 21 points
Baseline serum osmolarity of greater than 310 mOsm/L
Be admitted to the hospital within 36 hours of the mandatory dose of IV furosemide 40 mg at between 2000 and 2200 hour on Day -1
Be immunosuppressed defined as having CD4+(T4) lymphocytes = or < 400 cells/mm3  based on two measurements at least 1 week apart.
Best Corrected Visual acuity >20 /25
bifurcation lesions (side branch > 2 0 mm)
Bilirubin < 2 mg/dL
Bilirubin >= 1.5 times the upper limit of normal (ULN)
Bilirubin less than or equal to 1.5 mg/dL
Bladder capacity > 200cc (by any method)
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic 
BNP levels equal to or greater than 300 pg/ml.
Body weight >= 25 kg.
Bone marrow involvement (< 25% neuroblasts) by morphologic exam within the past 2 weeks
BPI 12 <= 4 (pain scale)
Calculated creatinine clearance of less than 30 ml/min or serum creatinine > 3 mg/dL
Calculated LDL-C concentration of at least 2.6 and 4.1mmol/l or less using the Friedewald equation  and triglyceride of less than 3.99 mmol/l
Calgary Depression scale score >10 or Simpson-Angus Rating Scale score > 20
CD4 cell count >100 cells/mL at screening
CD4 count 300-600 cells/mm3.
central venous pressure consistently < 6 mmHg
Chronic oral daily requirement of 80-240 mg of furosemide for at least 7 days before the study start
CKD stage 3 (GFR 30 - 59 ml/min) for CKD group
Clinical laboratory values must meet the following: Granulocytes greater than or equal to 1 500/mm(3)
Clinically significant anemia (HCT < 33%)
clinically significant diameter of stenosis (50-99 % according to visual assessment of operator)
combination of points 1 - 4
Common carotid artery diameter where the Mo.Ma device will be positioned is 5-13 mm.
Complete blood count and differential defined as: Hematocrit >= 30% for women  >= 38% for men
Corrected QT interval < 0.47 seconds
Creatinine > 1.5 x ULN
Creatinine >= 1.5 times ULN
Creatinine >= 2.0 mg/dL OR creatinine clearance >=  40 mL/min
Creatinine clearance less than 50 ml/min
Creatinine clearance or radioisotope GFR >=  60 mL/min
Creatinine less than or equal to 1.6 mg/dL
Creatinine within normal institutional limits or creatinine clearance (CrCl) greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
currently taking atorvastatin 10 mg daily and history has taken 80 % of daily doses for the preceding 6 weeks prior to Visit 3
D in one eye (non-stud eye) and the presence of the following characteristics in the second eye (study eye  eye to be treated): At least 5 or more intermediate (> 63 ??m) or larger soft drusen AND/OR Confluent drusen within 3000 ??m of the fovea center
Decreased helper/suppressor ratio < 1.0.
Diagnosis of high-risk neuroblastoma  meeting one of the following criteria: Refractory disease  defined as no response  mixed response  or progressive disease after completion of induction therapy administered according to clinical trials COG-A3973 or CO
Differential within institutional normal limits or approval of site physician
Dilatation of the pupil < 5 mm
Dilatation of the pupil < 5 mm
Dilatation of the pupil < 5 mm.
Discharge to a skilled nursing facility or long-term care facility (EXCEPTION: Subjects may be d/c'd to the 6A SNF unit at MetroHealth Medical Center)
Documentation of left ventricular ejection fraction (LVEF) less than or equal to 40% measured by nuclear scan  echocardiogram (ECHO)  or ventriculogram  within 90 days prior to surgery.
Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Donation of plasma (500 mL) within 7 days prior to drug administration
Donation of plasma (500 Ml) within 7 days to drug administration
Donation of plasma (500 Ml) within 7 days to drug administration
Donation or loss of hole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.
Donation or loss of whole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.
Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study)prior to the administration of the study medication (50 mL to 300 mL of whole blood within 30 days  301 mL to 500 mL of whole b
Doppler index < 0 8
Duration of insomnia complaint >1 month
ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.
ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.
ECOG (Eastern Cooperative Oncology Group) status: 0-1-2
ECOG 0-2
ECOG performance status < 2 (Appendix 1).
ECOG Performance Status >=1.
ECOG Performance Status 0-1
ECOG performance status 0-2
ECOG performance status 0-2
ECOG performance status 0-2 .
ECOG score < 0 to 2
ECOG score to be equal to or above 2
Ejection fraction < 40%
Ejection fraction >= 30%
Ejection fraction >=  50%
ET-743 at any time (Stage 1 only).
either HIV-seropositive  CD4+ T-cell count of >=350/mm3
Evidence of impaired renal function (eGFR <60 ml/min)
EXCLUSION CRITERIA include: Impaired renal function  demonstrated by creatinine clearance < 30 ml/min
Exclusion Criteria: Conditions associated with elevated TGF-Beta  
Exclusion Criteria: Have systolic blood pressure consistently <90mm Hg
Exclusion Criteria: Patients < 5 ans or > 65 ans
Exclusion Criteria: Planned aortic valve replacement or repair
Exclusion Criteria: Severe Hypertension defined by PAS > 180mmHg and/or PAD > 110 mmHg.
Exclusion Criteria: Subjects who do not have a FEV1/forced vital capacity (FVC) ratio of >=70% at Visit 1.
External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm.
Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5
falciparum of between 250 and 100 000 asexual parasites/mm3 as determined by microscopic exam of the thick or thin smear
fasting blood sugar greater than 110 mg/dl
Fasting triglyceride levels of >= 400 mg/dL (4.5 mmol/L)
FEV_1 and DLCO >=  30% OR normal chest x-ray  pulse oximetry  and venous blood gas
Forced vital capacity 50+%
Functionality score ('Get-up-and-Go' test) must be > 10.0 sec but < 20.0 sec
Granulocytes >= 1 500/ul  Platelets >= 100 000/ul  Creatinine >=ULN  Bilirubin >=1.5 mg/dl  AST >=2.5 x ULN
has a history of renal failure and a serum creatinine value greater than 3.0 mg/dl
has uncontrolled diabetes  defined as a documented plasma blood glucose value > 400 mg/dl (22.2 mmol/L) within three (3) days before surgery
Have 2 measurements of viral load (amount of HIV in the blood) during the 6 months before entering the study that are below 400 copies/ml by RT-PCR test or below 500 copies/ml by branched DNA test  measured at least 8 weeks apart.
Have a CD4 cell count of 200 copies/ml or higher within 60 days of study entry.
Have a CD4+ count of 50 cells/mm3 or more.
Have a Left Ventricular Ejection Fraction less than 40% (measured within 24 weeks before randomization)
have a systolic/diastolic blood pressure <= 140/90 mm Hg
Have a viral load below 50 copies/ml within 30 days prior to entry.
Have an HIV count of 5 000 copies/ml or more within 30 days prior to study entry.
Hb>10g/dl.
HbA1c > 10%
HbA1c > 7.5%
heart rate < 55 beats per minute
Hematocrit > 29%  ANC > 1 500  platelets > 125 000
Hemoglobin <10 g/dL.
Hemoglobin <8.5 g/dL (hemoglobin may be supported by transfusion  erythropoietin  or other approved hematopoietic growth factors
Hemoglobin > 10 g/dL
Hemoglobin >= 9.5 g/dL
Hemoglobin  >= 9 g/dL
Hemoglobin  >= 9 g/dL.
Hemoglobin greater than or equal to 9 g/dL
Hemoglobin should be >8 g/dL.
HER2-positive  defined 3+ by IHC or HER2 gene amplification by FISH
Hgb >=  10 g/dl  BUN < 25 mg and creatinine < 1.5 mg
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women 
HIV RNA <100 000 copies/mL
hospitalisation for less than 3 nights
hospitalised in internal medicine
Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days
If abnormal laboratory results such as : Hb<8 g/dl
If presence of the following mutations : in the protease : one among 32 47 48 50 82 84 90
Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)
Impaired hepatic function (liver enzymes greater than the upper limit of normal or bilirubin outside the normal range).
Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy
Impaired renal function (creatinine > 3.0 mg/dl or 265 ??mol/l)
in the reverse transcriptase : 215 or 184.
Inclusion Criteria: BW below 1 500 gm
Inclusion Criteria: HBV DNA positive with DNA levels at screening greater than or equal to 3 000 000 copies/mL.
Inclusion Criteria: Patient with left ventricular systolic dysfunction  left ventricular ejection fraction >=35%  as documented at the moment of ICD implant
Inclusion Criteria: Patient with mild or moderate hypertension defined with arterial diastolic pressure (PAD) at sit position between 90 mmHg and 110 mmHg and arterial systolic pressure (PAS) at sit position between 140 mmHg and 180 mmHg.
Inclusion Criteria: Two mandibular third molars containing at least one mesially angular impaction with crown exposed to oral cavity
Inclusion Criteria: visual acuity worse than 20/40  caused by central subepithelial fibrosis
Individuals diagnosed with osteoporosis  .  bone density of hip greater than 2.5 standard deviations below the mean) will not be enrolled in the study
International normalized ratio (INR) >1.5
irradiation to 25% of bone marrow-containing areas  or
Karnofsky/Lansky performance status 60-100%
Kidney function: stadium 1-4.
Laboratory evidence of hematologic disease (absolute leukocyte count <4000/mm3 or >14 500/mm3  absolute lymphocyte count <1500/mm3  platelet count <120 000/mm3  or hemoglobin <10.0 g/dL).
Laboratory evidence of hematologic disease (absolute leukocyte count 3.5-11/ul  absolute lymphocyte count 560-5280/ul  platelet count 120 000-400 000/ul  or hemoglobin 10.0-16.5g/dL).
Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).
Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).
Laboratory values within the following limits: Hemoglobin > 10.0 g/dL Neutrophil count > 1.5 x l09/L Lymphocyte count > Lower limit of institutional normal Platelet count > 80 x l09/L Serum creatinine < 2.0 mg/dL Serum bilirubin < 2 x upper limit of insti
Large (>=  3 cm) breast cancer
LDL-C >200 mg/dL (5.2 mmol/L)
LDL-C concentration greater than or equal to 2.5 mmol/L to less than or equal to 160 mg/dL (less than or equal to 4.1 mmol/L) based on blood specimens taken at Visit 1  using the Friedewald calculation as described in the Protocol Section 8.8
Left ventricular ejection fraction (LVEF) <55%
Left ventricular ejection fraction <50%
Left ventricular systolic dysfunction as evidenced by left ventricular ejection fraction < 40%  measured using contrast or radionuclide ventriculography or by echocardiography  within 180 days of the study start
lesion must be covered by stent length of no more than 24 mm and stent diameter of no more than 3 5 mm
liver transaminases (ALT  AST) < 50 % above the upper limit of normal  with no active liver disease  and CK < 50 % above the upper limit of normal at Baseline Visit.
Liver transaminases (ALT  AST) less than 50% above the upper limit of normal  with no active liver disease  and CPK less than 50% above the upper limit of normal as tested in blood specimens taken at Visit 1
Lumbar spine or total hip BMD T-score 1ess than or equal to -2.0 and >/= 1 prevalent osteoporotic fracture  or lumbar spine or total hip BMD T-score less than or equal to -2.5 with or without and >/= 1 prevalent osteoporotic fracture
Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).
Massive stroke (> 2/3 MCA territory) or any amount of midline shift due to cerebral edema on head CT.
Maximal cardiac troponin elevation >=  4 (measured at 37>=  C)
Medical disorder that would influence outcome of the study - e.g
More than 12 weeks (was 24 weeks  AMENDED 3/31/96) of total prior AZT ( > 500 mg/day without serious adverse event)
Morning FEV1 of 40-80% normal.
Must have anatomic stenosis greater than 70% by ultrasound or angiography performed in previous 30 days
Must have at least 1 of the following pancreatic manifestations of VHL documented by a non-invasive imaging study: Pancreatic cyst(s)
Nephropathy (proteinuria >500 mg/day)
NIHSS must be > 4 points.
No more than 3 sites of skeletal disease as determined by an >= I-MIBG scan (for regional involvement of the skeleton [e.g.  pelvis  spine]  the tumor involvement should be < 25% of the site)
Normal ALT (as defined by the range of the clinical site laboratories) and Creatinine (<= 1.6 mg/dL)
Normal amplitude of accommodation
Normal best-corrected visual acuity at 20/40 or better
or if serum creatinine > upper limit of normal  a calculated creatinine clearance < 60 mL/min/1.73 m2).
Patient has a Karnofsky Performance Status greater than or equal to 60%
Patient has an estimated creatinine clearance of < 60 ml/min calculated using the Cockroft Gault method
Patient in ability to undergone hepatic or pulmonary resection in case of recurrence during the follow-up (ECOG >= 2)
Patient with elevated Prostate Specific Antigen (PSA)
Patient with serum creatinine > 2 mg/dl or creatinine clearance < 60 ml/min
Patients ever having had a value of CD4+ T cell number < 250 will be excluded]
Patients must have an ECOG performance status of <2 (ECOG criteria published in [46])
Patients must have an ECOG performance status of less than or equal to 1.
Patients must have ECOG performance status 0-2.
Patients must have had a colonoscopy within the past 5 years
Patients must have normal organ and marrow function (as defined below) measured within one week prior to registration: Absolute neutrophil count >1 500/mm3.
Patients should have adequate organ function related to the following: White count > 3000/ul  Platelet count > 70 000/ul  Hemoglobin > 8 g/l  Bilirubin WNL  AST and ALT < 2.5 x ULN  and Creatinine < 1.5 x ULN or 24 hour creatinine clearance > 60 ml/min
Patients with clinically significant ECG abnormality  including prolonged QTc (defined as QTc >=450 msec using Fridericia's correction).
Patients with X-ray findings of acute fractures  severe loss of bone density  avascular necrosis and/or severe bone or joint deformity.
Performance Status
Performance status 0-2
Performance status contraindicating a hepatic or pulmonary surgery in case of recurrence.
Performance status Not specified
Performance status of 0-1
Plasma HIV-1 viremia levels <= 50 000 copies/mL
Platelet count < 100 000/ul
Platelet count <75 000/ul
Platelet count >
Platelet count  >= 100 000 platelet/mm(3) (100 >= 10(9)/L)
Platelet count  >= 100 000/mm??
Platelet count  >= 100 000/ul
Platelet count<50 000/ml
Platelets >= 100 000/mm3
Platelets greater than or equal to 100 000/mm(3)
Platelets greater than or equal to 100 000/mm3.
Poorly controlled hypertension  .  blood pressure: systolic >180 mm Hg or diastolic >100 mm Hg).
Positive infectious disease markers from mother's blood or cord at time of -collection (See below for details).
Presence of hypoalbuminaemia < 35 g/L
Presence of serious acute infection requiring parenteral treatment at time of study entry.
Presence of serious acute infection requiring parenteral treatment at time of study entry.
Presenting for CABG with or without mitral valve repair or replacement procedure
Previous enrollment in LABS-1
Previously performed stem / mononuclear cell therapy
PSA value equal to or above 2 ng/ml
PT-INR/PTT < 1.5 x upper limit of normal.
Radiation therapy to greater than or equal to 50% of the bone marrow
range of reference diameter 2.5 to 4.0mm
Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Reference vessel diameter >=  2.5 and >= 3.75 mm by visual estimate
remnant liver volume < 50%
remnant liver volume >= 70%
Renal anemia with hemoglobin (blood) < 10 mg/dl
Renal failure (serum creatinine stably > 1.7 mg/dl
Reported a stable weight history for at least 4 weeks prior to randomization at Visit 3 (baseline visit)
Required Initial Laboratory Data: *ANC >=  1 500/mm3  *Platelet count >=  100 000/mm3  *SGPT < 1.5 times ULN  *Alkaline phosphatase < 2.0 times ULN  *Bilirubin < 1.5 mg/dl  *Serum creatinine < 1.5 times ULN
Screening clinical laboratory values: Absolute neutrophil count <1500/ul
Serum albumin <2.5 g/dL.
Serum bilirubin < 1.5 times ULN
Serum creatinine < 1.5 mg/dl  BUN < 25 mg/dl  serum SGOT and bilirubin < 1.5 times upper limit of normal
Serum creatinine < 1.5 times ULN  or 24-hour creatinine clearance > 75 cc/min
serum creatinine > 175 ??mol/L
Serum creatinine >2.0 mg/dL
Serum creatinine greater then 2 mg/dl.
Serum Glutamate Pyruvate Transaminase (SGPT) >= 2.5 ULN  Serum Glutamate Oxaloacetate Transaminase (SGOT) >= 2.5 ULN 
serum glutamyloxaloacetic transaminase (SGOT) < 2.5 ULN
Serum potassium > 3.5 mEq/L.
Serum potassium > 5.2 meq/L
Seven of 10 patients in each treatment arm must have p24 antigen levels = or > 70 pg/ml (> 50 pg/ml at U
Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)> 5.0 mmol/L)
Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/
SGOT and SGPT >= 2.5 times upper limit of normal
SGOT and/or SGPT > 1.5 upper limit normal  associated with Alk.phosph > 2.5 ULN
SGOT less than 2.0 x ULN
Shortening fraction >=  25% by ECHO OR ejection fraction > 30% by MUGA
Show evidence of mild cognitive impairment (MCI) by meeting all of the following criteria: Global CDR score = 0.5  NYU Delayed Paragraph Recall less than 9  17-item HAM-D score less than 13  and HAM-D Item 1 (depressed mood) score =1.
Show evidence of significant active hematological disease such as a white blood cell (WBC) count <= 2500/ul (2.50 1E+09/L)  an absolute neutrophil count <= 1000/ul (1.00 1E+09/L)  or a platelet count <100 000/mm^3.
Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT  AST) elevations greater than 2 times the upper limit of the laboratory reference range.
Significant regional wall motion abnormality on echocardiography at the time of acute PCI (ejection fraction >= 50% on visual estimation).
Significant renal impairment  .  creatinine clearance < 45 mL/min by the Cockcroft-Gault formula)  or changing renal function during the 7 days before study start  or intrinsic renal disease
Stable elevations of liver enzymes  alanine aminotransferase (ALT)  and aspartate aminotransferase (AST) due to concomitant medications will be allowed if they are less than 2 times the ULN.
Stimulated C-peptide > 0.2pmol/L on MMTT
study participants had to have a normal Pap smear within the previous 12 months
Subject had abnormal pre-intervention blood counts with platelets < 50 000/cubic mm or > 700 000/cubic mm or white blood cell count < 3 000/cubic mm.
Subject has a Karnofsky Score &#8805
Subject has any of the following abnormal laboratory test results at screening: Hemoglobin &lt
Subject has severe chronic renal failure (creatinine > 2.5 mg/dl).
Subject is &#8805
Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
Subject must have an undetectable viral load (VL) &lt
Subjects must have a baseline FEV1 of >=65% of predicted normal value at Visit 1.
Subjects must have a FEV1 >=  0.70L at Visit 1.
Subjects must have an LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).
Subjects must have an LDL-C concentration >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).
Subjects must have liver transaminases (ALT  AST) < 50% above the upper limit of normal  with no active liver disease  and CK < 50% above the upper limit of normal at Visit 3 (Baseline Visit).
Subjects must have liver transaminases (ALT  AST) <50% above the upper limit of normal  with no active liver disease  and CK <50% above the upper limit of normal at Visit 3 (Baseline Visit).
Subjects must have triglyceride concentrations of < 3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).
Subjects must have triglyceride concentrations of <3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).
Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline visit).
Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline Visit).
Subject's serum AST and ALT levels must be &lt
Subjects who do not have a ??15 pack-year smoking history and a baseline breathlessness severity grade of ??2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 1.
Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL blood in 14 days (unless approved by the Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 18
Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL of blood in 14 days (unless approved by Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 180
Subjects with no stenosis or stenosis <50% on angiography
Subjects with serum creatinine greater than 3.
Subjects with serum total bilirubin greater than 4.
Systolic blood pressure (SBP) consistently < 90 mm Hg
systolic blood pressure < 105 mm Hg
Systolic blood pressure greater > 200 mm Hg or MAP > 120 mm HG when patient is initially monitored.
Target lesion involves bifurcation class D & type G including a side branch >=  2.5mm in diameter (either stenosis of both main vessel and major side branch or stenosis of just major side branch) that would require stenting of diseased side branch
Target lesion stenosis is >= 50% and <100% (minimum TIMI flow I at the time of the PCI procedure) (visual estimate)
Target lesion(s) is(are) located in a native coronary artery  which can be covered by one single stent of maximum 33 mm
The coronary artery lesion should be >=27 mm in length (a margin of 3mm proximal and 3mm distal is recommended) and should be entirely covered by one single Genous Bio-engineered R stentTM
The inability to position a stiff .035' guidewire in the external carotid artery (ECA).
The investigators will also exclude subjects with hematocrit < 30%.
The laboratory values used for exclusion of subjects will be fasting glucose > 110 mg/dl  glycosylated hemoglobin (HgBA1) > 6.5%  serum creatinine > 1.5 mg/dl  ALT or AST > 2x the upper limit of normal  cholesterol > 250 mg/dl
the need for urgent intervention  defined according to the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines as being patients who are required to stay in the hospital  but may be scheduled and operated on within a normal sch
The patient would be allowed to enroll in the study if the 24-hour test result is < 60 ml/min.
The presence of severe renal impairment (CrCl <30 mL/min or creatinine >3 x ULN)  nephrotic syndrome  or patients undergoing dialysis
Thrombocytopenia (plt < 100 k)  PTT > 100 sec  INR > 3.0 at time of treatment.
Thrombopenia < 100 000/ml
Total bilirubin < 3.0 mg/dL
Total bilirubin within normal institutional limits.
Total bilirubin within normal limits and AST/ALT less than 3 times the upper limit of normal (less than 5 times the upper limit of normal in the presence of liver metastases).
Total lymphocyte count >= 1000 cells/mm3
Transaminases (AST and ALT) <3 X ULN.
Treatment exclusion criteria (obtained after anesthesia induction and before chest incision prior to the start of study drug) include: mean pulmonary artery pressure consistently < or equal to 15mmHg
Treatment with thrombolysis followed by PCI with stent implantation.
Triglyceride concentration of less than 350 mg/dL (less than 3.99 mmol/L) based on blood specimens taken at Visit 1
triglycerides <= 4.00 mmol/L drawn  and liver transaminases (ALT  AST) <=50% above the upper limit of normal at Visit 2  with no active liver disease  and/or creatine kinase (CK) <=50% above the upper limit of normal
Uncontrolled diabetes mellitus (HbA1c >11% within the last 1 month prior to Screening)
Uncontrolled hypertension (diastolic BP > 100 mm Hg or systolic BP > 200 mm Hg)
Untreated  current  and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory
WBC > 15 000/mm3 within 72 hours of surgery
WBC > 4 000/ml  ANC > 1 500/ml  platelets>100 000/ml
Weight greater than 100kg.
White cell counts >= 4 000 cells/mm3
WHO diagnostic criteria for diabetes mellitus is fasting plasma glucose > 7.0 mmol/l (126 mg/dl) or 2-h plasma glucose > 11.1 mmol/l (200mg/dl).
with Karnofsky Score > 70
You must have stable glycemic control.
Zubrod performance status of 0 - 2
Zubrod performance status of 0-1.
Good physical health on the basis of medical history  physical examination  and laboratory screening.
Inclusion Criteria: Presence on a tissue biopsy of large non septated hyphae compatible with zygomycete
Laboratory results: Bilirubin >= Upper Limit Normal (ULN)
Low HDL cholesterol
Non echogenicity
Patient must have a modified SLEDAI score > 3 at both screening and qualifying visits (Appendix A-2)
Patients diagnosed with DME
Patients having any arthrogram of the signal joint within the past 3 months prior to Screening.
Physical examination and laboratory tests of hematologic  hepatic and renal functions
Physical examination and laboratory tests of hematologic  hepatic and renal functions.
Physically acceptable for this study as confirmed by medical history  physical exam  neurological exam  and clinical tests
Serum bilirubin >2.0 x upper limit of normal (ULN)
Stimulator parameters may not be changed for at least 1 month prior to Visit 1 or during the study
Malnourishment (body weight < -2.5 SDS for height and gender) or severe deterioration of fat metabolism
>= 4/5 on manual muscle testing for the deltoid on the affected side if isolated movement is present
Any clinically significant abnormality found during medical screening
Any clinically significant abnormality found during medical screening.
Certified as healthy by a comprehensive clinical assessment (detailed medical history and a complete physical examination).
Clinical diagnosis of exudative AM
Clinical laboratory tests (CBC  blood chemistries  urinalysis) must be within normal limits or clinically acceptable to the investigator at Visit 3 (Baseline Visit).
Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not clinically significant (some exceptions per protocol)
Cord blood meets all selection and testing criteria (see below).
Corneal  lens  or vitreous opacification precluding funduscopic exam.
Corneal  lens  or vitreous opacification that precludes funduscopic exam.
Exclusion Criteria: Abnormal marrow function as defined by leucocyte  neutrophil  or platelet counts outside of normal limits.
Full passive ROM at the wrist and the thumb  index and long finger MCP joints on the affected side
Preserved hematologic  hepatic  and renal function as defined by required lab values.
Patients with acute Intracerebral hemorrhage diagnosed by neuroimaging
Exclusion Criteria: Abnormal EKG
Between 15th and 95th BMI percentile for their age
weigh > 70 kg or have a bmi > 26 kg / m2 at time of screening. 
bmi must be > 27 and < 40 
exclusion criteria - for ra patients: bmi > or = 30. 
bmi (body mass index) 19-30 kg / m2 (42-66 lb / m2) 
normal body mass index (18-30 kg / m2). 
body mass index (bmi  kg / m(2)) > or = 30 and < or = 19. 
have a body mass index (bmi) >= 18 kg / m2 
body mass index (bmi) >= 85 th percentile for age and gender 
normal weight-for-height weight 50-80 kg 
patient is >= 60' in height. 
have height or weight < the 5 th percentile. 
normal high blood pressure of 80-89 mm hg. 
diastolic blood pressure between 78 and 89 mm hg 
blood pressure > 140 / 90 mm hg must be treated and maintained < 170 / 100 mm hg on antihypertensives 
systolic blood pressure < 120 mm hg 
Any food allergy  intolerance  restriction or special diet that  in the opinion of the Medical Sub- Investigator  could contraindicate the subject's participation in this study.
Exclusion Criteria: Habitual dietary intake of less than 30% fat
Had been previously prescribed a cholesterol lowering diet and exercise program at least 4 weeks prior to Visit 1 and had been advised to continue the same diet and exercise program during the study
Ingestion of grapefruit or grapefruit juice within 1 week of the study and a willingness to abstain from the consumption of grapefruit or grapefruit juice for the duration of the study.
Lack of access to regular meals
Subjects must have maintained a cholesterol lowering diet program for at least 4 weeks prior to the study and be willing to continue the same diet program during the study.
This patient must has been under proper but insufficient hygieno dietetic diet
Use of grapefruit juice products
Any use of dietary  herbal  and/or fitness/body-building supplements (with the exception of vitamins)
cholesterol lowering diet and exercise program for at least 4 weeks prior to and during the study  and stable weight history.
Subjects must have failed a cholesterol-lowering diet and exercise program of at least 4 weeks duration prior to Visit 3 (Baseline Visit).
Subject is willing to follow the AHA diet and exercise program throughout the study
Subjects who have been on an abnormal diet (for whatever reason) during the 28 days preceding the study
Abnormal cardiac or cardiovascular function  or serious cardiac illness or medical condition in the previous 6 months including  but not confined to: New York Heart Association (NYHA) grade 2 or higher congestive heart failure (CHF) or who has had angiopl
Inclusion Criteria: Clinical diagnosis of type I diabetes and using daily insulin therapy for at least twelve months
2 before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated  III or IV  totally removed  in total remission 
5 times normal (grade 2 or less) at the start of the study.
Absence of ischemic changes on EKG  
Accepts Healthy Volunteers: Grade II to IV GVHD
Patients who develop Grade II  III  or IV acute GVHD following allogeneic hematopoietic cell transplantation
Adequately treated stage I or II cancer for which patient is currently in complete remission
Advanced (Stage III or IV)  histologically-documented epithelial ovarian cancer or primary peritoneal cancer (excluding small  round-cell histologies).
All groups : Heart failure (NYHA class >= II)
American Society of Anesthesiology (ASA) physical classification I to III
Based upon a knee X-ray performed within 6 months prior to Screening  the radiograms must be classified as a Grade II or III for osteoarthritis of the knee according to the Kellgren & Lawrence grading system based upon a radiologist's written report or in
Baseline score >= 14 on the HAM-D17.
Cancer stage I or II (except T4 operated in emergency) or IV without possibility to remove metastasis or R2 after surgery.
CHF patients in Class III and class IV NYHA symptoms who have had a minimum of one acute decompensated episode in the previous six months
Clinical stage T 1-4  N 0-3  M0
Clinically significant valvular abnormality or pericardial effusion (associated with NYHA class II-IV symptoms)
Current treatment with an ACE-I or ARB (Note: can participate if on ACE-I after 6 week washout period)
Diagnosis: borderline personality disorder by DSM-IV criteria
Documented bacterial/fungal/viral infection requiring administration of IV antibiotics within 7 days before surgery
Early stage disease (any T  any N  M0)
Exclusion Criteria: Congestive heart failure (defined as New York Heart Association class III or IV heart failure)
Exclusion Criteria: HAM-D17 item 3 score>= 3.
Exclusion Criteria: Known significant CVD (history of MI  recurrent stroke  or NYHA class III or greater).
Exclusion Criteria: No DSM-IV diagnosis other than schizophrenia
Exclusion Criteria: Other current or past DSM-IV Axis I diagnosis
For panels B and C  subject may be treated with combination oral anti-hyperglycemic medications
Grade 1 or higher peripheral neuropathy.
Grade 2 or 3 AIN is interchangeable with high grade SIL.
Have at least one of the Class P-2 symptoms (by CDC criteria).
Have documentation indicating that the patient was consistently New York Heart Association (NYHA) Class III or IV during the 60 days before randomization
History of ACE-I induced angioedema
history of congestive heart failure (New York Heart Association [NYHA]Class III or IV)
History of diabetes (Type I or Type II)
History of grade 2 or higher peripheral neuropathy.
HLA-matched unrelated donor (10/10 match on high-resolution [HR] typing of HLA-A  B  C  DRB1  and DQB1)
IBS-C patients diagnosed on the basis of Rome II criteria
IIb-IIIa stage
Inclusion Criteria: CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease
Inclusion Criteria: Chronic symptomatic NYHA Class II or III CHF for at least 90 days before the study
Inclusion Criteria: confirmed diagnosis of schizophrenia according to DSM-IV-IV from patient's medical files
Inclusion Criteria: Diagnosis of idiopathic Parkinson's Disease  Modified Hoehn & Yahr up to stage III  UPDRS motor score (part III) must have a total of at least 10 at baseline.
Inclusion Criteria: DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence
Inclusion Criteria: Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
Inclusion Criteria: Japanese patients with a DSM-IV diagnosis of schizophrenia
Inclusion Criteria: NYHA class II-IV CHF
Inclusion Criteria: Proven  peripheral arterial disease  Fontain II-III stage  patient submitted to secondary prophylactic thrombocyte aggregation inhibiting treatment
Inclusion Criteria: Soft tissue sarcoma chemosensible  stage IV
Inclusion Criteria: Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
Insulin dependent diabetes (Type I)
Karnofsky performance status (KPS) >=  70% (see Appendix III).
May have history of substance use and other Axis II disorders
Meets DSM-IV>=  criteria for a primary diagnosis of schizophrenia.
Met the DSM-IV and NINCDS-ADRDA criteria for AD.
New York Heart Association heart failure stage III or IV
Not classified as morbidly obese (body fat greater than 30% for men and 35% for women)
NOTE: The terms condyloma  grade 1 AIN  and low grade SIL are interchangeable
NYHA Class III or IV heart failure
One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing)  mismatched at HLA-A  B  DRB1  or DQB1 (only when HLA-C mismatch is not available)
Patients entering the Phase 2 portion of the study must have a histologically or cytologically documented diagnosis of advanced (Stage IIIb/IV) NSCLC.
Patients must not have any pre-existing neuropathy of grade > 1.
Patients must not have history of congestive heart failure of any grade according to Heart Association (NYHA) (see Appendix 2).
Patients will be eligible for enrollment if they fulfill the following criteria: Histological diagnosis of surgically resected Stage IIB  IIC  Stage III or Stage IV (AJCC criteria) melanoma independent of NY-ESO-1 expression in a tumor biopsy
Patients with a removed colorectal tumour which is histologically proved and classified N+ and/or M+ (stage III or IV)
Patients with Kellgren-Lawrence Grade IV OA  .  large osteophytes  marked narrowing  severe sclerosis  and definite deformity) and Grade I OA of the knee.
Patients with moderate or severe cardiac failure (New York Heart Association class III and IV)
Peripheral neuropathy grade >=  2
Permission of the subject's primary physician to participate in the aquatic class
Phase I - Current grade 1 AIN  .  low grade SIL) OR treated or untreated grade 2 or 3 AIN  .  high grade SIL).
Phase II - Prior histologically confirmed grade 2 or 3 AIN / high grade SIL  with ablative therapy within the past 30-90 days.
Positivity for HBV antigens (HBs Ag  HBe Ag)  and HCV  HTLV-I and HTLV-II antibodies
Preexisting peripheral neuropathy must be equal to or less than grade 1
Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
Subjects with NYHA Class III or IV heart failure  or LVEF <30
Inclusion Criteria: Diabetes type II according to 1985 WHO criteria.
bifurcation lesion requiring stenting of main and side branch
Gastroenteritis within 7 days preceding the first study vaccine administration.
Pneumocystis carinii pneumonia prophylaxis.
Pulmonary disease (COPD  asthma or other condition) that required inpatient medical or surgical treatment within 60 days before surgery
Target lesion has excessive tortuosity unsuitable for stent delivery and deployment
Patient must be a candidate for resection of the recurrent tumor
(2) muscle weakness in a characteristic distribution (distal predominant)
(Was written as - No current retinal detachment (although old retinal detachments unrelated to HIV infection which have been repaired are permitted).
Within these three months of treatment  the subject's cognitive condition must be clinically unchanged or worse for the subject to be acceptable
Ventricular arrhythmias requiring chronic drug treatment or ICD
The patient has earlier /within 6 months/ obtained treatment because of BPH
Weakness of sufficient severity to justify treatment and provide a reasonable opportunity to observe a therapeutic effect
Allowed: Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).
Angina pectoris requiring anti-anginal treatment
CAD with indication for bypass surgery
CMV prophylaxis.
Currently undergoing or recommended to undergo treatment of pelvic organ prolapse
Radiologically-documented evidence of progressive disease.
>=  50% stenosis for symptomatic subjects
>=  80% stenosis for asymptomatic subjects or
Exclusion Criteria: Signs or symptoms of severe malaria
Not balanced diabetes
hallucinations) and /or sleep attacks.
Have uncontrolled partial seizures despite having been treated with at least three different AEDs (given concurrently or sequentially) for at least 2 years.
Exclusion Criteria: Congenital DM-1
Inclusion Criteria: Diagnosis of Juvenile or Adolescent Idiopathic Scoliosis
no CKD for control group
Inclusion Criteria: moderate to severe fatigue >6 months after last chemotherapy or radiation treatment >5 years from diagnosis
Relapsed following high-dose chemoradiotherapy including autologous stem cell transplantation
Achieved a complete remission (CR)  very good partial remission (VGPR)  or partial remission (PR) after >= >= 2 different salvage regimens  as defined by the following: In CR after treatment with some form of salvage therapy  .  >= I-MIBG  antibody-bas
sensation of incomplete evacuation
Be refractory to medication
Patients with chronic non-cancer pain that necessitates the use of non-injectable opioid analgesics
history of a neurologic event (cerebrovascular accident  transient ischemic attack or carotid endarterectomy)
Exclusion: Have onset of migraine after age 50
Exclusion Criteria: excluded medical conditions like: pre-existing neuropathy  active heart diseases or ischemia  serious infections  HIV infection  chronic hepatitis B or C  brain metastasis  seizures  hypersensitivity to taxanes  organ transplants  some
Presence of a progressive central nervous system (CNS) disease  including degenerative CNS diseases and progressive tumors.
There is no diffuse leptomeningeal disease
Any clinically significant history of ongoing problems or problems known to interfere with the absorption  distribution  metabolism or excretion of drugs of drugs
Any clinically significant gastrointestinal pathology or unresolved gastrointestinal symptoms susceptible of interfering with the absorption of drugs
de-novo stenosis
Diagnosed as having Plasmodium falciparum uncomplicated malaria.
Evidence of cathartic colon or a history of laxative use  that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study
Evidence of hand pain as defined by current metacarpophalangeal (MCP) joint pain upon palpation and/or wrist or MCP pain upon extension
History of schizoaffective disorder and not stabilized on a mood stabilizer  .  lithium  valproate  carbamazepine)
Immune compromise due to HIV infection  organ transplantation  or treatment of malignancy
Inclusion Criteria: History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.
Uncontrolled diarrhea or nausea preventing ingestion of medicine.
Exclusion Criteria: Systemic illnesses that have an adverse effect on balance
straining while having a bowel movement
Demonstrated reversible airflow restriction.
2nd or 3rd degree heart block without pacemaker treatment
Inclusion Criteria: Patients with acute myocardial infarction (ST elevation in at least 2 leads >=  0.2 mV in V1 V2 or V3 or >=  0.1 mV in other leads)  treated by one of the following procedures:
Untreated or under-treated major depressive disorder
(Note: Prior history of deep vein thrombosis will not exclude subjects from participating in this study.)
Significant prenatal diagnosed focal brain lesions
Marfan syndrome with recognized aortic root dilation
History of evidence of a medical or neurological condition that would expose the subject to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the trial
Patients with a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
Patients with the following are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Patients with the following conditions or symptoms are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Inclusion Criteria: Severe obstructive sleep apnea 
Chronic Hypertension
History of Stage III hypertension (diastolic BP > 110 mmHg or systolic BP > 180 mmHg) or a history of hypertensive urgency or emergency.
Again  if bilateral knee pain is present  the investigator will select the more painful knee and the contralateral knee must have a VAS pain score of < 30 mm.
Any condition or situation that  in the opinion of the investigator  might pose a risk to the subject or interfere with participation in the study.
Clinically significant medical history
Opioid-induced constipation (OIC) is defined as follows: less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions:
Patients who require the use of manual maneuvers to have a bowel movement
Unstable medical condition
Patients must have had knee pain in the signal knee on at least 50% of the days in the month preceding Screening.
(2) muscle weakness in a characteristic distribution (distal predominant)
Serious  non-healing wound  or bone fracture.
(Was written as - No current retinal detachment (although old retinal detachments unrelated to HIV infection which have been repaired are permitted).
A clinical diagnosis of AD.
Acute disease at time of enrollment.
Any cervical condition that would make ROM & strength testing painful.
Any disorder initiating or maintaining sleep such as Obstructive Sleep Apnea  Insomnia  Restless Leg Syndrome  Periodic Limb Movement Disorder  Circadian Rhythm Disorder and Parasomnia
Any other clinical relevant serious disease  including uncontrolled Diabetes  severe liver disease  or severe renal disease at the time of randomization
Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study
Any unstable cardio-vascular disease   unstable hypertensive disease needing modification or introduction of an anti-hypertensive treatment)
Axillary temperature >=  37.5??C and/or history of fever in the previous 48 hours without any other evident cause
Babies born to mother with either clinical chorioamnionitis  preterm and prelabor rupture of the membranes (PPROM)  or preterm labor
chronic diarrhea  inflammatory bowel diseases)  unresolved gastrointestinal symptoms  
chronic diarrhea  inflammatory bowel diseases)  unresolved gastrointestinal symptoms  
Chronic renal failure on hemodialysis
Clinically significant history or presence of any clinically significant gastrointestinal pathology  
Clinically significant history or presence of any clinically significant gastrointestinal pathology  
Clinically significant history or presence of any clinically significant gastrointestinal pathology  unresolved gastrointestinal symptoms  liver or kidney disease  or other conditions known to interfere with the absorption  distribution  metabolism  or ex
Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet
Co-existing Condition: Patients with any of the following conditions or symptoms are excluded:
Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Conditions listed in Exclusion Co-Existing Conditions and symptoms.
Congestive heart failure at time of enrollment
coughing up or vomiting blood
Current clinically significant suicidal ideation
Current history of panic disorder  obsessive-compulsive disorder  alcohol or substance abuse.
cystic fibrosis and coeliac disease) special educational needs  
Development of any of the medical conditions listed as exclusion criteria for the CHTF919N2201 study.
diarrhea  vomiting)  liver or kidney disease  or other conditions known as interface with the absorption  distribution  metabolism  or excretion of the drug.
diarrhea  vomiting)  liver or kidney disease  or other conditions known as interface with the absorption  distribution  metabolism  or excretion of the drug.
dry eye ocular signs
Excluded: Prophylaxis for oral candidiasis or otitis media or other infections.
Exclusion Criteria: Anti-GBM disease  Dialysis-dependency or pulmonary hemorrhage
Exclusion Criteria: chronic illnesses with dietary management implications  
Exclusion Criteria: Clinically significant abnormalities found during medical screening
Exclusion Criteria: Clinically significant illnesses within 4 weeks of the administration of study medication
Exclusion Criteria: Cognitively impaired
Exclusion Criteria: Diabetes diagnosed <6 months of age
Exclusion Criteria: Diabetics are excluded.
Exclusion Criteria: diagnosis of anxiety disorder or chronic pain syndrome chronic disabilities or developmental delays are currently on psychotherapeutic or sedating medication are on chronic pain medication or opiate any known adverse effect to the stud
Exclusion Criteria: History of ventricular arrythmias or any other arrythmias  
Exclusion Criteria: Known diabetics
Exclusion Criteria: Subjects must not have any significant medical condition which  in the judgment of the Investigator  is a contraindication to the use of phenylephrine HCl  might interfere with the study or requires treatment expected to affect the blo
Existing Mental Health issues
fever >38.5 C  vomiting  diarrhea  wheezing  or crackles).
fractures of the extremities combined with blunt/penetrating visceral trauma
Frequent vomiting or medical condition that could interfere with oral medication intake  
Have a history of psychogenic seizures in the past 2 years.
Have diarrhea an average of 3 times a day for at least 3 weeks.
Have nausea and/or vomiting an average of 2 times per day for at least 1 week.
History of acute MI within the last 6 months
history of bleeding diathesis (ie
History of previous closed head trauma or brain injury
history of coronary heart disease (type II diabetic patients > 30 years old with no CHD)
History of previous closed head trauma or brain injury
History of uncontrolled psychiatric condition within 6 months prior to Day 1.
If they have musculoskeletal or neurological deficits that preclude increased physical activity
immunocompromised
Inclusion Criteria: documented dry eye history
Inclusion Criteria  for health facilities were: 1) public and licensed private health facilities providing outpatient services  and 2) the level of care was appropriate for use of Integrated Management of Childhood Illness (IMCI) guidelines.
Inclusion Criteria: Patients with end stage renal disease on hemodialysis
Inclusion Criteria: Sexually active male patient with lower urinary tract symptoms indicative of severe BPH  at whom disturbances of urinary retention and urination are present
Inclusion Criteria: TID diagnosis confirmed by presence of at least 1 diabetes autoantibody Children >=  1 years
Intractable or frequent vomiting that regularly interfered with eating
Life-time history of bipolar disorders  schizophrenia or schizoaffective disorder.
Major deterioration of the abdominal cavity  
Major deterioration of the abdominal wall  
Measurable neurologic deficit other than isolated facial weakness  sensory loss or ataxia
Mixed UI as evidenced by stress and urge symptoms reported on MESA (either percent of urge-type symptoms >=  the percent of stress-type symptoms or urge symptom score >= 7 if stress predominant) followed by report of 'moderately' or 'greatly'/'quite a b
More than mild diarrhea (defined as more than transient or > 4 loose stools per day).
ocular symptoms
Orthostatic hypotension in the history
Patient has severe pain from causes other than PHN.
Patient must meet at least four of the eleven ACR criteria for systemic lupus
Patient with end stage renal disease or receiving hemodialysis treatment
Patients must also have measurable disease outside of the irradiated field
Patients must meet one of the following criteria: Have at least one of the class P-2 symptoms (by CDC criteria).
Patients of either sex  any race  aged over 50 years and over  diagnosed with exudative (wet) AMD in one eye (non-study eye) and non-exudative (dry) AMD (intermediate or large/confluent drusen  with hyperpigmentation  and no CNV or geographic atrophy) in 
Patients with a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
Patients with any inter-current chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6 month follow-up of the study such as peptic ulcer  liver disease  severe coronary disease  renal 
Patients with known history of inflammatory skin disorders  . psoriasis  lupus) that may be exacerbated by Resiquimod.
Patients with soft tissue disease are eligible provided they exhibit either a VGPR or PR in the primary soft tissue mass and in any sites of metastatic soft tissue disease
Patients with stroke will be selected based on the following criteria: 85 years old or less with a history of ischemic stroke within 3 months resulting in mild to moderate neurological impairment (Rankin scale < 3)
Patients with the following are excluded: History of seizures
Patients with the following symptoms or conditions are excluded: Active medical problems for which the patient is undergoing evaluations or for which prohibited therapy is required.
Platinum-resistant disease defined as having a best response of SD or disease progression during or within 6 months of discontinuing a platinum-based chemotherapy (carboplatinum  cisplatinum  or another organoplatinum compound).
post-stroke duration >=  1-mo  but < 24-mo
Post-traumatic aneurysm
shoulder pain sustained for >=  1-mo
Significant diarrhea
Stable disease
Subject has active hepatitis B (HbsAg +).
Subject has chronic or paroxysmal atrial fibrillation that is not treated by Coumadin.
Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach.
Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration.
Subjects with clinically apparent cardiovascular disease including prior history of cardiac angina  MI  interventional percutaneous procedures  coronary artery bypass graft  congestive heart disease  cerebral vascular accident  peripheral vascular disease
Subjects with moderate or severe COPD or on home oxygen.
tear use
Unevaluated hematuria
With a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
Women in an immunocompromised state (diabetes  HIV  on chronic immunosuppressants or steroids  etc)
Exclusion Criteria: Untreated hypothyroidism (TSH > 4.25 UIU/ML)
Exclusion Criteria: Patients with colorectal cancer  previous colonic surgery  active colitis and musculoskeletal problems Patients may also be excluded after the first insertion  if painful  routine care will proceed
(G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator
(Note: Prior history of deep vein thrombosis will not exclude subjects from participating in this study.)
(Patients with a CNS mass or history of seizure disorder may enroll.)
(Sharpening of the tibial spine is not considered to be an osteophyte).
(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)
(Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)
A 30-day washout period must be achieved for any patient involved in a previous clinical study.
A current diagnosis of active peptic ulceration.
A current diagnosis of acute  severe  or unstable asthmatic conditions.
A current diagnosis of any primary neurodegenerative disorder  e.g.  Parkinson's disease.
A current diagnosis of severe and unstable cardiovascular disease.
A current diagnosis of sick-sinus syndrome or conduction deficits (sino-atrial block  second or third degree atrio-ventricular block).
A current diagnosis of uncontrolled seizure disorder.
A diagnosis of unstable angina  NSTEMI  or STEMI
A disability that may prevent the subject from completing all study requirements  .  blindness  deafness  severe language difficulty).
A documented history of transient ischemic attacks.
A history of chronic obstructive lung disease 
A history of current or recurrent disease that could have an effect on the study
A patient will be ineligible for study entry if he/she meets any of the following exclusion criteria: has planned aortic dissection repair and/or requires aortic root reconstruction
A radiated bony lesion may not be considered an evaluable lesion  unless there is evidence of disease progression at that site prior to administration of study drug.
Ability to tolerate NMES to the ECR and EDC for full wrist and finger extension
Abnormalities on screening chest x-ray suggesting clinically significant active pulmonary disease other than CF  or new  significant abnormalities such as atelectasis or pleural effusion which may be indicative of clinically significant active pulmonary i
Absence of histologic or mycologic zygomycosis documentation 
Accepts Healthy Volunteers: Diagnosis of von Hippel-Lindau syndrome (VHL) by the Urologic Oncology Branch using germ line analysis OR clinical criteria and family history
Active AIDS-defining illness or other clinically significant or uncontrolled medical problems
Active asthma or bronchospasm
Active asthma or bronchospasm
active autoimmune disease.
Active bleeding diathesis or coagulopathy  or will refuse blood transfusions
Active cholecystitis  gall bladder symptoms  or potential hepato-biliary abnormalities
Active congestive heart failure  angina and/or arrhythmia requiring therapy or previous myocardial infarction
Active infection
active infection
Active infection
Active infection or fever or diarrhea within last 4 weeks.
Active infection requiring systemic antibiotics  antivirals  or antifungals including HIV/AIDS  hepatitis B  or hepatitis C infection.
Active infection.
Active opportunistic infections
active symptoms of coronary artery disease  uncontrolled seizure disorder
Active ulcus pepticum
Active  unstable severe cardiovascular disease  including poorly controlled angina  congestive heart failure (CHF)  arrhythmias  myocardial infarction (MI)  cardiomyopathy  atrioventricular (AV) block  electrocardiogram (ECG) evidence of acute ischemia  o
Acute and chronic heart failure
Acute bacterial  fungal or viral infection
Acute decompensated heart failure cohort defined as: Objective evidence of heart failure (of any cause/etiology) demonstrated by typical symptoms/signs combined with an imaging modality (see appendix for criteria)
Acute disc herniation  discopathy or spondylolysis
Acute gastric ulcer
Acute or chronic pulmonary  cardiovascular  hepatic  renal or neurological condition  malnutrition  or any other clinical findings that in the opinion of the clinical investigator may increase the risk of participating in the study
Acute or chronic pulmonary  cardiovascular  hepatic  renal or neurological condition  malnutrition  or any other clinical findings that in the opinion of the PI may increase the risk of participating in the study
Acute thrombosis
ADPKD  diagnosed by the following findings on ultra scan: for patients without ADPKD family history: > 5 bilateral cysts
Allowed: Prophylactic pentamidine for Pneumocystis carinii pneumonia (PCP).
An acute illness with fever (rectal temperature >=  100.4>= F [38.0>= C]) in the 72 hours preceding enrollment in the trial (defer enrollment).
Anamnestic or clinical signs of acute myocardial infarction  atrial fibrillation  heart valve disease or chronic heart failure
Anamnestic or clinical signs of disease in lungs  liver endocrine organs or brain or neoplastic disease
And absence of significant functional or anatomic abnormalities suggestive of atherosclerosis on non-invasive arterial studies (measurements of intima-media thickness  pulse wave velocity  ankle-brachial index  >= ).
And normal coronary angiography performed because of suspected coronary artery disease
and/or documented history of unstable angina or non-Q wave myocardial infarction.
and/or documented history of unstable angina or non-Q wave myocardial infarction.
Aneurysm developed on native infra-renal aorta or iliac.
Angina pectoris that requires antianginal medication
Antiretroviral therapy for human immunodeficiency virus (HIV)
Antiretrovirals.
Any active uncontrolled infection including AIDS  hepatitis B or C.
Any chronic organic disease of the CNS (other than schizophrenia)
Any clinically significant history of chronic gastrointestinal disease.
Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  immunologic  psychiatric  or metabolic disease
Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  psychiatric  or metabolic disease.
Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  psychiatric  or metabolic disease.
Any condition or disease that may interfere with the evaluation of at least 2 lumbar vertebrae (not necessarily contiguous)  determined in a screening radiograph by a radiologist at the central facility (eg  confluent aortic calcifications  severe osteoar
Any confirmed or suspected immunosuppressive or immunodeficient condition  based on medical history and physical examination (no laboratory testing required).
Any evidence of renal dysfunction (proteinuria
Any heart attack  stroke or TIAs within the last 6 months or serious arrhythmias needing medication
Any history of bleeding disorder.
Any known congenital heart disease
Any medical condition that may be exacerbated by bleeding  including a known bleeding disorder such as a coagulation defect  thrombocytopenia  active gastric or duodenal ulcer  or history of GI bleeding.
Any other solid lesion(s) of the pancreas
Appropriate studies will be undertaken in HIV-positive patients who are receiving or not receiving combination anti-retroviral therapy when indicated.
Are known to be infected with human immunodeficiency virus (HIV)  hepatitis B or hepatitis C
Arterial stenosis on unique kidney - arterial bilateral kidney stenosis
Asymptomatic aneurysm
Asymptomatic aneurysm
At least 6 years of education  or sufficient work history to exclude mental retardation.
Atrial fibrillation/flutter
Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at least once in the previous 7 days OR Having been treated with a course of oral or intraveno
Bi-dimensionally measurable lesions
bleeding disorder
both history of liver disease & abnormal liver enzyme lab results
Cardiac arrhythmia
Cardiac disease
Cardiovascular DiSease
caregivers having severe illnesses
Chest radiography showing evidence of active or acute cardiac or pulmonary disease
Chronic Heart Failure cohort defined as: Echocardiographic evidence of systolic or diastolic heart failure (see appendix for criteria)
Chronic inflammatory disease
Chronic liver  heart  kidney  or ( untreated) thyroid disease
Chronic medical  congenital  or developmental disorder that  in the opinion of the investigator  could interfere with trial conduct or completion.
Chronic or acute renal  hepatic or metabolic disorder.
Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
chronic total occlusion
Clinical findings: skin thickening  joint contraction  oral ulceration  diarrhea.
Clinical findings: skin thickening  joint contraction  oral ulceration  diarrhea.
Clinical signs of myopic retinopathy  or refraction higher than -8 diopter power.
Clinically asymptomatic HIV-1 infected individuals (CDC Clinical category A)  as determined by two positive Enzyme-linked immunosorbent assay (ELISA) and a confirmatory Western Blot
Clinically significant disease  as determined by the investigator  that would compromise the ability of the participant to complete the study requirements
Clinically significant fatigue (4.5+ on Fatigue Severity Scale with duration 3+ months plus impairment in 1+ categories of role function)
Clinically significant history of diabetes.
Clinically significant history of diabetes.
Clinically significant history of hyperthyroidism.
Clinically significant history of hyperthyroidism.
Clinically significant illness within 4 weeks prior to the administration of the study medication
Clinically significant illness within 4 weeks prior to the administration of the study medication
Clinically significant illnesses within 4 weeks of the administration of study medication
Clinically significant illnesses within 4 weeks of the administration of study medication
Clinically significant illnesses within 4 weeks of the administration of study medication
Clinically significant peripheral vascular disease.
Clinically significant pulmonary or neurologic impairment other than seizure disorder or CNS mass lesion.
Clinically significant pulmonary or neurologic impairment  such as intubation or coma
Coenrolled in AIEDRP CORE01 trial
cognitive deficits
Cognitive impairment
Cognitive impairment sufficient to warrant a diagnosis of dementia.
Co-infection with HCV or HIV
Coma.
Comatose at screening
Co-morbid illness expected to cause death within 6 months
complete occlusion of target vessel
Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation
Concomitant conditions listed in Exclusion Co-existing Conditions.
Concomitant conditions  diseases  medications and/or clinical history
Concurrent uncontrolled cardiovascular  hematologic  respiratory  CNS  gastrointestinal disease or chronic alcoholism.
Confirmed or suspected autoimmune disease
Confirmed or suspected autoimmune disease
Confirmed or suspected immunosuppressive or immunodeficient condition  including human immunodeficiency virus (HIV) infection
Confirmed or suspected immunosuppressive or immunodeficient condition  including human immunodeficiency virus (HIV) infection
Congenital disease constitutes ~10% of all cases of DM-1
Constipation  according to the investigator's clinical judgment  that is resulting from opioid use for non-cancer chronic pain
Constipation  according to the investigator's clinical judgment  that is resulting from opioid use for non-cancer chronic pain
Contraindication to ARBs  such as history of angioedema to ARBs  renovascular hypertension
Contralateral occlusion of internal carotid artery and vertebral arteries.
CT or MRI since onset of memory impairment demonstrating the absence of a clinically significant focal lesion
Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern  .  a history of severe heart  liver  or kidney disease or diabetes mellitus
Current enrollment in any other clinical study
Current evidence of or history of diabetes mellitus or hypoadrenalism
Current history of uncontrolled hypertension  insulin dependent or uncontrolled diabetes  cardiovascular disease unless controlled and stable for 6 months or more  bleeding disorders  or autoimmune disorders such as fibromyalgia  chronic fatigue syndrome 
Current presence of dyskinesias 
Current sleep disorders such as nightmare disorder  restless legs syndrome  or suspected sleep disorder requiring polysomnographic assessment  such as obstructive sleep apnea or periodic leg movements.
Currently receiving antiretroviral therapy (other than the intrapartum NVP or other peripartum regimens)
Cystic fibrosis (Celiac disease and adequately treated thyroid disease do not exclude subjects from enrollment)
death due to the sickness within four weeks
dermal infections or burns  hernia)
Developmental delay  neurologic disorder  or seizure disorder.
diabetes and currently taking an oral hypoglycemic agent or insulin
diabetes mellitus
Diabetes mellitus
Diabetes mellitus or liver and renal dysfunction or asthma
diabetes  autoimmune diseases  corneal thickness less tha 400 micron.
Diabetic patients of over 10 years duration with impaired glucose control  after at least 6 months of accepted treatment in a Diabetes Clinic by the study staff before inclusion in the study  who exhibit symptoms which could signify the possibility of dia
Diagnosis of asthma for at least 6 months.
Diagnosis of congestive heart failure for at least 3 months
diagnosis of dementia at admission
Diagnosis of probable Alzheimer's disease
Documented atherosclerotic disease  CHD  or diabetes mellitus
Documented CHF
documented coronary heart disease
documented history of atherothrombotic cerebrovascular disease
documented history of atherothrombotic cerebrovascular disease
documented history of cardiovascular disease including coronary artery disease  uncontrolled hypertension  aortic stenosis  congestive heart failure  cardiac arrhythmias or conduction defects greater that first degree atrioventricular (AV) block  sinoatri
Documented HIV-positive subject.
Documented or suspected liver disease (including laboratory evidence of hepatitis)
Does not have a chronic disease that affects calcium or bone metabolism  .  asthma with chronic use of high dose steroids  inflammatory bowel disease  Crohn's disease  primary hyperparathyroidism  seizure disorder with use of phenobarbital  etc.).
Drugs that have or will cause prolonged neutropenia  significant pancreatitis  significant nephrotoxicity  or peripheral neuropathy within 1 week of entry.
Early in life  the weakness in individuals with congenital DM-1 derives from maldevelopment of skeletal muscle rather than muscle degeneration
Encephalopathy
epilepsy  thyroid disease  HIV  etc.
ESRD
Evaluable CMV retinitis with photographable lesions.
Ever received any influenza vaccine  other than at Visits 1 and 2 of study GRC28  or known to have ever been diagnosed with laboratory-confirmed influenza.
Evidence of autoimmune disease including  but not limited to  ulcerative colitis  Crohn's disease  rheumatoid arthritis (RA)  systemic lupus erythematosus (SLE) sceloderma  or another diseases in which immune function or immune competence is known to be i
Evidence of clinical symptoms from a hemorrhagic or nonhemorrhagic stroke with all symptoms from previous stroke(s) completely resolved
Evidence of nasal or pharyngeal obstruction on physical examination.
Evidence of past or present CNV in the study eye
Excluded: (within 30 days prior to study entry)
Exclusion Criteria: absence of polycystic ovarian syndrome  hydrosalpinx or endometriosis.
Exclusion Criteria: Advanced  severe  and unstable disease of any type that may interfere with primary and secondary variable evaluations including any medical condition that could be expected to progress  recur  or change to such an extent that it may bi
Exclusion Criteria: Any severe medical illness that  in the opinion of the investigator  will interfere with the ability to adhere to therapy or will result in making therapy too risky for the patient
Exclusion Criteria: atrial fibrillation  abnormal hearth rhythms
Exclusion Criteria: Axis I diagnosis of schizophrenia  schizoaffective disorder  or bipolar I disorder during the subject's lifetime
Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Exclusion Criteria: Complicating medical issues that would interfere with blood drawing or monitoring.
Exclusion Criteria: Considered by the investigator to be at imminent risk of suicide or injury to self  others  or property.
Exclusion Criteria: Current evidence of other causes of dementia
Exclusion Criteria: depression: score > 12 on the Geriatric Depression Scale
Exclusion Criteria: Diabetes mellitus
Exclusion Criteria: Diagnosis is unclear or a suspicion of other parkinsonian syndromes 
Exclusion Criteria: Diagnosis of COPD.
Exclusion Criteria: Do not suffer from a serious mental illness
Exclusion Criteria: evidence of joint or overlying skin infection
Exclusion Criteria: Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
Exclusion Criteria: Existence of congenital anomalies and genetic disease
Exclusion Criteria: Have a diagnosis of learning disability or organic brain syndrome.
Exclusion Criteria: Have had a myocardial infarction within 30 days prior to Day -1
Exclusion Criteria: Health facilities in which the level of care was not appropriate for use of Integrated Management of Childhood Illness (IMCI) guidelines .  one referral hospital and one sub-specialty hospital).
Exclusion Criteria: Hemorrhagic stroke 
Exclusion Criteria: History of AIDS-related opportunistic or neoplastic disease
Exclusion Criteria: History of medical condition that would preclude scheduled study visits
Exclusion Criteria: History of mental illness
Exclusion Criteria: History of Type 1 diabetes
Exclusion Criteria: History of unstable angina  any recent angina (defined as chest pain) in the past 3 months  recent myocardial infarction (less then 3 months)  any history of ventricular arrhythmia  presence of left ventricular bundle branch block on E
Exclusion Criteria: History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy  e.g.  deep vein thrombophlebitis  thromboembolic disorders  cerebral vascular or coronary artery disease  etc.
Exclusion Criteria: History or presence of significant cardiovascular  pulmonary  hepatic  renal  hematologic  gastrointestinal  endocrine  immunologic  dermatologic  neurologic or psychiatric disease
Exclusion Criteria: History or presence of significant cardiovascular  pulmonary  hepatic  renal  hematologic  gastrointestinal  endocrine  immunologic  dermatologic  neurologic or psychiatric disease.
Exclusion Criteria: Hyperparathyroidism
Exclusion Criteria: lesion in saphenous vein graft
Exclusion Criteria: Not cases of Kawasaki disease
Exclusion Criteria: Other kidney disease
Exclusion Criteria: Patient has evolving stroke or intracranial hemorrhage
Exclusion Criteria: Patients who are in third degree heart block
Exclusion Criteria: Patients who are receiving opioids for abdominal pain or connective tissue disorders.
Exclusion Criteria: Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
Exclusion Criteria: patients with significant cardiovascular illness (recent acute myocardial infarction  uncompensated heart failure  cardiac arrhythmia)
EXCLUSION CRITERIA: Presence or history of clinically relevant cardiovascular  hepatic  pulmonary  gastrointestinal  renal  metabolic  hematological  neurologic or psychiatric disease  any acute infectious disease or signs of acute illness  and myasthenia
Exclusion Criteria: Prior myocardial infarction
Exclusion Criteria: Psychiatric conditions other than depression
Exclusion Criteria: psychiatric disorders
Exclusion Criteria: Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.
Exclusion Criteria: Respiratory disease other tha asthma
Exclusion Criteria: Sickness  psychopathology or developmental disabilities
Exclusion Criteria: Significant medical disease including: uncontrolled congestive heart failure
Exclusion Criteria: Significant neurologic disease such as Parkinson's disease  stroke  brain tumor  multiple sclerosis  or seizure disorder
Exclusion Criteria: Subject has a history of stroke  seizures  or other neurological disorders
Exclusion Criteria: Subject is mentally or legally incapacitated  has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder ov
Exclusion Criteria: Subject may not have Class IV congestive heart failure.
Exclusion Criteria: Subject with an HIV primo-infection status
Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study.
Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study.
Exclusion Criteria: Subjects with recent (within 30 days of randomization) or current opportunistic infection or neoplasm characteristic of AIDS (Category C of the CDC Classification System for HIV-1 infection  1993 Revised Version).
Exclusion criteria: Subjects with uncontrolled intercurrent illness including  but not limited to  ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements  significant history of uncontrolle
Exclusion Criteria: uncontrolled systemic disease
Exclusion Criteria: Uncontrolled systemic disease
Exclusion Criteria: Uncontrolled systemic disease
Exclusion Criteria: Uncontrolled systemic disease
Exclusion Criteria: Unstable angina oder MI within 3 months prior to inclusion
Exclusion Criteria: Weight loss due to factors other than AIDS-related wasting
Exclusion Criteria: Who are receiving opioids for abdominal pain or connective tissue disorders.
Exclusion Criteria: You are in the acute recovery phase following myocardial infarction.
Exclusion Criteria: You cannot be in this study if you any of the following:
Extensive diffuse atherosclerotic disease involving the arch or common carotid that would preclude safe introduction of catheters and sheaths for endovascular therapy
Family history of rupture of intracerebral aneurisms
fast atrial fibrillation  ventricular tachycardia  or supraventricular tachycardia) with hemodynamic instability
First episode of CMV retinitis.
Fit one of the zidovudine use groups listed in Disease Status
For patients who progress while receiving hormonal therapy alone  the patient may be enrolled on study as soon as they have recovered from all side effects of the hormonal therapy
for patients with ADPKD family history: < 30 years: 2 cysts (unilateral or bilateral) 30-60 years: 2 or more bilateral cysts > 60 years: 4 or more bilateral cysts
For the purposes of this study  CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing)
For the purposes of this study  CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing)
fractures of the extremities combined with blunt/penetrating thoracic trauma
Free of any clinically significant diseases other than hyperlipidemia  CHD  or diabetes mellitus that would interfere with study evaluations
Free of liver and kidney diseases  and with no evidence of uncontrolled hypertension and/or diabetes
Frequent headaches and/or migraine  recurrent nausea and/or vomiting (more than twice a month).
Fulfilled DSM->=  criteria for major depressive disorder.
Full functional independence prior to the present stroke indicated by an estimated premorbid mRS score of 0 or 1
gastric ulcer  intracranial bleeding
Gastrointestinal bleeding within 3 months
GI symptoms for at least 2 months before entering study
Glaucoma
Glaucoma
Group 1 (Non-ST-elevation acute myocardial infarction) : Chest pain less than 48 hours before admission 
Group 1 : Preexisting EKG abnormalities (including left bundle branch block) precluding accurate assessment of ST-T changes
Group 1: Co-morbid conditions such as severe heart  lung  kidney or liver disease.
Group 2 (Stable coronary artery disease) : Documented myocardial ischemia (stable angina or positive stress test)
Group 2 : History of acute coronary syndrome
Group 3 (Normal coronary arteries) : No history of coronary artery disease  neurovascular disease or peripheral artery disease 
Groups 1 and 2: Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is located in a bypass graft.
Had a biventricular pacemaker placed within the 45 days before randomization or a single or dual chamber pacemaker or an automatic implantable cardiac defibrillator placed within the 15 days before randomization
Had an uncontrolled thyroid disorder
Had severe obstructive pulmonary disease or active neurological events
had skin conditions resulting in oily  irritated or damaged skin at all potential application sites
has a history of chronic hepatic failure and/or hepatic cirrhosis
has a known or suspected hereditary complement deficiency
Has clinically significant valvular heart disease
has current cardiogenic shock  acute left ventricular rupture  acute septal rupture or acute papillary muscle rupture
Have a fungal infection of the affected fingernails
Have a history of central nervous system disease  such as seizures
Have a history of pancreatitis or gallstones.
Have a history of psoriasis or lichen planus involving any nail  or active contact dermatitis involving the affected fingernails
Have a known or suspected history of a genetic condition affecting the nails  .  Darier's disease  nail-patella syndrome  tuberculosis sclerosis)
Have a serious illness that required systemic treatment or a hospital stay unless treatment was completed at least 14 days prior to entering the study  or are on stable treatment  in the doctor's opinion  for at least 14 days prior to entering the study.
Have a significant psychiatric disorder
Have a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
Have an active  ongoing gastrointestinal disease or infection such as colitis  diverticulitis  Crohn's disease  peptic ulcer disease  giardiasis  or cryptosporidiosis.
Have an acute febrile illness or upper respiratory tract illness within 72 hours prior to administration of study medication
Have any acute or chronic disease  .  history of hepatitis or HIV-1)
Have any other concomitant life-threatening disease 
Have at least three of the five characteristics listed below  indicating presence of metabolic syndrome  as defined by NCEP-III: waist measuring more than 40 inches (for men) or more than 35 inches (for women) 
Have averaged at least three partial seizures per month  with no 21-day seizure-free period during the 2 months preceding randomization
Have been previously vaccinated within the last 10 years (vaccinia-experienced cohort only)
Have cardiac disease including congestive heart failure or arrhythmia
Have certain serious medical conditions  including an AIDS-defining clinical condition.
Have current signs or symptoms of severe  progressive  or uncontrolled renal  hepatic  hematologic  gastrointestinal  endocrine  pulmonary  cardiac  neurologic  or cerebral disease
Have had a diagnosis of probable Alzheimer's disease.
Have had systemic treatment with certain other drugs that may interfere with the study within 14 days of entering the study.
Have not engaged in an HIV risk behavior during the three-month period prior to the baseline evaluation.
have one or more of the following risk factors: diabetes mellitus
Have onycholysis (lifting of the nail plate off the nailbed) of the affected fingernails
Have or suspect they have acute hepatitis within 30 days of entering the study.
Have peripheral neuropathy (a condition affecting the nervous system) or other condition or prior therapy that  in the opinion of the investigator  would affect the study.
Have signs of bacterial  fungal or viral skin lesions that may interfere with measurement of the target lesions.
Have symptomatic ventricular tachycardia
Have the diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures according with the International League Against Epilepsy's Classification of Epileptic Seizures (1981)
Have uncontrolled hypertension
Head CT showing no evidence of intracranial hemorrhage or mass lesion which might increase the risk of bleeding.
Healthy subjects are defined as individuals who are free from clinically significant illness or disease (such as coronary arterial disease  chronic heart failure  bleeding disorder  hypertension  chronic renal failure etc.) as determined by their medical 
Healthy subjects as established by medical history and clinical examination before entering into the study.
hemodynamic instability
Hemorrhage on initial MRI or CT or other structural lesion that might raise the risk of intracranial bleeding.
Hepatic insufficiency /AST  ALT 3 fold of the upper limit of the normal value/
Hepatitis B or C infection AND liver enzymes of Grade 2 or greater OR evidence or history of severe hepatitis or cirrhosis
Higher degree heart valve disease
Higher degree ventricular arrhythmias
High-risk uncontrolled arrhythmias
History and/or presence of any clinically significant cardiovascular disease  clinically significant hepatic  renal  or endocrine dysfunction  stroke  uncontrolled diabetes  hyperthyroidism  convulsive disorders  neoplastic disease other than basal cell c
History and/or presence of any non-asthmatic acute or chronic lung disease  including but not limited to bronchitis  emphysema  active tuberculosis  bronchiectasis or cystic fibrosis
History bronchial asthma and bronchospastic diseases.
History bronchial asthma and bronchospastic diseases.
history of 2 myocardial infarctions  or a myocardial infarction that occurred greater than 48 hours but less than four (4) weeks prior to CABG
History of abdominal fistula  gastrointestinal (GI) perforation  or intra-abdominal abscess within 6 months prior to Day 1.
History of acute or chronic pancreatitis.
History of angioedema  hereditary or idiopathic
History of ascites  variceal hemorrhage or hepatic encephalopathy
history of asthma  bronchospastic lung disease  or hyper-reactive airway disease
History of bleeding disorder
history of congestive heart failure
History of encephalopathy  neuropathy  or unstable CNS pathology (HIV or non-HIV related)
history of gout
History of hepatitis or active liver disease.
History of HIV infection
History of hypertrophic or alcoholic cardiomyopathy
History of immunodeficiency disease (such as HIV) or autoimmune disease except vitiligo.
History of known presence of cardiogenic shock  sinus bradycardia  Wolff-Parkinson White Syndrome  congestive heart failure or angina.
History of known presence of cardiogenic shock  sinus bradycardia  Wolff-Parkinson White Syndrome  congestive heart failure or angina.
History of major complications of lung disease (including recent massive hemoptysis or pneumothorax) within 2 months prior to start of study treatment.
History of major ipsilateral stroke with sufficient atrophy to increase risk of procedure associated bleed
History of more than one seizure per month during the last year (or  since the stroke if no seizures prior to stroke)
history of myocardial infarction
history of myocardial infarction
History of non-HIV related neoplastic diseases  autoimmune diseases  angina or cardiac arthymias  or any other clinically significant medical problems
History of obstructive valvular disease
history of ocular fundus diseases
History of ophthalmic disease in the study eye other than AMD
History of other upper motor neuron lesion
History of pain syndrome
history of pre-stroke shoulder pain
History of psychiatric illness
History of pulmonary hypertension within the last 3 months
History of recent myocardial infarction  stroke  or uncontrolled CHF  epilepsy  or hypertension
History of restrictive cardiomyopathy
History of reversible cardiomyopathy
History of serious opportunistic infection.
History of severe and symptomatic cardiac valvular disease.
History of severe asthma  anaphylactic reactions  angioedema  angioneurotic oedema or Quincke's Oedema
History of severe hypoglycemia
History of significant maternal deprivation  abuse  or malnutrition
History of status epilepticus in the past year or seizure clusters where individual seizures cannot be counted.
History of stroke
History of symptomatic peripheral vascular disease or Raynaud's syndrome.
history of thromboembolic diseases
History of thromboembolic or cerebrovascular events  such as stroke  or transient ischemic attack (TIA)
History of use of diuretic therapy for CHF (including this admission) 
History or current psychosis or bipolar disorder
History or evidence of thromboembolic events or any first degree relative with a history of thromboembolic events
History or presence of central nervous system disease.
History or presence of clinically significant gastro-oesophageal reflux  stomach ulcers  or indigestions
History or presence of clinically significant myasthenia gravis
History or presence of clinically significant severe renal or hepatic dysfunction
HIV exposure
HIV Infected
HIV infection or active hepatitis
HIV negative
HIV positive
HIV seropositive.
HIV status or other severe illnesses will be assessed using medical records.
HIV/AIDS
HIV-HBV co-infected individuals from the Alfred Hospital  the Royal Melbourne Hospital and high case load GP clinics who are referred to the Alfred Hospital
HIV-positive
HIV-positive subjects are excluded from the study.
However  documentation of disease progression is not mandatory for enrollment.
Hypercalcemia
Hyperpigmentation
Hypersplenism
hypertension
i.e.  uncontrolled hypertension  unstable angina  recent myocardial infarction (within prior 3 months)  uncontrolled congestive heart failure  and cardiomyopathy with decreased ejection fraction.
ICP greater than 20mmHg  not related to a transient noxious stimulus and not responding to standard measures for controlling ICP (ventricular drainage  elevation of head of the bed and optimizing PaCO2)
ICP monitor in place
Identification of new parqueurs circulated in coronary artheriosclerosis and complications of the new differentiel technicology
If at any time prior to enrollment in the study  the patient's cardiologist determines that the patient should not participate in this study  the patient will not be enrolled in the trial.
If at any time prior to enrollment in the study  the patient's cardiologist determines that the patient should not participate in this study  the patient will not be enrolled in the trial.
If predilation of the lesion is visually deemed necessary it should be performed prior to measuring the length of the lesion.
If screen values do not meet the absolutely exclusionary values given below but are still outside the normal reference range  treatment for folic acid/B12 deficiency or thyroid disorder  as appropriate  may be initiated or adjusted with re-evaluation of t
If the only site of measurable disease is a previously irradiated area  the patient must have documented progression of disease in this area.
If the serology is documented to be a false positive or due to an adequately treated infection  the volunteer is eligible]
If they have cardiac disease or other severe comorbidity
If they have other pulmonary diseases
If you do not qualify for the trial  study personnel will explain the reasons.
Impaired glucose tolerance
In men  evidence of a mass lesion on clinical examination by their primary care physician within twelve months prior to entry into the study (specifically prostate or testicular mass on clinical exam or other signs of mass lesion) or evidence of mass lesi
In- or out-patients (change of institutionalization status during the trial period is allowed).
Inclusion Criteria: A clinical diagnosis of DM-1 according to accepted clinical research criteria.23 The clinical research criteria require each of the following: (1) clinically evident myotonia
Inclusion Criteria: Acute or early HIV infection  as determined by the NIH Acute Infection and Early Disease Research Program (AIEDRP) definition
Inclusion Criteria: ADHD diagnosis
Inclusion Criteria: Are HIV-positive.
Inclusion Criteria: Be diagnosed with multiple migraines per month of moderate to severe intensity
Inclusion Criteria: Be receiving care for HIV at one of the participating immunology clinics
Inclusion Criteria: biopsied-proved crescentic glomerulonephritis  with rapidly progressive renal failure
Inclusion Criteria: biopsied-proved primary glomerular diseases  and nephrotic syndrome
Inclusion Criteria: Clinical diagnosis of polycystic ovary syndrome
Inclusion Criteria: Clinically confirmed diagnosis of osteoarthritis from a physician
Inclusion Criteria: Coronary disease
Inclusion Criteria: Critically ill  postoperative/posttraumatic patients with severe systemic inflammatory response syndrome (SIRS) or severe sepsis
Inclusion Criteria: Critically ill  postoperative/posttraumatic patients with threatening acute renal failure
Inclusion Criteria: Diagnosis of depression
Inclusion Criteria: Diagnosis of DR.
Inclusion Criteria: Diagnosis of ocular hypertension or glaucoma
Inclusion Criteria: Diagnosis of ocular hypertension or glaucoma
Inclusion Criteria: Diagnosis of schizophrenia or schizoaffective disorder
Inclusion Criteria: Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who require IOP-lowering therapy in both eyes
Inclusion Criteria: First myocardial infarction
Inclusion Criteria: Free of active ocular or systemic disease
Inclusion Criteria: Group 1 (Non-ST-elevation acute myocardial infarction) :
Inclusion Criteria: Have a primary diagnosis of Bipolar I Disorder  current episode manic (DSM-IV 296.4x) or mixed (DSM-IV296.6x) as determined by a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)) at screening.
Inclusion Criteria: Have had a diagnosis of probable Alzheimer's disease
Inclusion Criteria: Have HIV infection or AIDS.
Inclusion Criteria: Logan student  staff  or faculty or general public with a minimal of 2 year history of diagnosed Multiple Sclerosis (MS)
Inclusion Criteria: measurable disease as defined by the presence of at least one measurable lesion
Inclusion Criteria: multiple trauma injury  injury severity score (ISS) > 18 with
Inclusion Criteria: ocular hypertension or glaucoma in both eyes
Inclusion Criteria: Ocular hypertension or glaucoma in both eyes
Inclusion Criteria: Ocular hypertension or glaucoma in both eyes
Inclusion Criteria: Patients diagnosed with AMD  or
Inclusion Criteria: Patients who fulfill the criteria of Kawasaki disease or atypical Kawasaki disease and their household family members
Inclusion Criteria: Patients who meet current indications for an ICD
Inclusion Criteria: Patients with acute ischemic stroke in whom treatment can be initiated within 12 hours of a clearly defined symptom onset
Inclusion Criteria: Patients with atrial fibrillation undergoing radiofrequency ablation
Inclusion Criteria: Poorly controlled asthma
Inclusion Criteria: Subject must have symptomatic AF
Inclusion Criteria: Subjects have participated in primary study HBV-280
Inclusion Criteria: Subjects who had completed the double-blind phase or discontinued due to lack of efficacy after at least 21 days of treatment  who signed the informed consent for the open-label phase  and who the investigator agreed that open-label tr
Inclusion Criteria: Type 2 diabetes
Inclusion: Mild to moderate Osteoarthritis of the target knee.
Incontinence symptoms present for at least (3) months*
indication for revascularization (angina status  myocardial ischemia  positive stress test  pathologic FFR)
Individuals who are obese.
Individuals with scoliosis carrying additional diagnoses of illness.
Intestinal obstruction /because of the castor oil content of the drug/
is receiving  or is planning to receive  any other investigational drug or device  or will participate in any other research study during the trial
isolated head injury with morphological changes in CCT
Isolated systolic Hypertension
ISS < 18
Key Exclusion Criteria: Obesity of known endocrine origin
Known bleeding disorder.
Known hepatic disease
Known history of carotid disease
Known history of corneal disease
Known HIV  Hepatitis B or C virus  or tuberculosis infection
Known HIV  Hepatitis B  or Hepatitis C infection.
Known HIV-infection (HIV testing is not required for participation).
Known immunodeficiency
Known positive HIV status.
Lack of ICP monitoring
Lacunae infarcts present in areas affecting cognition (entorhinal cortex  hippocampus  medial temporal lobe) will also exclude the subject from the study.
Later in life  these individuals are also subject to the added effects of a wasting process similar to classical DM-1
left main stenosis
lesion in native coronary artery
Less than 6 months post-stroke
leukopenia and/or thrombocytopenia
Low doses are allowed if received for 60 or more days before entering the study with no plans to change the dose during the first 24 weeks of the study.
Major congenital infections
Major fetal anomaly or congenital malformation
Major psychiatric illness (major depression  bipolar disorder  or schizophrenia) within twelve months of entry.
Measurable disease
Measurable disease
Measurable disease
Measurable disease defined as at least one malignant lesion that can be accurately and serially measured in at least one dimension (longest diameter to be recorded)  using a caliper (diameter > 10 mm) for superficial cutaneous disease  or using contrast-e
Measurable disease  defined as >=  1 lesion that can be accurately measured in >=  1 dimension
Measurable or evaluable disease determined as per RECIST criteria
Measurable or evaluable disease.
Medical disorder that would not allow use of olanzapine
Medical illness which would prevent assessment of muscle strength or function
Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study
Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study
Mental retardation
Mesenteric or peripheral vascular thrombosis.
Mild non-prolipherative retinopathy (based on ETDRS criteria)
Moderate to severe baseline disability (pre-stroke Rankin score of > 3)  severe or terminal concurrent medical illness with expected survival of < 3 months  or other concurrent medical or psychiatric condition which may limit neurologic assessment or pati
Mood disorder due to general medical condition.
Multiple carotid stenoses exist in the internal carotid artery (ICA) that cannot be covered by one stent.
Mycotic aneurysm  infectious false aneurysms
Myocardial infarction within 6 months prior to enrollment  uncontrolled angina  severe uncontrolled ventricular arrhythmias  or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Myocardial infarction within 90 days of study start  unstable angina within 14 days of study start  or any clinical evidence of active myocardial ischemia
Myocardial infarction within the last 6 months prior study entry
Myocardial infarction within the past 6 months
Need to acutely revascularize additional vessels  outside the infarct artery.
Neoplastic disease without documented remission within the past 5 years.
No active infection
No active opportunistic infection.
No active or recent (within the past 30 days) fungal infection
No AIDS opportunistic infection within 30 days of screening
No alarm indicators on clinical assessment (weight loss of more than 7kg  bleeding  recent recurrent vomiting  progressive dysphagia).
no bleeding diathesis or coagulopathy.
No concurrent combination antiretroviral therapy for HIV-positive patients
No convulsive disorders such as epilepsy
No current major depression or PTSD.
No hemorrhagic diathesis.
No history of CHF or cardiomyopathy
No history suggestive of small bowel obstruction
No neuroleptic malignant syndrome or physical fatigue associated with dehydration  malnutrition
No present illness or history of diabetes or risks of diabetes such as hyperglycemia and obesity
No previous heart attack or a stroke  or other forms of these diseases.
No prior end-organ CMV disease - PER AMENDMENT 4/25/96: No prior end organ CMV disease within the past 6 months
No prior or current history of AIDS.
No proven or suspected sepsis  pneumonia  or meningitis unless appropriate therapeutic measures have been initiated to control the infection and systemic signs are no longer life-threatening
No psychiatric illness or social situation that would preclude study compliance
No rapidly progressive disease
No uncontrolled intercurrent illness including  but not limited to  any of the following: Ongoing or active infection
Non infectious false aneurysms developed on prosthesis (Deleted by amendment n>= 1 at the request of AFSSAPS)
Non-healing wounds  ulcer  or long bone fracture
Non-ruptured symptomatic aneurysm or aneurysm complicated with emboli.
Non-stable diabetes mellitus
Not meeting entry criteria for ADAF (as above)
On moderate doses of ICS with inadequate asthma control.
one or more de novo lesions in 1  2 or 3 native coronary arteries
Ongoing acute illness including acute upper or lower respiratory infections within 2 weeks before start of study treatment.
or have acute contrast nephropathy
or infectious disease in the month before admission
Ostial target lesion
Other diseases that may make study completion difficult or unlikely
Other laboratory abnormalities that judged by the investigator would interfere with the patients participation in the trial or the evaluation of the trial results
Other retinal vascular disease
Other severe chronic diseases  .  cardiologic  renal  or hepatic diseases
Other system illnesses such as renal  hepatic  gastrointestinal  severe hyperlipidemia and hypertension that require medication
partial bowel obstruction).
Participant has a cold or upper respiratory distress
Patient diagnosed with liver disease  defined as AST or ALT > 3x the upper limit of normal
Patient has a history of chronic hepatitis B or C  hepatitis within the past 3 months  or HIV infection.
Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.
patient has active peptic ulcer disease
Patient has presence of non-contiguous satellite lesions
Patient has severe chronic diarrhea  chronic constipation [unless attributed to drugs that will be washed out]  uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
Patient has skin conditions in the area affected by the neuropathy that could alter sensation.
Patient must be treated for SLE with doses of prednisone < 30 mg/day (including those on NO glucocorticoid therapy) unchanged for > 6 weeks prior to study entry (including both screening and qualifying visits)
Patient must have a diagnosis of SLE > 6 months according to the 1989 revised ACR criteria
Patient must have glioma progression or recurrence following radiotherapy that was no less than 50 Gy (+/- chemotherapy
Patient with any condition which in the Investigator's or sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation  
Patient with disease worsening and in incapacity to move about to CHJM
Patient with left ventricular systolic dysfunction implanted wih ICD
Patients admitted within 24 hours and can be enrolled within 48 hours after qualifying ischemic stroke onset
Patients entering the Phase 1 portion of the study can have either measurable or evaluable disease.
Patients entering the Phase 2 portion of the study must have measurable disease meeting RECIST criteria.
Patients having significant bleeding diathesis.
Patients may be eligible for this study if they: Are HIV infected.
Patients may be eligible for this study if they: Are HIV-positive.
Patients must be: HIV positive by ELISA and Western blot.
Patients must have unidimensionally measurable disease (RECIST criteria)
Patients must have: A working diagnosis of HIV infection.
Patients must have: HIV infection.
Patients must have: HIV infection.
Patients must have: HIV infection.
Patients must have: HIV seropositivity.
Patients must meet the criteria for chronic idiopathic constipation for at least 12 weeks
Patients must not have had prior radiotherapy to areas of measurable disease unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
Patients must not have uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements
Patients must: Be HIV positive
Patients taking any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug  
Patients who are not clinically stable such as those who had cardiac arrest  who are intubated  who have active psychosis  or who are cognitively impaired.
Patients who are on regular automated peritoneal dialysis due to end stage renal failure for at least 3 months.
Patients will be excluded from the study if they fulfill any of the following criteria: Serious illnesses  e.g.  serious infections requiring antibiotics.
Patients with a hemiparesis of the lower limbs
Patients with a history of viral infections such as HIV or hepatitis B  C.
Patients with active infection of the skin near the potential injection site.
Patients with acute myocardial infarction (ST elevation in at least 2 leads >=  0.2 mV in V1 V2 or V3 or >=  0.1 mV in other leads)  treated by one of the following procedures: Acute PCI with stent implantation for acute ST elevation MI for either denov
Patients with an onset date of acute GVHD that is less than or equal to 100 days posttransplant.
Patients with an undeterminate colitis
Patients with any abnormal laboratory value or physical finding that  in the view of the responsible clinician  may interfere with interpretation of the study results  be indicative of an underlying disease state  or compromise the safety.
Patients with any abnormal laboratory value or physical finding that  in the view of the responsible clinician  may interfere with interpretation of the trial results  be indicative of an underlying disease state  or compromise the safety.
Patients with any coagulation  bleeding or blood disorders.
Patients with any coagulation  bleeding or blood disorders.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack  stroke or drop attacks termed transient ischemic attacks (TIAs)  or blockages of the arteries in the legs termed peripheral arterial disease (PA
Patients with any inter-current disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 6 month course of the trial (cancer  other rheumatic diseases  gout  severe congenital defects  etc.).
Patients with any of the following conditions or symptoms are excluded: Febrile illness with temperature > 38.5 degrees C (101.3 degrees F) within 3 days prior to study entry.
Patients with asthma  rhinitis  or nasal polyps.
Patients with asthma  rhinitis  or nasal polyps.
Patients with chronic candidiasis (yeast infection) or bacterial infection will be allowed.
Patients with Class IV heart failure.
Patients with Class IV heart failure.
Patients with clinically significant medio-lateral and/or anterior-posterior instability.
Patients with corneal disease associated with endothelial dysfunction  including pseudophakic corneal edema  Fuchs' dystrophy  posterior polymorphous dystrophy  endothelial failure from another cause  interstitial keratitis (non-herpetic)  or perforating 
Patients with disease accessible for biopsy will be preferentially selected for participation in the study
Patients with documented history of any gastrointestinal disorders  including bleeding ulcers.
Patients with documented history of any gastrointestinal disorders  including bleeding ulcers.
Patients with gout or calcium pyrophosphate (pseudogout) diseases that had flared within the previous 6 months prior to Screening.
Patients with inflammatory arthropathies such as rheumatoid arthritis  lupus  or psoriatic arthritis
Patients with measurable disease
Patients with medical condition which need urgent or special antihypertentive therapy  such as hypertensive encephalopathy  aortic dissection  acute renal failure  acute pulmonary edema  or acute myocardial infarction
Patients with OA that is dominantly in the lateral compartment or any significant valgus deformity
Patients with osteonecrosis of either knee.
Patients with peripheral neuropathy that would be severe enough to interfere with the evaluation of the patient.
Patients with severe aortic insufficiency  or aortic regurgitation.
Patients with severe aortic insufficiency  or aortic regurgitation.
Patients with significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia.
Patients with signs and symptoms of osteoarthritis of at least one knee: Diagnosed according to ACR criteria.
Patients with symptoms consistent with osteoarthritis of the knee for at least 6 months prior to Screening
Patients with the following are excluded: History of clinically important disease other than HIV infection defined by the investigator as possibly putting the patient at risk during study participation.
Patients with the following prior conditions are excluded: History of ventricular arrhythmias or myocardial infarction.
Patients with the following prior conditions are excluded: Unexplained temperature >= 38.5 C for 7 days or chronic diarrhea (>= three stools daily) for 15 days  if occurring within 30 days prior to study entry.
Patients with the following symptoms or conditions are excluded: Active cytomegalovirus disease.
Patients with the following symptoms or conditions are excluded: Evidence of retinal vascular or related infectious disease or other retinal lesions that would interfere with the ability to detect responses to therapy or progression.
Patients with the following symptoms or conditions are excluded: PER AMENDMENT 4/25/96: Retinal detachment not scheduled for surgical repair  in all eyes meeting other eligibility criteria
Patients with vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the patient.
PER AMENDMENT 4/25/96: Presence of CMV retinal lesions that are only in areas of the retina which cannot be photographed.
Percutaneous revascularization  if required or planned  must occur prior to randomization
peripheral vascular disease
Peritonitis episode less than 6 weeks before enrolment
Pleural effusion or ascites that causes respiratory compromise.
Polytraumatized patients with an ISS > 18 Controls: healthy volunteers
poorly controlled diabetes (HbA1c > 7.0)
Positive Helicobacter pylori serology.
positive serology to AgHbS  HCV or HIV
Positive testing for hepatitis B  hepatitis C or HIV at screening
Positive testing for hepatitis B  hepatitis C or HIV at screening
Positive testing for hepatitis B  hepatitis C or HIV at screening
Positive testing for hepatitis B  hepatitis C or HIV at screening
Positive testing for hepatitis B  hepatitis C  or HIV at screening.
Positive testing for hepatitis B  hepatitis C  or HIV at screening.
Post Acute Coronary Syndrome
Postoperative/posttraumatic critically ill patients admitted to the intensive care unit
Postoperative/posttraumatic critically ill patients admitted to the intensive care unit
PPROM before 22 weeks
Preeclampsia or eclampsia
Pre-operative signs and symptoms of hypofunction of the HPA axis
Presence of a detectable  volitionally-activated EMG signal from the paretic wrist or finger extensors (ECR or EDC)
Presence of a zygomycete in culture associated with clinical or radiological abnormalities compatible with fungal invasive infection.
Presence of major active psychiatric disease
Presence of multiple co-morbidities such as poorly controlled diabetes  dialysis-dependant renal failure  hepatic failure
Presence of nonmotor simple partial seizures only.
Presence of primary generalized epilepsies or seizures  such as absences  myoclonic epilepsies  Lennox-Gastaut syndrome.
Previous intracranial hemorrhage or brain surgery within the past twelve months
Prior personal history of Guillain-Barr?? syndrome.
Profound hypoxia or hypercarbia as defined as a PaO2 level less than 50 or a PaCO2 level of greater than 60.
Psychiatric illness on meds
Psychotic or bipolar disorder
Refractive error between six diopters of myopia and five diopters of hyperopia with regular astigmatism of any amount
refusal of the patient or close relative for participating in the study
Registered and followed for RAS at the same site at which they are being followed for SELECT
renal insufficiency (Creat > 2.0)
Restrictive or obstructive cardiomyopathy  constrictive pericarditis  pericardial tamponade  or other conditions in which cardiac output is dependent on venous return
Restrictive or obstructive cardiomyopathy  constrictive pericarditis  pericardial tamponade  other conditions in which cardiac output was dependent on venous return  or for subjects expected to have low filling pressures
Ruptured aneurysm after endoprosthesis (Deleted by amendment n>= 1 at the request of AFSSAPS)
Score of > 0.5 on the ACTG AIDS dementia complex staging test
second or third degree heart block without a pacemaker
Secondary Hypertension
Seizure disorder or traumatic brain injury.
Serious cardiovascular disease  wearing a pacemaker
serious infection)
Serious medical condition including but not limited to: Uncontrolled hypertension
Serious mental illness which makes them unsuitable for interviewing (accommodation will be made for HIV-related cognitive deficits & related illnesses)
Severe arrhythmia
severe behavioral or psychological symptoms in dementia (BPSD) judged by a geriatrician
Severe dementia
severe illnesses  judged by a geriatrician
Severe liver disease
severe malnutrition)
Severe migraine  epilepsy
Severe respiratory insufficiency
severe somatic disorders
Severe  known hepatic insufficiency
Severe  known renal insufficiency
Show evidence of clinically significant disease (cardiac  respiratory  gastrointestinal  renal disease  etc) that  in the opinion of the investigator  could affect either the patient's safety or the conduct of the study.
Show evidence of significant  active  hepatic disease
Sickle cell disease( SS SC  SBETA O  SDpunjab) and control without sickle cell disease
Significant cardiac disease or central nervous system lesions.
Significant hemoptysis within one year prior to Study Day 1.
Significant liver disease (GOT > 2x upper limit) or spontaneous INR > 1.5)
Significant neurologic/psychiatric disorders
Significant recent (within past 3 months) risk of committing suicide
Significant symptomatic cardiac disease.
Significant underlying medical condition that could impair continuous participation in study.
Significant underlying medical condition that could impair continuous participation in study.
Signs of liver impairment shown as elevated serum ALT or serum bilirubin
Soft tissue disease that has been irradiated in the past 2 months is not assessable as measurable disease
Soft tissue disease within a prior irradiated field must have progressed to be considered assessable
Spastic cerebral palsy
stenoses of bypass grafts
Steven-Johnson syndrome  bronchospasm  or hypotension)
stroke
Stroke or Transient Ischemic Attack (TIA) within 3 months prior to inclusion
Study partner or caregiver to assure compliance
Subject has a concurrent chronic or acute illness or other condition that might confound the results of safety assessments or that might increase risk to the subject
Subject has a history of clinically significant endocrine (except for Type 2 diabetes mellitus)  gastrointestinal  cardiovascular  hematological  hepatic  immunological  renal  respiratory  or genitourinary abnormalities or diseases
Subject has a history of seizures  any tic disorder  or a current diagnosis and/or a known family history of Tourette's Disorder
Subject has a history of stroke  chronic seizures  or major neurological disorder
Subject has a known family history of sudden cardiac death or ventricular arrhythmia
Subject has a major residual neurological deficit (stroke scales: Barthel >= 60  NIH >=  15 or Rankin > 3) at pre-procedure neurological exam.
Subject has a recent history of eye infection or other inflammatory eye conditions
Subject has any condition  which precludes compliance with study and/or device instructions.
Subject has congestive heart failure
Subject has glaucoma or is blind
Subject has had a stroke or retinal artery occlusion within one (1) month prior to index procedure.
Subject has had a transient ischemic attack (TIA) or amaurosis fugax within 48 hours prior to index procedure.
Subject has had active bleeding diathesis requiring blood transfusion within one (1) month prior to index procedure.
Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
Subject has history of a blood or platelet related disorder including prior deep venous thrombosis
Subject has peripheral vascular disease  which precludes safe femoral artery sheath insertion.
Subject has renal insufficiency
Subject has type 1 diabetes
Subject is both HIV positive and HCV positive (must be viremic for HCV  not just antibody positive).
Subject is known or is suspected to suffer from intestinal obstruction.
Subject is suffering from dementia.
Subject may not have uncorrected electrolyte imbalance.
Subjects in this group experience increased premature mortality and increased risk of microvascular and cardiovascular complications (25).
Subjects is currently considered a suicide risk  has previously made a suicide attempt or has a prior history of  or is currently demonstrating suicidal ideation
Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations  procedures or participation.
Subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
Subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
Subjects must have a pre-established primary clinical diagnosis of COPD.
Subjects must have documented coronary heart disease (CHD)
Subjects must have documented coronary heart disease (CHD)
Subjects must meet all the following criteria in order to be included in the study.
Subjects must meet all the following criteria in order to be included in the study.
Subjects who are poor medical risks because of active nonmalignant systemic disease.
Subjects who are positive for HIV antibodies.
Subjects who have acute or unstable medical illness or organic failure.
Subjects with a pacemaker or persistent LBBB
Subjects with a prior history of depression (but not currently depressed) are allowed in the study.
Subjects with concurrent infectious disease.
Subjects with moderate or severe aortic stenosis  aortic regurgitation  mitral stenosis or mitral regurgitation
Subjects with recurrent head and neck cancer with no clinically measurable distant disease as well as those subjects in whom distant disease was of low volume and local and regional palliation is clinically warranted will be eligible.
Suffer from a serious and persistent mental illness (SMI)
Supra-renal thoracic-abdominal aneurysm
Suspected or known ulcerative colitis
Suspected seizure at the onset of stroke.
Symptomatic as evidenced by transient ischemic attack or non-disabling stroke in the hemisphere supplied by the target vessel within 180 days of procedure
Symptomatic cardiomyopathy.
Symptomatic congestive heart failure
Symptomatic is defined as carotid stenosis associated with ipsilateral transient or visual TIA evidenced by amaurosis fugax  ipsilateral hemispheric TIAs or ipsilateral ischemic stroke within 6 months prior to enrollment.
Symptomatic ischemic heart disease (CCS class 1-4  Braunwald class IB  IC  and/or objective evidence of myocardial ischemia)
Symptomatic liver or kidney disease  insulin requiring diabetes or type 2 diabetes requiring oral anti-diabetic agents.
Symptomatic pancreatitis.
symptomatic peripheral vascular disease (claudication)
symptomatic peripheral vascular disease (claudication)
symptoms (stable or unstable angina pectoris) or objective evidence of myocardial ischemia
Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.
Technical constraints (validation of experience form) : Trained operator (at least 15 endoprosthesis in asymptomatic patients)  Endovascular materials at disposal
The common carotid artery ostium has stenosis that requires treatment.
The last chemotherapy must have been at least 4 weeks prior to study drug administration.
The presence of any of the following diseases or another disease that the investigator believes to be a contraindication to participation in the protocol: Asthma if treated with systemic or daily inhaled corticosteroids in the last 6 months (Intermittent 
The presence of any of the following will exclude a subject from study enrollment: Subject has dysphagia
The presence of ipsilateral intracranial stenosis that requires treatment.
The presence of severe liver disease with cirrhosis  recent active hepatitis  active chronic hepatitis  ALT or AST >3 x ULN  biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
The study center will determine if you meet all of the criteria
The study center will determine if you meet all of the criteria
The subject should be excluded if peripheral neuropathy  macrocytic anemia  or myxedema is present.
These may include hyperthyroidism  hypothyroidism  uncontrolled diabetes mellitus  coronary heart disease  ischemic heart disease  elevated intraocular pressure  prostatic hypertrophy.
These symptoms must include knee joint pain  and may include crepitus  swelling and/or effusion of the knee.
This exclusion would include individuals with orthopedic  cardiac  or pulmonary disorders which preclude proper positioning on the myometry testing table  or restrict their ability to tolerate repeated maximum muscle contractions.
thrombus in target lesion as visualized by angiography
throughout the study and for 3 months after the study.
Thyroid disease
transient ischemic attack
Tuberculous  diabetic  or hypertensive retinopathy  or other retinal lesions that would interfere with measurements of response or progression.
Tumorous disease
Type 1 Diabetes
Type 2 diabetic patients with Mild non-prolipherative retinopathy fulfilling the inclusion criterion.
Ulcers
Unable to communicate with local study staff
Uncontrolled cardiac arrhythmias
Uncontrolled cardiac conditions or severe unstable medical illnesses
uncontrolled diabetes mellitus
Uncontrolled high blood pressure  uncontrolled diabetes mellitus  unstable angina  symptomatic congestive heart failure (CHF)  myocardial infarction (MI) within 6 months  or uncontrolled arrhythmia.
Uncontrolled hypertension
Uncontrolled hypertension
Uncontrolled hypertension
Uncontrolled maternal illness
Uncontrolled or secondary hypertension
Uncontrolled severe arterial hypertension
Uncontrolled systemic illness.
Underlying liver disease
Unmixed infection with P
Unstable angina
Unstable angina pectoris
Untreated and uncontrolled hypertension
Untreated endocrine disorders such as hypothyroidism  hypopituitarism  hypogonadism detected by pre-operative measurement of TSH  FT4  LH  FSH and free testosterone
Untreated thyroid disease (hypo or hyperthyroidism)
upper extremity hemiplegia due to hemorrhagic or nonhemorrhagic stroke
Urodynamic Stress Incontinence
Ventricular arrythmias requiring medical or defibrillatory intervention
Vitreous syneresis or posterior vitreous detachment
Vitreous syneresis or posterior vitreous detachment
Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process
With a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
with contradiction of cardiac and pulmonary diseases
without contradiction of cardiac and pulmonary diseases
You cannot be in this study if you any of the following: History of cardiac disease  with New York Heart Association Class II or greater with congestive heart failure
You have Major Depressive Disorder  an Anxiety Disorder  or some other psychiatric illnesses that the doctor will ask you about.
You have uncontrolled narrow angle glaucoma.
You may be eligible for this study if you: Are HIV-positive.
Confirmed sodic depletion.
Inclusion Criteria: Symptomatic Chiari malformation
similar findings in a first degree relative.
Co-existing Condition: Patients with the following conditions or symptoms are excluded.
Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Inclusion Criteria: Patient has completed the 12 week double blind treatment of study CHTF919N2201
Another member of the same household is participating in this study.
Participation in any HIV vaccine trials
Patients in Phase IV studies may be eligible.
Subjects participating in the protocol entitled 'IRB: 0701014
Patients included in others clinical trials of imagery.
Inclusion Criteria: Post-angioplasty patients who had previously participated in an RCT designed to motivate multi-behavior change.
Coenrolled in any other HIV treatment or investigational drug trial
Have participated in a clinical trial of an investigational drug or device within 30 days before randomization
Participated in a previous clinical trial of Exelon.
Inclusion Criteria: Participation in a previous MPC-7869 randomized protocol
Have participated in a study involving administration of an investigational compound within 3 months of Visit 1 (Screening)  or within 5 half-lives of the previous investigational compound  whichever is longer  or who have been previously treated with E20
Participation in any previous clinical trial conducted by Orexigen Therapeutics
Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Ongoing participation in any other therapeutic clinical trial.
participation on another clinical trial at the same time
Not currently enrolled in another medical study
Previous participation in an MPC-7869 clinical study.
Are enrolled in another anti-HIV drug study while participating in this study.
Participation in an intervention study (including psychological studies) in past 6 weeks.
Participation in another clinical study
Participation in another clinical trial within the last 30 days
Participation in other clinical trial
participation in other trials
Participation in other trials
Prior enrolment in the POISE-2 pilot trial
- Subjects must NOT meet any of the following exclusion criteria: Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Concurrently participating in another clinical study  at any time during the study period  in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
Enrolled in other studies at the same time
Enrollment in any other clinical trial
Exclusion Criteria: Will not be eligible if not a part of the previous study
Must have been in the previous study.
Participation in another trial that may influence the results of this study
Participation in any other clinical trial or use of an investigational product within 30 days of entry into the study.
Participation in any other interventional clinical trial within 30 days prior to enrollment  or planned participation in another interventional clinical trial prior to termination of the subject's participation in the study.
Participation in other clinical trial within 30 days prior to inclusion
Participation in other investigational trial within 30 days.
Participation in other trials
Participation with 30 days in investigational study.
Patient has been excluded from other multi-institutional trials
Patient is currently enrolled in another investigational drug or device study
Patient is participating in another clinical study that may have an impact on the study endpoints.
Patients currently enrolled in ACTG 051 who have not reached the study end points but who meet the entry criteria for ACTG 144 may be co-enrolled in ACTG 144.
Patients participating in an experimental drug/device study or any clinical trial within the previous 30 days prior to Screening.
Patients who are participating in another study that requires Ethics Committee approval
Previous participation in this trial
Simultaneous participation in any other interventional clinical trial
Simultaneous participation in any other interventional clinical trial
Subject has participated in  is participating in  or plans to participate in another clinical study that may affect either the pre-procedure or follow-up results.
Subject is currently participating in another clinical trial with an investigation product/device (or within 30 days of screening).
Subjects who have participated in another clinical trial with 28 days of study start.
Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other study.
Have participated in any investigational drug or device trial in the last 4 weeks or plan to participate in any other study during the year.
participation in another trial
Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study
Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
Use of an investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication.
Have not participated in any clinical trial using investigational product within past month
Having received an investigational product within the last 12 weeks preceding the trial
Inclusion Criteria : Previously enrolled in study GRC28 and received 2 vaccinations of the assigned lot.
This study will include thirty males and females who took part in a previous study of a single oral dose of vitamin D.
Enrollment in another clinical trial in which AZT is a treatment.
Exposure to another investigational drug within 14 days prior to start of study treatment.
Have received another investigational agent within the 4 weeks before administration of test drug
Participation in another drug trials or planned use of vascular interventions within the previous 30 days
Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.
Subjects who have participated in another clinical trial within 28 days of study start
Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Use of any experimental HIV therapy or participation in another experimental protocol within three (3) months of pre-study screening
Enrollment in other trials designed to modify post-procedure behaviors.
Enrollment in other trials designed to modify post-procedure behaviors.
Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Enrollment in a conflicting trial
Currently participating in an investigational drug or another device study that has not completed the primary endpoint  or subject to inclusion in another investigational drug or another device study during follow-up of this study
has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization
Patient who participated in any prior DHEA study or administration of DHEA within the past 3 months
Subject has participated in any investigational clinical or vaccine trial within 30 days prior to the first dose of study drug
participated in another investigational study within 4 weeks prior to the prestudy (screening) visit
Enrollment in another treatment protocol that expressly prohibits concomitant treatment with zidovudine (AZT).
Patients must identify their ethnicity as Latino or Hispanic
Self-identified African Americans  English speaking African-born individuals and Latinos.
Inclusion Criteria: Caucasian men and women
Inclusion Criteria: Patients must be self-identified as African-Americans.
Self-identify as being Latino/Hispanic.
Inclusion Criteria: Patients must be self-identified as African-Americans.
Inclusion Criteria: Healthy male non-asian subjects
Inclusion Criteria: Caucasian
African-Americans.
Latino or Hispanic
Not currently exercising  defined as engaging in an average of less than 60 minutes of exercise/week during the last month
Physician has placed no restrictions on physical exercise
exercise < 20 min / day two days a week 
amount of physical activity exceeds 120 minutes of moderate exercise per week 
moderate exercise examples: brisk walking  golfing  gardening  housework  house painting 
no concurrent regular exercise of 3 or more hours a week 
subjects who exercise vigorously 
ability to walk for exercise 
performs insufficient exercise 
performance of exercise training at regular intervals (> once per week) at a moderate to vigorous intensity at any time in the 6 weeks prior to study entry
current participation in a regular exercise program 
inability to perform bicycle exercise test 
heavy exercise within 24 hours before study entry evaluations are done
able to exercise > 6 minutes on the treadmill 
initiation of an exercise program within 4 weeks of screening or initiation of an exercise program during the study
female
Females or Males
Gender: Female
Genders Eligible for Study: Both
Genders Eligible for Study: Female
Genders Eligible for Study: Male
If female 
Inclusion Criteria: Female
Inclusion Criteria: Female gender
Inclusion Criteria: Males and Females
Inclusion/Exclusion Criteria: Male and Female
Male and female patients will be eligible for enrollment
male sex
Males and females
Clinical parameters: Life expectancy > 2 months
Exclusion Criteria: life expectancy < 24 hours
Exclusion Criteria: Life expectancy below 72 hours 
Life expectancy < 1 year
Life expectancy > 12 weeks
Life expectancy > 6 months
Life expectancy > 6 months.
Life expectancy >12 weeks.
Life expectancy greater than 3 months.
Life expectancy Not specified
life expectancy of at least 12 weeks
Life expectancy of at least 2 years.
Life expectancy of at least 3 months.
Life expectancy of at least 6 months
Life expectancy of at least 6 months.
Patient life expectancy is less than 12 months
Patient must have a life expectancy of at least 3 months
Patient with a life expectancy less than the follow-up period (5 years)
Patients whose life expectancy is less than 12 months
Subject's life expectancy is less than twelve months.
Exclusion Criteria: inability to read or understand English
Exclusion Criteria: Non-English speaking
Ability to read and understand English  Dutch  Danish  Flemish  French  German  Italian  Spanish or Swedish to ensure compliance with cognitive testing and study visit procedures.
Able to read and write in the study related documents translated into the primary local language
Able to speak and read English
Able to understand and speak English
English-speaking
inadequate knowledge of the Swedish language
Inclusion Criteria: English speaking
Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.
non-english speaking caregivers/parents
poor understanding of French language
Spanish-speaking if individual site allows
Speak English or Spanish
Speaks English
Subjects must be able to read and write in English.
Subjects must have a reliable caregiver who can read  understand and speak English or Spanish.
Subjects must have a reliable caregiver who can read  understand and speak same language.
Unable to understand and speak English
Patient must be able to read and speak English and willing to sign an informed consent in English
Patients must be able to complete a questionnaire in either English or Spanish.
Patients must be able to provide informed consent in English.
Exclusion Criteria: Known or suspect estrogen-dependent neoplasia
Any history of lymphoproliferative disorder.
bone metastasis) as clinically indicated is allowed as long as it is not evidence of progressive disease (see 4.5.2)
Exclusion Criteria: clinical evidence of metastatic disease
Accepts Healthy Volunteers: Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme  anaplastic astrocytoma  or anaplastic oligodendroglioma.
Accepts Healthy Volunteers: Confirmed diagnosis of malignant melanoma
Accepts Healthy Volunteers: Diagnosis of high-risk neuroblastoma  meeting one of the following criteria:
2 before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated  III or IV  totally removed  in total remission 
If in the opinion of the treating physician  sufficient time has elapsed  such that it is extremely likely that the patient has been cured of a prior malignancy  the patient may be eligible for the protocol.
Other active malignancies requiring systemic therapy.
Inclusion Criteria: Histologically-confirmed diagnosis of breast (females only) or prostate cancer
Phase 2 no previous or concurrent malignancy
Anti-cancer agents (exception: stable doses of hormonal therapy  e.g
Active malignancy requiring chemotherapy.
Any history of malignancy except for surgically cured skin cancer or pilomatricoma (benign tumor of the hair follicle that is associated with DM-1).
Any investigational  anti-cancer therapy within 6 weeks prior to Day 1.
Exclusion Criteria: Previous or current hormonal treatment of prostate cancer
more than two prior anticancer chemotherapy regimens
No prior or concurrent brain metastases (treated or untreated)
patient treated for prostate adenocarcinoma and overexposed during radiotherapy in a prostate adenocarcinoma in the radiation department of the a prostate adenocarcinoma in the radiation department of the Jean MONNET hospital/ service de radiotherapies be
Patients with metastatic disease who have a resectable primary tumor and are deemed a surgical candidate may have undergone prior resection
previous hormonal therapy as adjuvant treatment for breast cancer
Prior irradiation other than basal cell cancer of skin
Proven prostate cancer in need for endocrine treatment  except for neoadjuvant hormonal therapy  but including patients with a rising PSA further to prostatectomy or radiotherapy
Subject is currently being treated for cerebral carcinoma or sarcoma.
Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix  with measures other than a minor  complete surgical excision  .  chemotherapy)  or radiation therapy.
Metastatic disease OR unresectable primary tumor
Accessible disease includes lymph node metastases.
Inclusion Criteria: Clinically documented metastatic or unresectable locally recurrent clear cell renal carcinoma
Inclusion Criteria: Patients with a removed colorectal adenocarcinoma since less than 6 months  in total remission and for whom a monitoring is necessary to detect recurrences precociously.
Previous removal of kidney except if the size of the tumor was less than 5 cm or there was extensive liver or bone metastasis
Subject has a history of neoplastic disease (including leukemia  lymphoma  malignant melanoma)  or myeloproliferative disease  regardless of the time since treatment
unresectable liver metastasis
Histologically confirmed adenocarcinoma of the breast
Histologically or cytologically confirmed renal cell carcinoma (RCC)
Active brain metastasis or patients with meningeal metastases
Airway tumor or airway pathology
Allowed: Basal cell carcinoma of the skin  in situ carcinoma of the cervix  Kaposi's sarcoma.
Any other cancer for which patient has been disease free for 5 years
Available paraffin block or unstained paraffin sections on glass slides containing representative tumor tissue from the most recent tumor biopsy/resection.
Cancer disease within the last 5 years except for prostate cancer and some skin cancers
Central Nervous System (CNS) metastasis if neurologically unstable or requiring steroid use.
Concurrent neoplasms not specifically allowed.
Current CNS metastases or history of CNS metastases
Current or past history of metastasis
Currently have any known malignancy or have a history of malignancy other than non-melanoma skin cancer
Evidence of measurable recurrent or residual primary CNS neoplasm.
Exclusion Criteria: History or evidence of  active malignancy  except for basal cell carcinoma or squamous cell carcinoma of the skin  within the 24 months prior to entry
Exclusion Criteria: Islet cell or neuroendocrine carcinomas of the pancreas.
Exclusion Criteria: Metastatic disease-
Exclusion Criteria: Patient with concurrent malignancy (except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of cervix and/or breast) or patients with prior malignancies that have not been disease-free for five years
Exclusion Criteria: Previous history of excision biopsy of the primary tumour
Exclusion Criteria: Subjects who have brain metastases.
FISH+ HER2 gene amplified breast cancer
Group 2: Patients with inoperable esophageal cancer (adenocarcinoma oe squamous cell CA) with lesions extending beyond the mucosa but limited to the esophageal wall (T1sm or T2N0)
Had Pap smear evidence of atypical squamous cells or adenocarcinoma or other malignancy
has a history of malignancy  excepting basal cell carcinoma and malignancies in remission (greater than 2 years)
Hepatic and/or pulmonary metastasis would have been totally removed since less 6 months before inclusion.
Histological or cytological diagnosis of pancreatic adenocarcinoma
Histologically confirmed myxoid liposarcoma.
Histologically or cytologically documented metastatic breast cancer
histologically proven HR+ operable invasive breast cancer
History of invasive cancer within the past two years (excluding non-melanoma skin cancer)
History of malignancy within the last 5 years (except basal cell carcinoma  which must be in remission for at least 6 months prior to the study.
History of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (BCC/SCC) of skin
History of other malignancies within 3 years of Day 1  except for adequately treated carcinoma in situ of the cervix  ductal carcinoma in situ (DCIS) of breast  or basal or squamous cell skin cancer.
History of prior malignancies within 3 years  except for basal cell or squamous cell carcinoma of the skin  carcinoma in situ of the cervix or breast.
History of second cancer (except adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  or other cancer for which the patient has been disease-free for five or more years).
History of  or evidence of  active malignancy  except for basal cell carcinoma or squamous cell carcinoma of the skin  within the 24 months prior to entry
if metastatic  all metastasis would have been removed  the last surgery dating less 6 months.(amendment 1)
Imaging must show recurrent  unilateral  supratentorial tumor(s)
in situ carcinoma of the cervix
Inclusion Criteria: Histologically confirmed malignant melanoma that is advanced or metastatic.
Inclusion Criteria: Histologically verified breast cancer
Inclusion Criteria: Pathologically confirmed head and neck malignancy
Inclusion Criteria: Patient must have a histologically confirmed unilateral  supratentorial malignant glioma (grade 3 or 4  anaplastic astrocytoma  gliosarcoma  glioblastoma multiforme or malignant oligoastrocytoma)
Inclusion Criteria: Patients must have histologically confirmed thyroid cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
Inclusion Criteria: Patients must have locally advanced  recurrent  or metastatic adenoid cystic carcinoma of the head and neck which is considered incurable by known therapies  as judged by the investigator.
Inclusion Criteria: Unilateral operable palpable breast cancer
Known central nervous system or brain metastases.
Male breast cancer patients
Malignancy other than Kaposi's sarcoma or limited cutaneous basal cell carcinoma.
measurable tumor lesions
Men with prostate cancer may be enrolled at the discretion of the sponsor.
Metastatic disease to the central nervous system.
More than 2 weeks since prior local radiotherapy to the sites of metastatic disease
Must have archived tumor tissue for tissue testing.
No concurrent or prior malignancies within the past 5 years  except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
No history of prior malignancy  with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer  unless there is a 3-year disease-free interval.
No metastatic disease
No other prior malignancy  except for the following: Adequately treated basal cell or squamous cell skin cancer
No prior malignancy other than curatively treated carcinoma in-situ of the cervix or skin cancer
Non-epithelial ovarian tumors.
NOTE: Patients with malignancies being managed with local therapy  .  Kaposi's sarcoma  basal cell carcinoma) may enroll at the discretion of the site investigator.
or other cancer if the patient has been disease-free for more than 5 years
Other malignancy prior to entry into the study.
Other progressive tumoral affection known  or colorectal cancer in progression.
Past or current history of neoplasm other than breast cancer  except for: curatively treated non-melanoma skin cancer  in situ carcinoma of the cervix  other cancer curatively treated and with no evidence of disease for at least 7 years
Patient has had a malignancy within the past 2 years other than basal cell carcinoma.
Patient has measurable tumor on CT  spiral CT  or MRI scan that meet RECIST criteria.
Patient with a history of prostate cancer
Patients entering the Phase 1 portion of the study must have a histologically or cytologically documented diagnosis of cancer (solid tumors) refractory to conventional therapeutic modalities or for which no conventional treatment exists.
Patients should have cytologically or histologically confirmed adenoid cystic carcinoma of the head and neck.
Patients with a history of another primary malignancy < 5 years
Patients with a history of malignancy of any organ system  treated or untreated
Patients with a prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening  unless specific permission/waiver by the Sponsor is granted.
Patients with a T4N0M0 tumour and operated in emergency (because of a tumoral perforation) can be included
Patients with any evidence of cancer or kidney  liver  lung  blood  or brain disorders.
Patients with carcinomatous meningitis are excluded from the study.
Patients with clinical concern for brain metastases must have a negative brain CT scan or MRI within the past 56 days
Patients with known malignancy(ies).
Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective.
Patients with the following are excluded: Active malignancy requiring concomitant chemotherapy.
Personal history of colorectal cancer (CRC) or adenomatous colonic polyps and at least 5 years since last colonoscopy or no sooner than 3 years prior to enrollment date as long as their prior colonoscopy revealed at least one of the following high risk co
Previous diagnosis of noninvasive breast cancer is OK.
previous history of invasive malignancy within the last 5 years  other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix  adequately cone biopsied
Previous or concurrent malignancy except: inactive non-melanoma skin cancer
resectable liver metastasis
Solid enhancing lesions suspicious for pancreatic neuroendocrine tumor(s)
Solid lesions suspicious for microcystic adenoma(s)
Subjects with malignancy (except for prostate ca  or basal cell carcinoma of the skin) diagnosed within the last year  or on concurrent chemotherapy.
The presence of any intracranial tumor(s)  arteriovenous malformation(s) (AVMs)  or aneurysm(s) requiring treatment.
Uncontrolled brain metastases in the judgement of the Investigator.
with other organ metastasis or peritoneum metastasis
without other organ metastasis or peritoneum metastasis
Arterial bleeding
Menopausal status not specified
>= >= 4/5 on manual muscle testing for the deltoid on the affected side if isolated movement is present
No visual or vestibular condition that would affect balance
ELIGIBILITY CRITERIA include: Post-menopausal women who have used risedronate or alendronate continuously for at least 24 mos prior to enrollment
Adequate liver  renal  and bone marrow function
Any unstable joints of the lower extremity  recent hip and knee joints or fitted hip or knee pins  bolts and/or plates
muscle strength in a distal muscle group (ankle dorsiflexors or deep flexors of the fingers) which is less than or equal to grade 4 (Medical Research Council grade).
Normal thyroid function
Exclusion Criteria: Cases where one of the molar on either side is grossly carious or restored
Inclusion Criteria: Fully erupted bilateral first or second permanent molar teeth.
Occlusal fissures of molar teeth.
Normal cardiac function 
Absent sensation of the affected limb
adequate bone marrow  liver and kidney function
Affected wrist extensors >= >= 4 on MRC scale
Any unstable joints of the lower extremity
Have two target fingernails identified at baseline
Molar teeth with antagonist tooth not present or extracted
muscle strength in a proximal or mid-limb muscle group
Must have adequate bone marrow  renal and liver function.
Normal cardiac function
Patients must have adequate renal  hepatic  cardiac function and hematologic values
Patients with significant axial deviation of the knee.
Third molars
In addition  agree to be contacted monthly after week 24 for follow-up  until the entire study has been completed
Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg  steroids [other than those inhaled for treatment of asthmatic conditions]  nutritional supplements [other than vitamins or minerals]  dronabino
Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks (14 days) prior to study participation and for two weeks (14 days) after the end of their study participation.
Surgeon unwilling to have patient participate in a participate in a perioperative clonidine/ASA trial
Willing to abstain from any illegal or recreational drug substances for the duration of the trial
Inclusion Criteria: Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
Patients will agree to self-administer topical study medication  and will agree to complete all study procedures
Subject has confirmed his or her willingness to participate in the study after being informed of all aspects of the trial that are relevant to his or her decision to participate  by signing and dating the IRB / IEC approved informed consent form.
The informant must see the subject at least once a week for several hours and be available to accompany the subject to the screening and baseline visits  and at a minimum  be accessible by telephone for other scheduled visits.
The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent  approved by the appropriate Ethics Committee (EC).
Exclusion Criteria: Unwilling to consent
If they refuse to participate.
Patients and/or their parents (or guardians) who are willing to give written informed consent and willing to participate in and comply with the study protocol.
Patients who refuse to participate will be excluded.
Patients who refused to participate
Refusal to sign the informed consent form
Willing and able to comply with the protocol  including the inpatient requirements and outpatient visits.
Willing and able to give written informed consent.
Patient and patient's physician agree to have the patient return for all the required clinical contacts following study enrollment
Willing to comply with intensive diabetes management
Willing to consume one of the nutritional supplements for the study period.
Willing to participate in 3-day a week monitored strength-training program.
Have a friend or family member who is willing to participate in the study as an informant
Inclusion Criteria: Must be willing to participate with an additional blood draw.
no willingness of follow-up examinations
Parent/legal representative willing to permit venipuncture for purposes of collecting a blood sample.
Primary care pediatrician not willing to participate
The patient is willing to comply with the specified follow-up evaluation
Willing to return to the National Institutes of Health for follow-up
Willing to undergo serial non-invasive imaging
Willingness to be randomized and to commit to the 5-month study period
Willingness to come to the health facility for the following 28 days
Willingness to control visits
Agree to provide a blood and urine sample for submission to central laboratories
Must agree to have blood samples banked for future research testing
Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition  including their knee pain with the exception of acetaminophen  up to 1000 mg (2 tablets) four times a day (q.
Subject does not require and agrees not to take  for the duration of the study  any medication that is contraindicated with Kaletra?? (list will be in the protocol).
be willing to switch their current method of contraception
Willing to use acceptable methods of contraception
Exclusion Criteria: Refusal of village chief (for village inclusion)  or refusal of parent or guardian (for individual inclusion)
Agree to come to the clinic up to 2 times per week (according to randomization) for 16 weeks of study drug infusions and to participate in all required follow-up assessments through week 24
and agree not to use any other steroid hormonal therapy other than topical corticosteroids or inhaled corticosteroids for asthma  during the course of the study.
Patients must also be willing to abstain from any intra-articular (i.a.) or peri-articular injections to the knee or surgery during the course of the trial  except for the assigned study product.
Willing to undergo cranial osteopathic manipulation
These patients must be willing to use only acetaminophen as a rescue pain medication for the knee pain during the study period and refrain from even acetaminophen use 24 hours prior to any office visit
Willingness not to become pregnant during the first five months of the study for female participants
> 2 cycles carboplatin  or
> 2 cycles mitomycin C  or
Women who do not want the Gardasil vaccination series
spermicide
Contre-indication lactose
Avoid: Drugs with potential to cause peripheral neuropathy or pancreatitis.
Adjuvant trastuzumab during radiotherapy allowed
Women who decide they wish to get the Gardasil vaccination series
Women who had their first Gardasil injection prior to their referring Pap smear
Patient is not currently receiving  or is not anticipated to receive  concomitant anticancer agent(s) during the course of this study
Use of a medication such as oral/inhaled glucocorticoids that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
Being on drugs (a) that affect cortisol synthesis (eg
Patients with any of the following prior conditions are excluded: History of prior saquinavir (SQV) therapy for more than 14 days.
Current use of psychotrophic drugs
Patients on unstable doses of bisphosphonate or patients on stable doses for the past month prior to Screening  and are unwilling to remain on these stable doses throughout the course of the trial.
Accepts Healthy Volunteers: Have never received smallpox vaccine or previously received an experimental smallpox vectored vaccine (for vaccinia-naive cohorts only)
You must have been taking the same dose of amitriptyline once daily at bedtime for at least four (4) weeks.
Exclusion Criteria: Prior treatment with sorafenib or m-TOR inhibitors
Planned discontinuation or an increase or decrease by more than 30% of the current opioid dose
Exclusion Criteria : Receipt of any vaccine within the past 7 days (subjects may be deferred until after the seven days has passed.)
Allowed: Gammaglobulin  intravenous or intramuscular .
Dosing regimens allowable are continuous (ie  uninterrupted) daily or weekly formulations of risedronate (5 mg once daily [OD] or 35 or 30 mg once a week [OAW]) or alendronate (10 mg OD or 70 mg OAW)  for a minimum of 24 months prior to enrollment into st
Previous treatment with lamivudine  lobucavir  adefovir  famciclovir  or any other investigational nucleoside for HBV infection
a drug or treatment known to cause major organ system toxicity during the past four weeks
Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period.
Any concomitant therapy that would preclude use of cidofovir  foscarnet or ganciclovir.
Any concomitant therapy that would prohibit use of ganciclovir.
Any current statin therapy at maximum recommended dosage
At least 28 days since prior antiangiogenesis agents or immunotherapy comprising interferon and/or aldesleukin and recovered
Beta-blocker treatment at least three months
Change in treatment with systemic or inhaled corticosteroids within 14 days prior to start of study treatment.
Concomitant treatment with systemic corticosteroids greater than physiologic doses
Current or prior therapy with immunomodulators or immunosuppressive drugs and anticoagulant drugs within 30 days prior to study medication administration
Currently taking a stable dose of antipsychotic
currently treated with brimonidine
Depot injection vitamin D >10 000 IU in the past 9 months prior to starting the investigational product
Exclusion Criteria: Currently receiving antiviral  immunomodulatory or corticosteroid therapy
Exclusion Criteria: Patients taking greater than 81mg aspirin daily.
Exclusion Criteria: Patients who have previously not responded to treatment for PHN with gabapentin at doses of >=  1200 mg/day or pregabalin at doses >=  300 mg/day.
had received any experimental drug or device within 30 days of enrolment
Have received oral antifungal treatment within 3 months of baseline visit
Have required recent outpatient IV vasoactive (milrinone  dobutamine  dopamine  nitroglycerin  or open-label Natrecor) therapy as defined as >2 outpatient (excluding emergency room or inpatient) infusions in the last 30 days without a subsequent hospitali
History of any prior protease inhibitor therapy other than SQV.
Investigational drug therapy outside of this trial during or within 4 weeks prior the screening assessment
Maintenance therapy with amphotericin B (l mg/kg) up to 5 days/week.
Medical treatment arat form antihypertensives and oral anticonceptives
No prior trastuzumab or bevacizumab therapy
No prior treatment with other camptothecin drug.
No prior treatment with systemic anti-EGFR inhibitors or Pemetrexed
No therapeutic pharmaceutical class changes for at least 1 month
Other contraindication of steroid treatment
Patient receiving treatment with ACTH within the 3 months preceding study entry
Patients on concomitant therapy with anticoagulants (low dose aspirin  not exceeding 325 mg per day as an anti-thrombotic agent is permitted if stable for one month prior to Screening and remains stable throughout the study.
Patients receiving an intra-articular hyaluronan in any joint within the previous 6 months prior to screening.
Patients receiving GVHD prophylaxis including cyclosporine or tacrolimus
Patients who take medications on a chronic basis  such as antihypertensive medications or thyroid replacement therapy  etc
Previous treatment with D-serine
Previous treatment with interferon must have ended at least 6 months prior to screening visit
Previous treatment with polyene or other antifungal active on zygomycete (posaconazole  itraconazole) over 5 days during the month previous inclusion
previously treated with ezetimibe or participated in a clinical study with ezetimibe
Prior therapy with anti-VEGF agents.
Prior treatment with anti-angiogenic agents.
Prior treatment with glucocorticoids  anabolic steroids  testosterone  growth hormone  or IGF-I within 1 year of entry
Progression during or following treatment with topotecan or liposomal doxorubicin.
Receiving a stable medical regimen for CHF for at least 60 days before the study start  including angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs)  and/or beta-blockers.
Recent or current treatment with any drugs modifying the testosterone level
requirement for chronic corticosteroid treatment
Requirement for permanent catheters for IV ganciclovir administration.
Started antidepressant medication for treatment of depression during past 6 weeks
Subject has been prescribed ADVATE by their treating physician
Subject is being treated with aspirin or has used this agent within 3 weeks prior to administration of screening
Subjects receiving androgen or anti-androgen therapy.
Subjects who require treatment with an anti-coagulant with the exception of low-dose Aspirin?? (>= >=81 mg/day)  warfarin (>= >=1 mg/day)  or heparin for IV catheter patency.
subjects with current treatment with typical or atypical neuroleptics which should be changed
Systemic ketoconazole and acyclovir  or oral nystatin for acute therapy.
The patient did not improve on earlier alpha-1 blocker treatment
treatment with a non-approved or experimental drug during 1 month before entry into the study
Treatment with an investigational drug within 30 days.
Treatment with antidepressants at entry into the study before 2 weeks.
Treatment with antiresorptive agents other than risedronate  alendronate  and hormone replacement therapy within the last 36 months before study entry (ie  ibandronate  pamidronate  etidronate  raloxifene  clodronate  or zoledronate)
Treatment with IV tPA or other thrombolytic agent.
Treatment with lipid-lowering drug other than Hydroxy-Methylglutaryl Coenzyme A (HMG-CoA)-inhibitor within 3 months prior to inclusion
Treatment with magnesium sulfate
Treatment with other antihistamines in the last month before study entry.
Treatment with psychotropic medication in the previous month.
Are receiving optimal treatment with long-term oral medications  .  diuretics  angiotensin converting enzyme (ACE) inhibitors  angiotensin II receptor blockers (ARBs)  and beta blockers  unless these are documented to be contraindicated or not tolerated)
Patients receiving any intra-articular or local peri-articular corticosteroid injections to the study joint/knee within the previous 3 months prior to Screening.
Patients receiving any intra-articular  intra-muscular or local peri-articular corticosteroid injections to any other joint (beside the study joint) or soft tissue area within the past 3 months.
Treated with PPAR agonists within 12 weeks prior to study start
(Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)
(The use of inhaled or intranasal steroids or oral steroids at a dose of >= >=10 mg/day prednisone or its equivalent are permitted.)
Are on a stable dose of the same AEDs for the 1 month prior to Visit 1.
Metrifonate during the past three months
More than 14 days since prior and no concurrent inhibitors or inducers of CYP3A4  including any of the following: Rifapentine
Ongoing use of thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR ??) agonists  eg  rosiglitazone (Avandia?? or equivalent) or pioglitazone (Actos?? or equivalent).
Stabilized on atorvastatin 10 mg daily and by subject reported history had taken at least 80% of daily doses for the 4 weeks preceding Visit 1
Steroid inhalants are permitted if the patient has been on a stable regimen for the past month prior to Screening and remains on this regimen throughout the course of the trial.
Subject must be currently taking simvastatin 20 mg daily and by history has taken 80% of daily evening doses for the preceding 6 weeks prior to Visit 3 (Baseline Visit).
Systemic corticosteroid use for <21 days for acute problems is permitted as clinically indicated
Use of open-label nesiritide within 48 hours of study drug administration.
Chronic administration of immunosuppressants since birth.
Fluconazole (doses > 200 mg/day)
Have had an injection of botulinum toxin in the head or neck within 6 months prior to enrollment
Have used any topical cosmetics or medicated products on the affected nails within 2 weeks of baseline visit
Recommended: Standard immunizations
Allowed: Erythropoietin  G-CSF  or GM-CSF.
Allowed: G-CSF and GM-CSF.
Excluded: G-CSF (filgrastim).
Planned discontinuation of opioids during the study
Prescription or herbal muscle stimulants  relaxants  etc
Subject has been prescribed or has taken amphetamine products in the past  including childhood
Clofazimine.
Currently taking diabetes mellitus medications  St
Exclusion Criteria: Planned discontinuation of opioids during the study.
For atorvastatin  fluvastatin  lovastatin  pravastatin and simvastatin 80 mg QD at the time of the index event and for rosuvastatin 20 mg QD to 40 mg QD
However  chronic systemic corticosteroid use should be avoided.
If using sleep medications  medication and dosage have not been changed in the past month  and will remain unchanged for the duration of the acute treatment phase of the study  .  4 weeks)
In general  patients should be using opioids on a daily basis.
Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
Opiates.
Patients currently taking Organic germanium  or who have taken Organic germanium within the past three months
Patients enrolled in ACTG 128 and ACTG 138 must meet study end points or meet protocol definitions for being permanently off zidovudine (AZT) before enrolling in this study.
Patients taking unstable doses of glucosamine- or chondroitin sulfate-containing compounds  or patients taking stable dose for less than 4 months prior to Screening  or patients taking stable dose for at least 4 months prior to and unwilling to remain on 
Patients who  if they are currently taking low dose aspirin (325 mg/day or less)  are willing to remain on a stable dose throughout the study and are willing to refrain from any aspirin dose 24 hours prior to any office visit.
Used investigational compound within 30 days.
> 2 opioid and/or nonopioid analgesic for shoulder pain  .  > 2 regardless of class)
A depot injection or an implant of any drug (other than contraceptives) within 3 months prior to administration of study medication.
A history of non-response to an adequate course of l-dopa or a dopamine agonist 
A minimum of four weeks washout of antidepressant medication should occur prior to screening
Acyclovir (up to 1000 mg/day).
Administration of immune globulin or other blood products within the last three months  or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine
Aerosol ribavirin for short-term treatment of RSV.
All other analgesic medications for any chronic condition must be stopped (see exceptions for acute treatment of transient flares of pain)
Allowed: Atovaquone  IV pentamidine  trimethoprim-dapsone  clindamycin-primaquine  trimetrexate  or TMP/SMX for acute PCP.
Allowed: Topical and/or antifungal agents  except ketoconazole.
Alternative medications including megadose vitamins  herbal preparations  tonics  extracts  etc
Amikacin.
amitriptyline  nortriptyline  imipramine)
Amphotericin B.
Analgesics.
Antacids within 2 hours of zidovudine (AZT) dose.
Antibiotics for bacterial infections.
Anticonvulsants  SNRIs  opiates and benzodiazepines should be tapered appropriately  using product label instructions as a guide.
antidepressant medication during the past four weeks.
Antiemetics.
Antiepileptics (phenobarbital and other barbiturates).
Antifungal prophylaxis with oral fluconazole or ketoconazole.
Antihypertensive medication other than diuretics.
Antipyretics.
Antiviral prophylaxis with a maximum of 1 gram of oral acyclovir per day.
any medication or supplement use
Any nephrotoxic agent.
Any sulfonamide medications.
Are on their first combination of stable anti-HIV drugs (have not changed drugs for at least 6 months  except for reasons other than failing treatment or short interruptions of less than 7 days).
Are receiving investigational drugs or are participating in a clinical trial involving anti-HIV medications
Are receiving medications and/or medications at certain doses that might interfere with the study.
Are taking a stable Videx-containing anti-HIV regimen  using Videx tablets either once or twice a day  for at least 2 weeks prior to the screening visit.
Are taking Videx in liquid form  nelfinavir  or amprenavir.
Aspirin.
Azithromycin.
Benadryl and/or aspirin.
Benzodiazepines (diazepam  triazolam).
Beta-blockers.
Biologic response modifiers such as interferon and IL-2.
Biologic response modifiers.
-Biological response modifiers  such as G-CSF  within 3 week prior to study entry
Carafate.
Carbamazepine
Change in intranasal medications (including use of corticosteroids  cromolyn  ipratropium bromide  phenylephrine  or oxymetazoline) within 14 days prior to start of study treatment.
Chloramphenicol.
Cholestyramine resin.
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first immunization
Chronic systemic antibiotic use
Chronic use of steroids or other immunosuppressive agents for other conditions.
Chronic use of systemic steroids or immunosuppressive agents
Cimetidine.
Ciprofloxacin.
Clarithromycin
Clarithromycin.
Clindamycin.
Clinically indicated antibiotics  unless excluded.
Concomitant application with another alpha-1 blocker
Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1.
Concomitant use or use within the 4 weeks prior to Visit 1 of neuroleptics  monoamine oxidase (MAO) inhibitors  barbiturates (except for seizure control indication)  benzodiazepines (other than occasional intermittent use)  and narcotic analgesics.
Concurrent Medication: Allowed
Concurrent Medication: Excluded
Concurrent Medication: Required
Concurrent Medication: The following medications / substances may NOT be ingested up to one hour before or 4 hours after a Nevirapine dose:
Concurrently taking (within the past 30 days) phenytoin  cimetidine  rifampin  cyclosporin or tacrolimus.
Conditions requiring use of H2 blockers or other antacids.
Corticosteroids.
Coumadin
Current use of corticosteroids or erythropoietin
Current use of MAO inhibitors  tricyclic antidepressant medications  or cyclopropane or halothane anesthetic agents.
Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).
Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)
Currently taking NSAIDs (with the exception of aspirin).
Currently taking psychostimulant medication
Currently taking warfarin or other anticoagulants.
Currently treated with clozapine  lamotrigine or carbamazepine  or defined as treatment refractory
Cyclosporine trough blood level < 110 ng/ml
Dapsone.
darbopoeitin [Aranesp??] is permitted)
Dicumarol  warfarin  and other anticoagulant drugs.
Dicumarol  warfarin  and other anticoagulant medications.
Didanosine (ddI).
Digitoxin.
Diltiazem
Doxycycline.
Drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
Erythromycin
Erythropoietin.
Estrogens)  (b) any form of glucocorticoid which would inhibit CRH and ACTH secretion.
Ethambutol.
examples of inhibitors: antidepressants (SSRI)  cimetidine  diltiazem  macrolides  imidazoles  neuroleptics  verapamil  fluoroquinolones  antihistamines) within 30 days prior to administration of the study medication.
Exceptions are products containing glucosamine/Chondroitin/methylsulfonylmethane (MSM) if stable for 4 months prior to Screening and remain stable throughout study and fulfill the VAS pain entry criteria).
Excluded Medications: Experimental drugs
Excluded within 20 days prior to study entry: G-CSF (filgrastim).
Excluded within 30 days of study entry: Antiretroviral agents other than zidovudine (AZT).
Excluded within 30 days prior to study entry: Anti-HIV medication other than zidovudine (AZT).
Excluded within 4 weeks of study entry: Any approved or investigational antiretroviral  immunosuppressive or cytotoxic drugs.
Excluded: Antiretroviral agents other than zidovudine (AZT) or dideoxycytidine (ddC) within 4 weeks of study entry.
Excluded: Antiretrovirals other than study drugs.
Excluded: Any approved or investigational antiretroviral  immunosuppressive  or cytotoxic drugs.
Excluded: Immunomodulators  biologic response modifiers  interferon  or investigational agents that may influence course of CMV infection.
Excluded: Immunomodulators.
Excluded: Non-nucleoside reverse transcriptase inhibitors.
Excluded: Oral contraceptives.
Excluded: PER AMENDMENT 4/25/96: Use of IV ganciclovir  foscarnet or cidofovir within 6 months prior to study enrollment
Excluded: Zidovudine (AZT)  other antiretroviral agents  biological modifiers  and investigational medications.
Exclusion Criteria: Previous vaccination with a investigational vaccine or a rabies vaccine
Exclusion Criteria: Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine  or planned use during the study period.
Failure to observe the designated washout periods for any of the prohibited medications
Flucytosine.
Fluvoxamine
for those on Coumadin  INR > 3.0
Foscarnet.
Frequent need of rescue benzodiazepines (two or more times a month).
Ganciclovir.
G-CSF.
Glucocorticoids and steroid hormones (including oral contraceptives).
Had received medroxyprogesterone acetate injection <=12 weeks prior to enrolment
Had used barbiturates  antiepileptics  rifampin  griseofulvin  or other hepatic enzyme inducing drugs within 30 days of enrolment
Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).
Have received a vaccine within 30 days prior to study entry.
Have received any other investigational agent during this study
Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks.
Have taken medications that affect your immune system within 30 days prior to study entry.
Have used any HIV vaccine or drugs affecting the immune system within 30 days prior to entering the study.
Have used any investigational drug within the previous 1 month or 5 half-lives of the investigational agent  whichever is longer  or 3 months for any biologic of unknown half-life
Having received any approved or investigational antiretroviral  immunosuppressive  or cytotoxic drugs or any other experimental drug with 4 weeks of study entry.
HIV protease inhibitors
Hypericum perforatum (St
Ibuprofen.
If patients are not taking any analgesic/anti-inflammatory medication or have not taken any pain medication (prescription [Rx] or over-the-counter [OTC]) in the previous 3 days from Screening then they should have a VAS pain score after walking on a 50 ft
If using other psychotropic medications  medication and dosage have not been changed in the past 2 months  and will remain unchanged for the duration of the acute treatment phase of the study  .  4 weeks)
Immunoglobulin  IV (IVIG).
Immunoglobulin.
Immunomodulating agents such as interferons  isoprinosine  or interleukin-2 within 2 weeks of entry.
Immunomodulators.
Immunosuppressive agents: prednisone and other corticosteroids (taken orally or by injection)  methotrexate  cyclophosphamide  cyclosporin  tacrolimus  etc.
Insulin
Interferon.
Interferons.
Interleukins.
Investigational drugs not specifically allowed.
Isoniazid.
Itraconazole
Itraconazole.
John's Wort  appetite suppressants  ephedrine-containing medications  theophylline  clonidine  reserpine  methyldopa  or anti-anginal medications  .  beta-blockers  calcium channel blockers  nitroglycerin preparations)
Ketoconazole
Ketoconazole  acyclovir  or nystatin for prophylaxis.
Ketoconazole  etomidate) or protein binding (eg
Ketoconazole.
Live attenuated vaccines within 60 days of study [NOTE: Medically indicated sub-unit or killed vaccines  .  influenza  pneumococcal  hepatitis A and B) are not exclusionary  but should be given at least 4 weeks away from HIV immunizations]
Lupron  estrogen  are permitted)
May not be receiving any other investigational agents.
mefloquine  artesunate  quinine  tetracycline  or clindamycin
Metronidazole for up to 14 days.
Mitomycin-C or nitrosurea within 42 days.
Modafinil
More than 28 days since prior investigational agents
More than 4 months of prior ganciclovir or foscarnet  or within 4 weeks prior to study entry.
More than 6 months since prior and no concurrent amiodarone
Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).
Need for psychoactive medications other than the study drugs  except for one benzodiazepine or hypnotic given at a stable dose.
Nefazodone
Neuroleptics and lithium
Nitroglycerin
Nitroglycerin.
No concomitant medications may be taken during the study
No prior investigational drug within the last 30 days
No prior trastuzumab (Herceptin??)
No prior tubule  DNA  or mitosis-targeting agents for RCC
Non-nucleoside reverse transcriptase inhibitor or protease inhibitor.
Ofloxacin.
Omalizumab within 3 months.
or any investigational agent within 60 days of entry.
Oral corticosteroids within one month  cromolyn sodium or nedocromil within 14 days  theophylline  LABA  ZYFLO  or leukotriene modifiers  warfarin or propranolol  inhaled anti-cholinergics  or combination LABA/ICS.
other cholinergic drugs  .  donepezil  tacrine  succinylcholine-type muscle relaxants) during the past two weeks (topical pilocarpine will be permitted)
Other medications
Oxcarbazepine
Patient has used injected anesthetics or steroids within 30 days of baseline.
Patient ingesting body building/anabolic steroids within the last 6 months preceding the study
Patient is currently taking an alpha-2 agonist  alpha methyldopa  reserpine  clopidogrel  or ticlopidine
Patient is not maintained on a stable corticosteroid regimen
Patient must have a minimum washout period of greater than 5 times the half-life of the drug of any of the following medications: benzodiazepines  skeletal muscle relaxants  orally administered steroids  capsaicin  mexiletene  centrally acting analgesics 
Patient must not have received other investigational drugs within 14 days before enrollment.
Patient received Mannitol prior to placement of ICP monitor
Patient receiving androgens  immunoglobulins  cyclophosphamide  cyclosporin A  or other immunosuppressive agents  except azathioprine  methotrexate  and hydrochloroquine within the last 3 months
Patient treated with azathioprine  methotrexate  or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study
Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent
Patients currently receiving Neurontin?? (gabapentin)  glutamine supplements  Elavil?? (amitriptyline)  Dilantin??  Tegretol??  tricyclic antidepressants or other similar medications during the study period
Patients currently treated with gabapentin or pregabalin at screening may be eligible for the study  but must have a tapering period wherein the dose of gabapentin or pregabalin is reduced gradually over a period of at least 7 days plus a 2-day or 3-day w
Patients must not have any prior anthracyclines (doxorubicin  epirubicin  daunorubicin  idarubicin) or mitoxantrone  or bortezomib.
Patients receiving an intra-articular hyaluronan in the study joint within the previous 9 months prior to screening.
Patients receiving any oral corticosteroid within the previous month
Patients taking a stable dose of selective serotonin reuptake inhibitor antidepressant (except fluvoxamine) will be allowed.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin  during the last two weeks.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.
Patients taking any of the following medications for less than 3 months  or who plan to take them for the first time during the next 3 months: ACE-inhibitors  angiotensin receptor blockers  calcium channel blockers  or statins.
Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study
Patients taking nonsteroidal anti-inflammatory agents will be asked to discontinue these medications 3 days prior to muscle biopsy.
Patients who have received investigational drugs < 28 days prior to registration.
Patients will not be eligible for this study if they: Are receiving high doses of testosterone
Patients with chronic non-cancer pain that necessitates the use of non- injectable opioid analgesics.
Phenobarbital
Phenytoin
Plan to change their medications within 8 weeks following the screening visit.
Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose
Previous exposure to a Ras pathway inhibitor (including herceptin  EGFr inhibitors  farnesyl transferase inhibitors or MEK inhibitors)
Previous lack of response to two or more antidepressants at adequate dosage.
Prior ddI  ddC  3TC or d4T (more than 2 weeks total).
Prior Medication: Allowed
Prior Medication: Excluded within 20 days prior to study entry
Prior Medication: Excluded within 30 days of study entry
Prior Medication: Excluded within 30 days prior to study entry
Prior Medication: Excluded within 4 weeks of study entry
Prior Medication: Excluded
Prior Medication: Excluded: PER AMENDMENT 4/25/96
Prior receipt of HIV-1 vaccine in a previous HIV vaccine trial
Probenecid.
propylthiouracil  methimazole  iodides).
Protease inhibitors except IDV.
Pyrazinamide.
Pyrimethamine.
Rapamycin intolerability
Recombinant erythropoietin (rEPO) and granulocyte-colony stimulating factor (G-CSF  filgrastim).
regular intake of pain medications for any other chronic pain
Regularly prescribed medications  such as antipyretics  antidepressants  oral contraceptives  megestrol acetate  testosterone  or any other medication.
Related investigational agents.
Required: Stable prescribed dosage of zidovudine (AZT)  = or > 500 mg/day.
Requirement for anticoagulation with IV heparin or warfarin in the first 48 hours after enrollment.
requirement for concurrent immunosuppressive drug(s)
Requirement for intravenous diuretic whilst either an inpatient or in an emergency room setting with intravenous diuretics  vasodilators or inotropes
Requirement for systemic aminoglycoside antibiotics within 14 days prior to start of study treatment.
Requires beta-blockers  MAO inhibitors  tricyclic antidepressants  oral or intranasal anticholinergics
Rifabutin
Rifabutin and rifampin.
Rifabutin.
Rifampin
Rifampin.
Should repeat MMR 3 months after discontinuing study.
Simvastatin consumption meant that subjects must be currently taking simvastatin 20mg daily  and by history have taken at least 80% of daily evening doses for the preceding 6 weeks prior to baseline visit
Stable medications for 4 weeks prior to screening
steroid injections to the shoulder in the last 6-wks
Steroids other than topical.
Subject has received an investigational drug within 30 days prior to the initiation of study dosing.
Subject is being treated with coumadin  heparin  clopidogrel or has used these agents within 2 weeks of screening
Subject must not be taking any medication that could interact with Kaletra?? to enhance hepatic toxicity.
Subjects must be actively taking ZDV for at least 4 continuous weeks up to the time of study entry.
Subjects must not be currently taking an approved statin
Subjects taking antihypertensive medication.
Subjects taking antithyroid medication  
Subjects taking MAO inhibitors.
Subjects taking topical or oral decongestant products within 7 days of Visit 2.
Subjects taking trycyclic antidepressants  
Subjects that have received any other investigational agents within 28 days of first day of study drug dosing.
Subjects who are taking concomitant immunomodulatory agents including  but not limited to  interferons  interleukins  systemic steroids  cyclosporine  tacrolimus  calcineurin inhibitors  chronic low-dose methotrexate  or azathioprine
Subjects who have been receiving monoamine oxidase inhibitors
Subjects who have been receiving monoamine oxidase inhibitors.
Subjects who have not observed designated washout periods for prohibited medications (eg  potent inhibitors of CYP3A4  prescription or over-the-counter agents know to lower lipid levels  corticosteroids)  or have been on a stable regimen of any cardiovasc
Subjects who have not observed the designated washout periods for any of the prohibited medications
Subjects who have received an investigational drug within 30 days prior to study dosing.
Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
Subjects who have taken prescription medication 14 days preceding administration of study medication or over-the-counter products 7 days preceding administration of study medication  except for topical products without systemic absorption
Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication  except for topical products without systemic absorption
Subjects with a previous history of statin use must have not used a statin for at least 6 months prior to Visit 3 (Baseline Visit).
Sucralfate.
Sulfa drugs.
Sulfadiazine.
Systemic acyclovir or any nephrotoxic agent  specifically aminoglycosides  amphotericin B  and parenteral pentamidines.
Systemic acyclovir.
Systemic steroids.
Taken any of the following substances: An investigational drug during the past four weeks
Taking any drug except penicillin-V  folate or iron supplementation  hydroxyurea
Taking any medications (including over the counter products)  herbal products  mineral supplements or vitamins (other than a daily multivitamin preparation)  other than contraceptives (for women)  within 2 weeks of start of the study
Terfenadine  astemizole  cisapride  triazolam and midazolam.
The equivalent dose of 300 mg morphine per day is the maximum opioid analgesic dose allowed
The following medications / substances may NOT be ingested up to one hour before or 4 hours after a Nevirapine dose: Antacids (particularly those containing calcium carbonate).
They should only be given nevirapine as part of an initial study regimen if resistance testing can be done to confirm that they do not have nevirapine resistance.
This includes any dose level of oral steroids or inhaled steroids  but not topical steroids
Tolbutamide.
Topical (but not at the proposed vaccination sites) or inhalational steroids are permitted
Topical antifungals  clotrimazole  ketoconazole  fluconazole  and amphotericin B for mucosal and esophageal candidiasis.
Topical steroids.
Treated with antipsychotic medications for at least 6 months in the past  and on a stable dose of the same antipsychotic medication over the past month
treated with any other investigational drug within 30 days prior Visit 1
Treated with investigational drug or device within last 30 days
Trimethoprim / sulfamethoxazole (Bactrim).
Troleandomycin
Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization  or planned use up to 30 days after the third immunization
Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates  carbamazepine  phenytoin glucocorticoids   omerprazole
--Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates  carbamazepine  phenytoin glucocorticoids  omerprazole
Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
Use of any estrogen  progestin  androgen containing medications or tibolone within 12 weeks before screening.
Use of any investigational agents within 30 days prior to screening
Use of any medication within one month prior to study start  except occasional use of acetaminophen or ibuprofen.
Use of any prescription or over-the-counter medications or dietary/herbal supplements (with the exception of oral or implanted contraceptives) within 1 week or 5 half-lives  whichever is longer  of the study.
Use of bimatoprost or an ocular prostaglandin (eg  latanoprost  travoprost) within 6 weeks prior to baseline (Day 0)
Use of carbamazepine  phenytoin  phenobarbital
Use of combination alendronate and risedronate  either simultaneously or sequentially  within 60 months prior to enrollment  or use of any anti-resorptive agent in combination with risedronate or alendronate
Use of cyclosporin
Use of excluded concomitant medications
Use of herbal or anabolic supplements
Use of ketoconazole  itraconazole  and ritonavir
Use of or requirement for inhaled gentamicin or amikacin within 14 days prior to start of study treatment or during study treatment.
Use of prescription medication within 14 days prior to administration of a study medication or over the counter products (including natural food supplements  vitamins  garlic as a supplement) within 7 days prior to administration of study medication  exce
Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication  except for topical products without systemic absorption
Valproic acid.
Verapamil
Vitamin D (25-hydroxyvitamin D) between 16 ng/ml and 80 ng/ml
Voriconazole
With a previous use of tegaserod within 3 months prior to baseline.
You are currently taking an anticonvulsant  cisapride (Propulsid)  or if you have taken an opioid for three or more consecutive days during the 14 days prior to Visit 2.
Subject uses insulin  PPAR gamma agonists (rosiglitazone or pioglitazone)  exenatide (Byetta)  acarbose (Prandase  Precose) or dipeptidyl-peptidase 4 (DPP-4) inhibitors (JANUVIA>= 1)
Hormonal contraceptives (starting al least 4 weeks prior to study administration)
Use of oral contraceptives  insulin sensitizers  d-chiro inositol  or any other supplements affecting weight or insulin sensitivity during the preceding two months
Inclusion Criteria: Female subjects may not be pregnant and/or will agree to use appropriate method of contraception beginning at least 2 weeks prior to administration of the first dose of study drug in the first treatment period  throughout the study and
Both women and men must take adequate precautions to prevent pregnancy during treatment.
Male and female patients of reproductive potential must agree to use adequate contraception  
Women of childbearing potential must have a pre-treatment pregnancy test
Female patients of child bearing age who have a positive pregnancy test on admission.
Have a positive urine pregnancy test (for women of child-bearing capacity)
a negative urine pregnancy test at admission
Negative pregnancy test (for females of childbearing potential).
Negative pregnancy test for female patients
Negative urine pregnancy test for females (to be confirmed at screening and prior to every dose of study medication)
Positive urine pregnancy screen
Positive urine pregnancy test at screening (performed on all females)
Positive urine pregnancy test at screening.
Be breast feeding a child
Intent to breastfeed infant
The presently used contraceptive method were any of condoms alone  abstinence  withdrawal  or a rhythm method
<12 months post-partum*>= ???>= 
A reliable method for this study is defined as one of the following: oral or injectable contraceptives  IUD  contraceptive implants  tubal ligation  hysterectomy  a barrier method (diaphragm with spermicidal foam or jelly  or a condom).
All forms of contraceptive medication are permissible for this study and would not result in a female's exclusion from participation
Inclusion Criteria: women admitted to the postpartum floor during the study period
Give birth to the target child at participating hospitals
Have a negative pregnancy test within 14 days of study entry  if a woman able to have children.
Exclusion Criteria: Multiple birth greater than twins
If abstinent  women must agree to use double-barrier contraception throughout the study period should they become sexually active.
The acceptable methods of contraception are condom + spermicide (at least 14 days prior to study drug administration)  diaphragm + spermicide (at least 14 days prior to study drug administration)or intrauterine contraceptive device (placed at least 4 week
>= ???>= 'Partum' is defined as a delivery or other termination that occurs after 20 weeks gestation.
they do not use an effective method of contraception until all follow-up procedures are complete
Had a desire to conceive in the subsequent 9 months of enrolment
Non-surgically sterilized women or non-menopaused women.
vasectomized partner (six months minimum)
(Methods of contraception considered effective are an oral  injectable or implanted contraceptive agent  or an intra-uterine device with a failure rate of 1% per year  and abstinence).
Pregnant or has not completed child bearing*
Acceptable methods of contraception: Intra-uterine contraceptive device
Additionally  participants who were menopausal
both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial
Acceptable methods of birth control include oral or transdermal contraceptives  condom  spermicidal foam  intrauterine device (IUD)  progestin implant or injection  abstinence  vaginal ring  or sterilization of partner
Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner  as appropriate throughout the course of the study
Females who are nursing  pregnant  or intend to become pregnant during the time of the study  or females of child-bearing potential who have a positive pregnancy test during screening evaluation
women of childbearing potential and men able to father children must use non-hormonal-based birth control while on study.
Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy
Women who are pregnant  breast feeding  or of child bearing potentials
Acceptable methods of contraception: Intra-uterine contraceptive device (place al least 4 weeks prior to study drug administration)
Agree to use a barrier method of birth control  men and women  while receiving study drugs and for 3 months afterwards.
Agree to use an effective barrier method of birth control during the study.
Also  male patients whose sexual partners are women of child bearing potential not using effective birth control will be excluded.
Breast- feeding subject.
Breast-feeding subject
Female of childbearing age not practicing contraception
Female patients of child-bearing potential must have a negative pregnancy test within 14 days before initiation of study drug dosing
Female subjects must be postmenopausal or otherwise unable to have children
If subjects who are not sexually active with members of the opposite sex become so during the study  these subjects must agree to use a medically accepted method of contraception.
Patient is a nursing mother.
Post-menopausal women must be amenorrheic for at least 12 months to be considered non-child-bearing potential
Sexually active female subject who is not surgically sterile or 2 years post menopausal must agree to use contraception/birth control measure while on study  .  oral contraceptives  diaphragms with spermicide  condoms with spermicide  intrauterine devices
Subjects of child-bearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment (about 5 half lives).
Those females using hormonal contraceptives must also be using an additional approved method of contraception  .  a barrier method plus spermicide or IUD) starting with the Baseline Phase and continuing throughout the entire study period.
Women must use a medically acceptable form of contraception (steroidal contraceptive  double-barrier  or intra-uterine device) during the entire study period  or they must be surgically sterilized or post-menopausal
Women of child-bearing age who are sexually active and not practicing an acceptable form of contraception
Women of child-bearing potential  must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug
Non-pregnant  non-breastfeeding females
All patients (males and females) who are fertile must agree to use an effective barrier method of birth control  .  latex condom  diaphragm  cervical cap  etc) to avoid pregnancy.
All WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant .
Are male or female without child-bearing potential  .  surgically sterilized [via bilateral tubal ligation bilateral oophorectomy  or hysterectomy]  at least one year postmenopausal  or using adequate birth control).
Are pregnant or breast-feeding.
Are pregnant  nursing  or planning pregnancy prior to study enrollment
Be pregnant or breast-feeding
Breast feeding
Current pregnancy or breast-feeding
Exclusion Criteria: Are pregnant or nursing
Exclusion Criteria: Breast feeding female subjects
Exclusion Criteria: Pregnancy
Exclusion Criteria: Pregnancy or lactation
Exclusion Criteria: pregnant or breast feeding women  or with a reproductive potential and no practicing an effective method of contraception during the second part of ovarian cycle ( PET is realised during the first part of ovarian cycle)
Exclusion Criteria: Pregnant or lactating women.
Exclusion criteria: Pregnant women.
Exclusion Criteria: Women of childbearing potential may not be entered if:
Female patient of childbearing potential (not surgically sterile or at least 2 years postmenopausal) has a negative pregnancy test at baseline/day 1 and is not lactating
Female patients who are pregnant or breast feeding or patients of reproductive potential not using an effective method of birth control will be excluded
Female patients who are pregnant or breast feeding.
Female subject is pregnant or lactating.
Female subjects of childbearing potential having unprotected sexual intercourse with any non- sterile male partner  
Female subjects of childbearing potential must be using medically acceptable birth control measures.
Female subjects of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing
Female subjects of childbearing potential who have had unprotected sexual intercourse with any non-sterile male partner  
Female subjects who are pregnant or breast-feeding.
Female volunteers who are not documented to be surgically sterile must be willing to abstain from sexual intercourse during the study or be willing to use intrauterine devices or 2 forms of barrier contraception for at least 7 days prior to the initial do
Females must have the urine or serum pregnancy test (HCG) that is negative at Screening and Day 1 of Period 1.
Females should be either of nonchildbearing potential as a result of surgery or menopause (1 year after onset)  or of childbearing potential and practicing a medically acceptable method of contraception  .  abstinence  a barrier method plus spermicide  or
Females who are pregnant  nursing or unwilling to use/practice adequate contraception (hormonal  I.U.D.  barrier method  etc.).
Females whom are pregnant or nursing>= ???>= ???>= ???>= ???>= 
Fertile patients must use effective contraception
General exclusion criteria: Women who are pregnant or women of childbearing potential who do not use adequate contraception
If female subject  is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.
If female  must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and throughout the study: hormonal  .  oral  transdermal  implant or injection)
If female  not be pregnant  including negative serum pregnancy test
If female  subject must have a negative pregnancy test and agree to use  for the duration of the study  a barrier method of birth control that has a history of proven reliability as judged by the investigator.
In addition  men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control
Inclusion Criteria: Negative pregnancy test for women of childbearing potential within 3 days prior to baseline evaluation and use of an acceptable means of contraception (condom  hormonal or mechanical method) for one month prior to immunization and the 
Inclusion Criteria: Pregnant between 32-36 weeks estimated gestation
is pregnant or breast-feeding.
known or suspected pregnancy
Male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.
Negative pregnancy test
Non-childbearing potential female subjects is defined as post-menopausal state: absence of menses for 12 months prior to drug administration or hysterectomy with bilateral oophorectomy  or tubal ligation at least 6 months prior to drug administration
non-pregnant and
not breastfeeding
Not pregnant or lactating
Not pregnant or nursing
Not pregnant  if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.
others: pregnant or breast-feeding patients
Patient has no childbearing potential or has negative pregnancy tests within one week prior to procedure.
Patient with the potential for pregnancy or impregnating their partner and who do not agree to follow an acceptable birth control method to avoid conception
Patients of childbearing potential must have a negative urine pregnancy test at screening/randomization  and must use medically acceptable methods of birth control
Patients who are pregnant or plan to become pregnant during the study
Patients will not be eligible for this study if they: Are pregnant or breast-feeding.
Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Pregnancy
Pregnancy (based on urine test)  since this group of patients receives other drugs for malaria treatment in accordance with Peruvian national guidelines.
Pregnancy and breast-feeding.
Pregnancy on going or planned within 3 years
Pregnancy or breastfeeding
Pregnancy or breast-feeding
Pregnancy or breast-feeding.
Pregnancy or lactation
Pregnancy or lactation.
Pregnancy  breast feeding
Pregnancy  breast feeding 
Pregnancy  breast-feeding
Pregnancy.
Pregnant (positive pregnancy test) or lactating.
Pregnant female patients  females of childbearing potential who are unwilling or unable to use adequate contraception methods.
Pregnant female.
Pregnant or breast feeding females
Pregnant or breast feeding.
Pregnant or breastfeeding
Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug
pregnant or lactating
Pregnant or lactating females
Pregnant or lactating females not allowed.
Pregnant or lactating females or females of childbearing potential who are unwilling to use reliable  medically accepted methods of contraception
Pregnant or lactating females.
Pregnant or lactating women
Pregnant or lactating women  as treatment involves unforeseeable risks to the participant and to the embryo or fetus
Pregnant or lactating women.
Pregnant or nursing women
Pregnant patients
Pregnant women are excluded from this
Prior to study enrollment  women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy
Subject is pregnant
Subjects who are women of childbearing potential and sexually active males must be willing to use effective contraception while on study.
The reason for non-childbearing potential  such as bilateral tubal ligation  bilateral oophorectomy  hysterectomy  or postmenopausal for >=  1 year  must be specified in the patient's case report form (CRF).
they are nursing
Willingness of male and female patients  if not surgically sterile  to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and follow-up periods.
Women able to become pregnant must have a negative pregnancy test
Women of childbearing potential (included women who were less than 1 year postmenopausal and women who became sexually active) must have been using an acceptable method of birth control (for example  hormonal contraceptive  medically prescribed IUD  condo
Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who became sexually active) must be using an acceptable method of birth control (eg  hormonal contraceptive  medically prescribed IUD  condom in combination 
Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control  .  hormonal contraceptive  medically prescribed IUD  condom in combination w
Women of childbearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment
Women of childbearing potential could not be pregnant or nursing
Women of childbearing potential had to agree to use effective contraception for the duration of the study and for two weeks after the last dose
Women of childbearing potential may not be entered if: their pregnancy tests (urine test) are positive 
Women of childbearing potential must have a negative serum pregnancy test within 2 weeks of the first administration of chemo
Women of childbearing potential not using a medically acceptable means of contraception.
Women of childbearing potential who are not using effective birth control
women of non-childbearing potential or using acceptable method of birth control.
Women who are pregnant currently trying to conceive
women who are pregnant or lactating.
Women who are pregnant or nursing.
Women who become pregnant again during study follow-up will not be eligible for re-enrollment in the trial
Women who were pregnant or nursing
hormonal or barrier method of birth control)
Fecund women not currently using barrier methods of contraception
Sexually active
Inclusion Criteria: Healthy females  who were sexually active and at risk of pregnancy were eligible to participate in this study provided that they had regular menses occurring every 25 to 35 days (except for those women using medroxyprogesterone acetate
Hormonal receptor status assessed
Hormone receptor status not specified
hormone receptor status: estrogen receptor positive 
epidermal growth factor receptor (egfr) positive 
estrogen and progesterone receptor positive 
estrogen receptor positivity 
estrogen receptor and / or progesterone receptor positive (by laboratory / institutional standard) at the time of initial diagnosis or determined during subsequent biopsy / surgery of metastases 
Inclusion Criteria: Patients must be adults 
Be an emancipated minor
Contact with an immunosuppressed individual.
Included in Neonatal Research Network Generic Database
NOTE: Protocol is approved for prisoner enrollment.
Premature groups: Preterm-born (32-34 weeks of gestation)
male who has not been sterilized by vasectomy for al least 6 months) within 14 days prior to study drug administration
male who has not been sterilized by vasectomy for at last 6 months) within 14 days prior to the study drug administration
Born after a gestation period of >=  32 weeks 
Inclusion Criteria: Attendance at out-patients clinics at Bristol Royal Hospital for Children  Southmead Hospital in Bristol  Weston General Hospital  The Royal United Hospital in Bath  Gloucestershire Royal Hospital in Gloucester or the Musgrove Park bra
Receive their prenatal and well-baby care from MediCal
Fewer than four years of formal education.
20 healthy subjects
Inclusion Criteria: Subjects with a live twin living in the same household who is also enrolled in this study.
Healthy subjects
Inclusion Criteria: Patients
Inclusion Criteria: All workers from a specific company  including administrative and production sections.
Inclusion Criteria: healthy subjects
Students from the Nova Southeastern University Colleges of Osteopathic Medicine and Optometry
General good health based on history and clinical examination
NOTE: This protocol is approved for prisoner participation.
elderly patients hospitalised in the internal medicine department of a suburban Parisian hopital
Accepts Healthy Volunteers: ELIGIBILITY CRITERIA include:
Accepts Healthy Volunteers: General inclusion criteria
Donors must meet one of the following criteria: Matched  related donor (6/6 or 5/6) (bone marrow donor allowed)
Inclusion Criteria: Subjects enrolled in the study will be members of the community at large
Homeless or travelers who may not be followed-up
Inclusion Criteria: Healthy volunteers
Non member of the social security or CMU
Patient non-affiliated to the social security and the protected people
Accepts Healthy Volunteers 
Anyone who does not meet the inclusion criteria.
Exclusion Criteria: Workers absent from the workplace during all the study period.
Inpatient population
Military returnees from OIF/OEF
Accepts Healthy Volunteers. Basic Inclusion Criteria:
Accepts Healthy Volunteers  
Accepts Healthy Volunteers: Inclusion/Exclusion Criteria:
Accepts Healthy Volunteers: Inclusion:
Accepts Healthy Volunteers: Key Inclusion Criteria:
Patients with the following symptoms or conditions are excluded: Malignancy requiring systemic cytotoxic chemotherapy.
All subjects requiring radiotherapy to the head and neck for a poor-prognosis malignancy will be eligible.
Have had systemic treatment for cancer within 30 days of entering the study.
if no metastatic  removed surgery must have been done since less 6 months
Patients with a history of tracheostomy
14 days or more since prior therapy and recovered from all side effects
Patients unable to be withdrawn for 2 weeks from AT-II antagonist or ACE- inhibitor therapy
Patients that are receiving or performing physical therapy regimen during the previous month from Screening  and/or will not or cannot maintain a stable physical therapy regimen throughout the course of the trial.
No prior allogeneic hematopoietic stem cell transplantation
>=  21 days since completion of prior chemotherapy  >= 6 weeks since prior Mitomycin-C
A minimum time period of 4 weeks should elapse between the completion of prior chemotherapy and enrollment in the study.
More than 2 weeks must have elapsed since previous radiation therapy and prior radiation must be less than or equal to 15% of the bone marrow.
Prior tandem autologous stem cell transplantations (according to clinical trial COG-ANBL0532) allowed
Also  chemotherapy as part of initial potentially curative therapy  
In VGPR or PR after salvage therapy
More than 2 weeks must have elapsed since previous chemotherapy and 6 weeks from previous treatment with nitrosoureas or mitomycin-C.
More than 3 weeks since prior chemotherapy  immunotherapy (including anti-GD2 regimen)  or biologic response modifiers and recovered
Prior chemotherapy is allowed as long as the patient has recovered from any toxicity
Radiotherapy for the treatment of a symptomatic  
Allowed: Local radiation therapy.
An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy  and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery  radiotherapy  or chemotherapy.
Any non-investigational  anti-cancer therapy within 4 weeks prior to Day 1.
Are receiving or plan to receive chemotherapy for cancer.
At least 21 days since prior radiotherapy and recovered
Candidate for curative treatment such as prostatectomy or radiotherapy
Cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years.
Chemotherapy Not specified
Chemotherapy within four weeks prior to study drug administration.
Chemotherapy  if given  should have been given post-operatively  ie  patients who received neoadjuvant chemotherapy are ineligible
Cytotoxic chemotherapy.
Excluded within 20 days prior to study entry: Radiation therapy.
Excluded within 30 days prior to study entry: Radiation therapy.
Excluded: Chemotherapy  hormonal therapy  or other immunotherapy.
Excluded: Radiation therapy.
Exclusion Criteria: CNS metastases  Concomitant myelosuppressive radiotherapy  C/T  hormonal therapy or immunotherapy.
Exclusion Criteria: No prior chemotherapy for recurrent / metastatic adenoid cystic carcinoma
Exclusion Criteria: Women who have had previous cryotherapy of the cervix  LEEP or cervical conization
For patients with previous radiosurgery or enhanced radiotherapy  based on neurosurgeon's judgment  the area of enhancement can be removed during the surgery
high-dose chemotherapy requiring hematopoietic stem-cell reinfusion.
History of cytotoxic chemotherapy within one month of study entry
May have had no prior chemotherapy or up to 1 prior treatment regimen with immunotherapy or chemotherapy
More than 2 months since prior autologous stem cell transplantation  myeloablative therapy  total-body irradiation  whole abdominal radiotherapy  or therapeutic >= I-MIBG
More than 2 prior chemotherapy regimens for the treatment of advanced melanoma.
More than 2 weeks since prior radiation therapy
Must have received either whole or partial breast radiotherapy by external beam or brachytherapy after completion of primary surgery
Must have undergone complete surgical removal of invasive cancer by mastectomy or lumpectomy with either sentinel or axillary lymph node dissection within the past 84 days
Mycobacteriosis requiring maintenance chemotherapy.
No prior chemotherapy
No prior chemotherapy for this disease
No radiation therapy  prior biological therapy or surgery within 4 weeks prior to first dose of study agent.
Other chemotherapy.
Patients entering the Phase 1 portion of the study may have received up to two prior chemotherapy programs including adjuvant or neoadjuvant therapy.
Patients entering the Phase 2 portion of the study may have received only one prior chemotherapy program including adjuvant or neoadjuvant therapy for NSCLC.
Patients heavily pretreated with chemotherapy and radiation  defined as follows: >=  12 cycles of an alkylating agent-containing regimen  or
Patients likely to undergone chemotherapy  surgery or radiotherapy during 2 weeks before PET-TDM.
Patients may have received multiple treatments of radioactive iodine  one prior biologic treatment  and at least half of the patients will have had no prior chemotherapy for metastatic disease
Patients may have received up to 2 prior systemic chemotherapy regimens (including dacarbazine  and alternative dosing schedule of temozolomide)
patients who have not received chemotherapy and whose primary surgery was completed more than 8 weeks before starting the study treatment
patients whose chemotherapy was started more than 8 weeks after completion of primary surgery or whose chemotherapy was completed more than 8 weeks before starting the study treatment
Patients with a planned coronary intervention.
patients with ray-treatment or chemotherapy within the last three months
Planned future chemotherapy is also allowed after the one month evaluation.
Previous bone marrow or stem cell transplant.
previously irradiated.
Prior chemo therapy < 21 days prior to registration.
Prior full field radiotherapy < 28 days or limited field radiotherapy < 14 days prior to registration.
prior immunotherapy (up to 2 regimens) or prior radiotherapy is permitted but at least 4 weeks must have elapsed prior to enter study
Prior radiation therapy will be allowed
Prior surgery  chemotherapy  hormonotherapy for breast cancer
Prior treatment for another cancer in the last 5 years
radiation of the ovaries
radiotherapy during study or within 4 weeks prior to study entry
Radiotherapy must have been completed at least 4 weeks prior to study drug administration.
Radiotherapy Not specified
Received chemotherapy or radiation therapy within 30 days of study entry.
Scheduled to undergo definitive radiation therapy (either brachytherapy or external beam)
Subject is receiving systemic chemotherapy.
Three or fewer prior chemotherapy regimens (including a platinum-based therapy).
Toxoplasmic encephalitis requiring suppressive therapy.
Visceral Kaposi's sarcoma requiring chemotherapy and/or irradiation.
contraindication for dual antiplatelet therapy for the following 6 months
Use of any investigational therapy within 30 days  or 5 half-lives  whichever is longer  and/or use of AD immunotherapy prior to screening.
Are currently being treated with one to three (maximum) marketed and approved AEDs and are known to take their medications as directed
Hormonal therapy for patients with hormone receptor-positive disease allowed
Patients may have received or be receiving hormonal therapy
Exclusion Criteria: Patients with a known or suspected difficult intubation
Patients must have fully recovered from the toxic effects of prior therapy.
Prior cardiac or renal allografts
History of cholecystectomy.
Concurrent Treatment: Allowed:
Organ allografts.
Inclusion Criteria: Heart transplantation (> 6 months post-operation)
Patients having a ligament reconstruction to the study knee.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
PEG feeding
Women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the durat
Recipient of heart transplant
Inclusion Criteria: Kidney or heart transplant recipients
Liver transplant patients
Have received a blood transfusion within the 3 months before administration of study medication
No prior chemotherapy or prior vaccine or immunotherapy.
Up to 1 prior biologic/targeted therapy regimen is allowed
women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and continue same regimen during the study.
Women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and willing to continue the same regimen for the duration
Patients for whom previously treatment with dopamine agonists needed to terminate because of induction of psychosis  
Mechanically-ventilated during the first week of life
Mechanically-ventilated for at least 48 hours
At least 4 weeks must have elapsed and patients must have recovered from all side effects associated with surgery.
Patients requiring fissure sealant due high caries risk.
Had  or during the course of the study are anticipated to have  any organ transplantation (heart  liver  lung  kidney  or bone marrow)
If using a vagal nerve stimulator  it must have been implanted at least 5 months prior to Visit 1
Patient implanted with a wireless-transmission-enabled Medtronic ICD or CRT-D
Patients having any surgery to the study joint within the previous 12 months prior to Screening  and surgery to the contralateral knee or other weight-bearing joint if it would interfere with the study assessments.
Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per minute.
Prior biologic or immunotherapy < 14 days prior to registration
Patient who has been under a none satisfied antihypertensive treatment  and for whom this treatment was stopped at least 2 weeks prior to inclusion.
Major surgery and related complications not resolved within 12 weeks prior to Day 1.
Treatment with any investigational product in the last 1 month before study entry.
No hormone replacement therapy within the 90 days immediately prior to the screening evaluation.
requires IOP-lowering therapy in both eyes
Contraindication to ??-adrenoceptor antagonist therapy or brimonidine therapy
Patients who underwent major surgery within 3 months prior to screening.
History of surgical or device  
Have had implantation of an automated implanted cardiac defibrillator (AICD) or synchronization device within the preceding 7 days
Have previously undergone destructive ganglionectomy affecting C2/C3 occipital and/or trigeminal distribution or have an occipital blockade or radio frequency procedure currently in effect
Implanted stimulator (such as a pacemaker)
Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant.
Excluded: Antiretroviral treatment or experimental treatment within 2 weeks of entry.
Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry
Patient has had a bare metal stent in the six weeks prior to randomization
Patient has had a drug eluting stent in the year prior to randomization
Inclusion Criteria: Coronary artery stenting between March 1  2001 and March 30  2006
Exclusion Criteria: Presence of ventriculoperitoneal shunt
Antiretroviral therapy.
History of allogeneic hematopoietic cell transplant (HCT).
Inclusion Criteria: Consecutive patients undergoing percutaneous coronary intervention at an enrolling center by study investigators
Patient requires IOP-lowering therapy in both eyes
Patients having significant surgery of lower limbs (hip  ankle  foot) that may interfere with knee assessments.
Planned elective spinal surgery in which the modified Jackson table will be used.
Received more than one month of prior antiretroviral therapy
Require IOP-lowering therapy in each eye
Use of antiretroviral therapy within 3 months of pre-study screening.
Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment.
Who underwent major surgery within 3 months prior to screening.
+/- surgery)
Acceptable candidate for coronary artery bypass surgery (CABG)
Acute therapy for intercurrent infections so long as that therapy is not an excluded medication of an excluded opportunistic infection.
Allowed: Blood transfusion.
Allowed: Blood transfusions for hematologic toxicity.
Allowed: Blood transfusions.
Alternatively  patients can enter after refusing standard curative therapy only if therapy was clearly discussed with the treating physician or if they have failed another biologic therapy due to toxicity.
Anticipated spinal fusion surgery
Any number of prior systemic therapies is allowed.
Any other experimental therapy within 1 week of entry.
Any spinal manipulation within 48 hours
Aortic surgery within 6 months
Are currently receiving chronic dialysis or have the expectation that dialysis will be required during the next 12 months.
At least 28 days since prior surgery and recovered
At least 3 weeks must have elapsed since prior treatment.
Be admitted for heart transplant surgery or have had a heart transplant 
Be an appropriate candidate for the surgical procedures required for this study
bilateral oophorectomy
Biologic therapy Not specified
bone marrow transplant
Cardiac surgery patients
cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission
Chemoprophylaxis for candidiasis and herpes simplex.
Concurrent Treatment: Excluded:
Contra-indications to lumbar puncture
coronary artery bypass graft (CABG)  or
Currently require mechanical ventilation  ultrafiltration  or hemodialysis 
Deviation from standardised surgical procedure
ECT treatment within the past two months
Eligible for both treatment interventions
emergency endotracheal intubation
emergency surgery
Endocrine therapy Not specified
Excluded within 14 days prior to study entry: Transfusion.
Excluded: Prior treatment for CMV retinitis.
Exclusion Criteria: Have a history of surgery of the affected fingernails
Exclusion Criteria: Patients who received thrombolytic therapy (intravenous or intraarterial)
Exclusion Criteria: Previous surgery of the ascending aorta  or surgery planned
Exclusion Criteria: Recent cervical spine injuries or surgeries
Exclusion Criteria: Subjects receiving escalating doses of immunotherapy  oral immunotherapy or short course (rush) immunotherapy for rhinitis
gastric banding) intervention for obesity
Have had treatment with ABC.
Have previously been treated with occipital nerve stimulation
History of non-compliance with other therapies.
history of percutaneous coronary intervention (primarily PTCA with or without stent placement)
History of solid organ or hematological transplantation.
History of splenectomy
Hormone replacement therapy.
Hospitalization in the previous 2 weeks for a medical condition or surgery for which recovery overlaps with the study onset and duration
Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).
Inclusion Criteria: Elective surgery
Inclusion Criteria: elective surgery requiring endotracheal intubation
Inclusion Criteria: Multilevel surgery
Inclusion Criteria: Patients for elective surgery  requiring general endotracheal anesthesia
Inclusion Criteria: Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress
Inclusion Criteria: Patients undergoing noncardiac surgery who fulfill the following criteria:
INCLUSION CRITERIA: The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump
indication for bypass surgery
Intraocular surgery in the study eye within 60 days prior enrollement
Major elective surgery planned in study period
Major surgery < 28 days prior to registration.
Major surgery within 4 weeks prior to Day 1.
Major surgery within 8 weeks prior to the Baseline Visit
Major surgical procedure or trauma within 2 months
Not scheduled for joint replacement surgery during the study period
Ongoing or chronic dialysis (either hemodialysis or continuous ambulatory peritoneal dialysis)
OR any 3 of 9 risk criteria: undergoing major surgery [i.e.  intraperitoneal  intrathoracic  or orthopedic surgery]
Other experimental therapy.
Other indicated/planned concomitant surgery
Patient has had gastric reduction surgery.
Patient has had neurolytic or neurosurgical treatment for PHN.
Patient must have recovered from toxicity of prior therapy
Patient received any of the following within the specified time period prior to initiation of treatment in this study: Chemotherapy  major surgery  significant traumatic injury  or irradiation  whether conventional or investigational within 28 days
Patient undergoing intracranial surgery  carotid endarterectomy  or retinal surgery
Patients enrolled in the adjuvant setting must have received standard curative therapy  e.g.  surgery  radiation
Patients may have received prior surgery
Patients receiving any articular procedures  such as transplants  to the study knee.
Patients should have recovered from prior surgery or radiation therapy
Patients undergoing liver resection other than left lateral hepatic sectionectomy.
Patients who can tolerate a hemodialysis session lasting up to 9 hours.
Patients who have other cardiac surgeries or procedures planned but not yet performed during the duration of the study
Patients who have undergone surgery for the treatment of PD 
Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
Patients within 6 months of a coronary intervention  including PCI or CABG.
Percutaneous coronary intervention or cardiac surgery within 90 days of study start
Planned surgical procedure that can impact the conduct of the study
predicted difficult intubation
Pre-treatment with devices other than balloon angioplasty  although direct stenting is allowed
Previous laser therapy
previous percutaneous coronary intervention (PCI)  or
Prior bariatric surgery
prior CABG
PRIOR CONCURRENT THERAPY: Biologic therapy
PRIOR CONCURRENT THERAPY: See Disease Characteristics
Prior cranial manipulative treatment/craniosacral therapy
Prior to aortic root surgery
Prior Treatment: Excluded within 20 days prior to study entry:
Prior Treatment: Excluded within 30 days prior to study entry:
receiving physical or occupational therapies for shoulder pain
Recent intraocular surgery
requires salvage intervention as defined by the ACC/AHA guidelines as being ongoing cardiopulmonary resuscitation on the way to the operating room
scheduled for non-emergent abdominal hysterectomy (with or without salpingo-oophorectomy) or myomectomy under general anesthesia
Six weeks since major surgery (three weeks since minor surgery)
Subject has had (coronary artery bypass graft) CABG or vascular surgery within 30 days PRIOR TO index procedure (percutaneous coronary intervention is permissible provided cardiac enzymes are normal within 24 hours of index procedure)  OR has planned CABG
Subject has undergone prior stenting of the ipsilateral carotid artery.
Subject meets one or more of the high surgical risk criteria .
Subject must have adequate anticoagulant therapy
Subjects must have fully recovered from the effects of any prior surgery  chemotherapy  or radiation therapy
Subjects undergoing spine surgery in the prone position.
Such patients will receive any appropriate treatment prior to surgery
Surgery Not specified
Systemic treatment with glucocorticoids within the 12 months prior to study entry
Transfusions.
undergoing emergent/urgent surgery
undergoing major vascular surgery  .  vascular surgery except arteriovenous shunt  vein stripping procedures  and carotid endarterectomies)
Houston  Texas
Orinda  California
Participants must live within easy commuting distance of Duke Medical Center  Durham  North Carolina
Must live in the United States
Must live in selected communities in eastern Massachusetts
Foreign (non-U.S.) residence
Must live within 50 miles or one hour of the study site and have reliable transportation to the site.
Lives more than 100 miles from alcohol treatment facility.
Homeless or unstable residence.
Lives within 50 miles of the study site.
Lives within 50 miles of the study site  has a stable living situation  and a reliable source of collateral reporting.
Residence in a specific domicile  shelter  or prison cell block within 6 months of a known outbreak of MDR TB.
Living in the geographic area surrounding Kings County Hospital in Brooklyn  New York
Is a resident of the Temple-Belton  Texas area.
INCLUSION CRITERIA: Patients must live in the Metropolitan Washington Area.
Live within adequate commuting distance to the treatment center.
Other: Must reside within 60 km (37.5 miles) of a treatment site
Residence outside of the St
Are a resident of the United States of America.
Residence making follow-up unlikely (eg lives outside U.S.)
resides within 30 miles of Duke University
They reside in the United States and will be available for at least six months of follow up.
Patients living in USA  Puerto Rico  Australia  Brazil  Singapore  and Thailand can be at least 12 years old (need consent of parent or guardian if under 18).
Mary's Hospital  Marianhill  South Africa
polyclinics in Chitungwiza District  Zimbabwe.
Reside within 15 km of Mulago Hospital  the study site.
Live in a commutable distance to the University of Pennsylvania and agree to followup visits.
Lived within a 9-county area surrounding the city of Cincinnati
reside in the Metropolitan Washington  D.C
History of varicella or long-term (greater than or equal to 30 years) residence in the continental USA.
Must be a resident of the Washington DC area.
New York Metro Area resident
Resident of the New York Metro Area
Local residence
Live in the following counties at the time of diagnosis: Churchill  Lyon  Mineral  Storey  Douglas  Carson City  Nevada  and Kings County  California
Live in Ottawa County  Oklahoma
residence in one of the study communities
History of Varicella or long-term resident (greater than or equal to 30 years) in the continental United States.
Exclusion: patients living outside the greater Boston area
Residence within 40 miles of Wills Eye Hospital in Philadelphia  PA
Young population Less than 30 Resident of Kaohsiung metropolitan  Taiwan
Planning to live in the greater New Brunswick  NJ  area for at least 3 years
Live within a one-hour drive of the study site
Residence within 20 km of Kampala city
Resident of Zomba or Blantyre Districts  Malawi
Live in Kisumu District  Kenya
new york city local address
Maximum age 18 years In France and the United Kingdom
Lives in the Kansas City area
reside in targeted counties
Must live in the Northeast Ohio area.
Planning to live in the San Francisco Bay Area in the year following study entry
Smoker lives in the household
Plans to live in the San Francisco Bay Area for the next 12 months
Lives in a nursing home
Single live intrauterine fetus in cephalic presentation
Family lives in the San Jose area
INCLUSION CRITERIA: Patients who self-identify as Hispanic and currently live in the United States.
Live in the USA or Canada.
Place of Residence: Child and participating parents must live in a rural county and within the same house.
plan to live in the area for 9 months  report upset with CR function dependence or behavioral occurrences.
Plans to live in area for 8 months
plan to live in the area for 6 months  and
Participants must live in San Diego and meet all of the following inclusion criteria: Has VA primary care provider for heart failure care
live in a private home
Patients who at admission did not live in the Funen County.
Mental incapacity  unwillingness or language barrier precluding adequate understanding or cooperation
Confusion or other factors that would impair ability to assess symptoms
Unable to sustain a breath-hold for 25 seconds
Unable to remain in supine position for at least 60 minutes
Able to understand a written informed consent and comply with the study protocol
unable to complete neuropsychological testing
Subjects must be able to show efficient use with a jet nebulizer
Subjects unable to follow up for study visits
Subject is willing and able to complete required follow-up
Must be able to complete the micturition diary
Availability for follow-up during the study.
Patient capable of understanding(including) the advantages and the risks of the try
Patients who are unable to undergo radical hysterectomy for complication of excessive obesity  liver cirrhosis  or bleeding tendency
Ambulatory and able to use a toilet independently and without difficulty.
You must be able to swallow the LY317615 tablets
Ability to visit the doctor's office for scheduled visits
You are a woman of childbearing age and unwilling or unable to use effective contraceptive.
Are capable and willing to do specified study procedures
Patients must be able to swallow capsules
Able to visit the doctor's office at least every 14 days during the actual treatment
Ambulatory and capable of self-care(eg  up and about greater than 50% of waking hours)
Must be able to come in for follow-up visits for the duration of the study.
able to visit the doctor's office every 28 days for at least 6 months
Subjects who were available for the duration of the study (from enrollment to study completion).
Ability to complete the follow-up period of 84 days
who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol
who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
Ability to complete follow-up period of 188 days as required by the protocol
Ability to complete the follow-up period of 90 days (single-dose groups) or 120 days (two-dose group) as required by the protocol
Persons being able to participate in the trial for 1 month from the inoculation of the trial vaccine to the completion of the trial.
Persons being able to be contacted (by phone  hospital visit or house visit) by the trial staff at the time of testing after 28 days from the inoculation of the trial vaccine.
Persons judged to be impossible or difficult to be contacted for requesting hospital visits to carry out clinical evaluation and tests during the trial term.
Unable to follow study procedures  illiteracy  or poor comprehension of the language used in the psychometric tests
Able to perform activities of daily living without considerable assistance
Available for follow-up for up to 5 years
Subjects lacks the capacity to provide informed consent
the subject is able to return for frequent follow-up care
subjects unable or unwilling to comply with study procedures or illiterate
Not able to adhere to the protocol.
Candidate will not be available for the next 18 weeks (2 weeks run-in  12 weeks study  4 weeks follow-up)
Able to be regularly followed up.
Patient unable to be regularly followed-up.
Subjects who are able to use a Diskus inhaler
Subjects or their parent/ guardian who are able to understand and complete a DRC
Able to follow 2-step commands
Able to walk without assistive devices
Subjects must be available for follow-up visits to comply with the requirements of the protocol.
Inability to comply with the study protocol
History of noncompliance with prior medical care
Willing to comply with all study requirements
Be able to comply with the requirements of the entire study
Able to comply with study procedures
Subjects unlikely to comply with study procedures
Concerns for subject's compliance with the protocol procedures
Concurrent or history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent
Subjects unlikely to comply with protocol
Able to comply with study procedures.
Willing and able to comply with all study requirements
Able to understand and comply with planned study procedures
Have demonstrated compliance with the study medication and treatment visits
In addition  patients non-compliant with study medication during 2 ?€??? 4 week study periods
Must comply with all study procedures and be literate.
Understand and sign informed consent document  able to communicate with the investigator  and understand and comply with the requirements of the study.
Patients unwilling to  or unable to  comply with the protocol
History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative
Subjects unlikely to comply with the requirements of the protocol
Able to comply with study procedures
Willing and able to comply with all study requirements
Be able to give informed consent and comply with study procedures
Ability to understand and comply with planned study procedures
Any other clinical condition or prior therapy that  in the opinion of the clinic physician  would make the subject unsuitable for the study or unable to comply with the dosing requirements
Able to understand and comply with study requirements
Patient compliance doubtful.
Subjects must be willing and able to comply with the requirements of the protocol.
Patient able to comply with the protocol
Willing to comply with all study-related procedures
Inability to comply with follow-up visits
Able to comply with study procedures and follow-up examinations
Able to comply with the protocol
Unlikely to comply with protocol.
Subjects with high probability for compliance and completion of the study
Subject will comply with protocol  in the opinion of the investigator.
Persistent non compliance with taking medication
Subject can comply with the protocol requirements
Inability for treatment compliance.
Suspicion that patient compliance will be poor
Expect to comply with protocol procedures and schedule
Perceived inability to comply with the study protocol
Inability to comply with study requirements.
History of poor compliance (Missing two or more clinic appointments in the past year).
Subject must be willing to comply with study-mandated evaluations
Inability to comply to the protocol
Able to understand and comply with planned study procedures.
History of non-compliance with other therapies
A participant whom the investigator believes can and will comply with the requirements of the protocol.
Ability to comply with all study requirements
Good compliance
Expected bad compliance
failure to comply with study CLIC477D2303
Compliance with taking HU treatment of at least 70 % for 6 months prior to study entry
Be likely to comply with the study protocol
compliance (pt not taking at least 85% of two week placebo were excluded)
Subjects who in the investigator's opinion are unlikely to complete the 48 week study period or unlikely to comply with the dosing schedule and protocol evaluations.
Compliance by the patient seems guaranteed  and the patient seems to be able to understand and complete the patient diary.
Suspicion of abuse or non-compliance
Ensured compliance
Participant is likely to comply with the study treatment during the study period
would limit compliance with study requirements
Probability of poor compliance and termination of the study
Be willing to comply with study requirements if they meet study eligibility criteria.
Compliance by the patient seems guaranteed  and patient seems to be able to understand and complete the patient diary.
Poor compliance with the visit schedule or medication intake in the previous brivaracetam trial
Parents of study participants must agree to comply in good faith with the conditions of the study  including attending all of the required baseline and follow-up assessments.
Non-pregnant females of childbearing potential must comply with contraceptive restrictions.
Able to provide written informed consent and comply with study protocol
Non-compliance
Are able to comply with study procedures and visits
Expectation of protocol compliance
Patients with poor compliance
Expected non-compliance with follow-up or study treatment
Inability to comply with study requirements.
Noncompliance with current medical regimen
Expect to comply with protocol procedures and schedule
Patients unable to comply with the requirements for the trial.
Foreseen difficulties with study compliance  especially the long-term follow-up
Unable to comply with the protocol.
Non compliance
Poor compliance to treatment and follow up
Patients who cannot comply with the study requirements
compliance with daily questionnaire
Be able to comply with follow up over two years.
able to comply with study procedures and protocol
Must understand the requirements of the study and agree to comply with the study protocol.
There is a risk of non-compliance with study procedures
Problem of compliance
Expected to comply with protocol
expectation of protocol compliance
Mechanical assist device
intrauterine device (IUD)  oral contraceptives  Depo-Provera
Has intrauterine device (IUD) or subdermal contraceptive implant 
(3) an aneurysm clip in their brain
Presence of pacemaker or ICD
Patients with pacemaker
Catheter likely needed for 2 weeks or less
Patient with an implanted pacemaker or defibrillator
Have other implantable devices such as pacemakers
Implantable cardioverter defibrillator
Subject is implanted with intracranial electrodes.
Subject is under constant medical supervision while implanted with the intracranial electrodes.
Subject is implanted with a medical device that might interfere with the eRNS
intrauterine progesterone contraceptive system
patient requires the use of invasive ventilatory support
patient requires the use of noninvasive ventilatory support while awake and in an upright position
Have a mechanical tricuspid prosthesis
Must receive a commercially available Guidant CRT-P or CRT-D device
A respirator with a device for delivery of gaseous NO to the inspiration gas and equipped with analysis tools for lung mechanics
Cervical cap
8 weeks for oral preparations or progestogen containing intrauterine device (IUD).
Comprehension of PCA and virtual reality device
Has cardiac pacemaker or other electromedical implant
Devices incompatible to MR studies (eg pacemakers  ear implants  etc.)
On Ventilator
intra-uterine device
barrier contraceptive with spermicide
Have a tricuspid prosthesis
Subjects with an existing ICD or CRT device
Patient has received a drug eluting stent within the last 1 year.
Presence of cardiac implants (ie implantable defibrillators)
Presence of previously placed intravascular stent or intravascular graft in the ipsilateral distribution
second or third degree heart block without a pacemaker
No cochlear implant
Permanent pacemaker 
Pre-existing endocardial pacing leads 
Patient has an epicardial ventricular lead system.
Implanted ventricular pacing device
concomitant valve surgery
cardiac pacemaker
Subjects who are able to use a Diskus inhaler
Ureteral stent
Nephrostomy tube
Required pre-operative intra-aortic balloon pump (IABP)
intrauterine device (IUD)
Placement of a permanent central venous line
Currently using a pacemaker
Has an implantable cardioverter defibrillator
Have no regular care provider present at meals.
Dietary calcium-to-protein ratio (in mg:g  as assessed by 7-day food diary) does not exceed 13
Nutritional support (for children with wasting syndrome and/or malnutritional) including hyperalimentation (TPN) of dietary supplements.
Unable to tolerate the standard diet required for the study.
Diet will be lactose free  maximum 7 g fat/day with unlimited calorie intake
EXCLUSION CRITERIA: Subject non-compliance with restricted diet.
Patient on a regular diet without difficulties.
Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT
patients following a low sodium diet
Ability to eat solid food three meals per day
Diet
Usual and customary diet maintained throughout study  eg  medium-chain triglyceride oil
Must maintain low calcium diet (less than 800 mg calcium daily)
Gastrointestinal: No requirement for special diet or additives
No diet that would preclude taking study medications
Grapefruit juice
Already on unusually restrictive diet
Have changes in diet or physical activity that might explain changes in body fat.
Willing to adhere to dietary restrictions as required during the study.
Are dieting or doing heavy exercising.
No concurrent grapefruit juice
No concurrent grapefruit juice or grapefruit
No concurrent diet high in soy products
Other: No concurrent grapefruit or grapefruit juice
Use of herbs  high-dose vitamins  or non-traditional diets
Grapefruit juice
No adherence to vegan diet or other special dietary requirements that would preclude study participation
No concurrent grapefruit juice
Omnivorous diet
Follows the ketogenic diet.
At least 1 week since prior grapefruit juice
Able to follow dietary restrictions associated with the protocol.
Co-morbidity requiring a specific diet
Medication which contraindicates consuming a high-fiber diet
regularly eats 3 meals/day
No concurrent grapefruit juice during the first month of study participation
No concurrent grapefruit  grapefruit juice  or grapefruit-containing food or vitamins
Currently following a vegetarian diet
Dietary soy allowed
No concurrent grapefruit juice
Follow a vegan diet
No concurrent ingestion of high-fat meals
Normal  balanced diet (20-40% calories from fat)
Current dietary pattern includes suboptimal total fat  saturated fat and vegetable and fruit consumption
Dietary patterns meet current recommendations for saturated fat and vegetable and fruit consumption
Willingness to maintain current activity level and diet
Limited habitual intake of dairy products according to dietary questionnaire.
Active dieting
Dietary restrictions such as bread  dairy  peanut  aspartame  or meat products used in the study
consuming special diets
Currently following a vegetarian diet
medically prescribed or slimming diet
Prior use of the Atkins diet for more than 1 week
Prior use of the Atkins diet for over 1 week
Dietary intake of vitamin K below 120 mcg
Usual dietary intake of phylloquinone greater than 120 ??g/d
Usual dietary calcium intake greater than 1500 mg/d
Usual dietary vitamin D intake greater than 1500 IU
Currently following a vegetarian diet
Exercise less than 20 min/day two days a week
The subjects must be relatively sedentary  not currently engaged in strength-training exercises.
Amount of physical activity exceeds 120 minutes of moderate exercise per week
Moderate exercise examples: brisk walking  golfing  gardening  housework  house painting
Current participation in a structured aerobic exercise program
Patients for whom exercise is contraindicated or whose physicians believe that exercise is contraindicated.
Men should exercise appropriate contraceptive measures while participating on the study.
Have evidence of reduced exercise tolerance lasting longer than one week on either the St
Have no exercise intolerance
No physical handicap that would prevent resistance or aerobic exercise
No concurrent regular exercise of 3 or more hours a week
Medical conditions for which changes in diet and exercise levels would be contraindicated
Cannot avoid strenuous exercise or constant activity for the study period.
normal physical activity
subjects who exercise vigorously
No exercise intolerance
History of excessive exercise (greater than 10 hours a week).
Significant exercise-restricting disease
Participation in an exercise program or strength training within the previous 4 weeks
Are dieting or doing heavy exercising.
Successful completion of a food and exercise diary over a 5-day period
Caffeine  alcohol or strenuous exercise within 24 h before each test period.
Major (greater than 3 hours/week) athletic/physical exercise activities.
Failure to complete the two-week run-in for dietary intake and exercise.
Complex ventricular arrhythmia at rest or with exercise (eg  ventricular tachycardia).
They may continue with any ongoing exercise program
Perform bicycle exercise test
No exercise intolerance
Taken exercise class for back pain within past year
Individuals unable to exercise independently
Health status that prohibits patient from performing graded exercise test
Structured exercise more than once per week for 20 minutes or longer during the 3 months prior to study entry
Any condition (other than CHF) that could limit exercise
Willing to refrain from exercise for 24 hours prior to study entry
No contraindications for exercising maximally
Have exercise-limited non-cardiac chest discomfort
less than 150 minutes regular exercise per week
The patient already engages in more than one hour of weekly exercise.
Unable to exercise safely
Cannot engage in moderate intensity exercise (eg  walking)
No contraindication to exercise as determined by a fitness test
Physically capable of exercise
Able to tolerate a moderate intensity exercise program
Able to participate in exercise classes that meet 3 times per week for a minimum of 6 months.
Physical challenges such as deformities that would impair ability to perform physical activities
Currently exercising for more than 30 minutes  3 times per week
Dyspnoea on exertion and a reduced exercise capacity
Patients with handicaps for exercising
Currently exercising less than 3 times per week
Baseline exercise of more than 20 minutes two times per week
regular exercise ( participating in 2 or more structured exercise sessions weekly for more than or equal to 6 months prior to enrolment).
not currently exercising 120 min/wk or more
Concurrent major health problems or disabilities that would limit participation in an exercise program.
Not currently participating in 20 minutes or more of physical activity 3 times a week
Female gender only
Male sex
Participants must be female gender.
Female gender-to evaluate effects in the target population for clinical trials.
Male gender
Female sex
Male adolescents
Female adolescents
Male or female gender
Female gender
For all subjects female gender
Males and females
Female
Genders Eligible for Study: Female
Are female.
Sex distribution: Male and female.
Male and female subjects.
Male and female patients will be accepted.
Sex: Female or male
Healthy male volunteers
Genders Eligible for Study: Male
Genders Eligible for Study: Female
male/female.
Male and females
Subjects may be male or female
Gender: Patients may be male or female
male or female  in- or outpatients
Male or female subjects
1) Male or female of any race or ethnicity
Male patient
Genders Eligible for Study: Male
Sex Male or female
Genders Eligible for Study: Female
Genders Eligible for Study: Male
Female gender.
May be male or female
Genders Eligible for Study: Female
Sex Female
Healthy males or females.
1.Male or female patients.
Healthy male or female newborn
Healthy male volunteers
Female Gender
Both male and female
Sex: Male and female
both mal and female
Hormone receptor status: Not specified
Hormone resistant disease required of receptor positive patients
Progesterone receptor positive or negative
No concurrent selective estrogen-receptor modulators
Hormone receptor status: Any status
Progesterone receptor positive
Peptide receptor antagonists
Hormone receptor status: ER/PR status known
Estrogen receptor (ER) and progesterone receptor status known by immunohistochemistry
Estrogen receptor negative
Kit receptor tyrosine kinase by immunohistochemistry using the Dako anti-CD117 antibody
ER/PR negative
Hormone receptor status: Estrogen and/or progesterone receptor positive
Hormone receptor status: Estrogen receptor and/or progesterone receptor positive
Progesterone receptor status known
Hormone receptor status: ER status known
Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of primary diagnosis or determined during subsequent biopsy/surgery of metastases.
Selective estrogen receptor modifiers
Hormone receptor status: Estrogen receptor (ER) status known
Progesterone status known if ER analysis is negative
Selective estrogen-receptor modulators
ER  PgR and HER-2 status not determined.
Patient already receiving AT1 receptor blocker
Peptide receptor antagonist
Positive estrogen and/or progesterone receptors as >10% cells or >10fmol/mg.
ER and PgR negative
Hormonal receptor status not determined.
Erbb2 negative and/or ER and PgR negative
Hormone receptor status: Estrogen receptor- (ER) or progesterone receptor- (PR) positive or negative tumor
Hormone receptor status: Estrogen receptor-negative and progesterone receptor-negative tumor
Patients with hormone receptor (ER and/or PgR) positive or both unknown.
Previous or current use of ACE-inhibitors or Angiotensin II-receptor blockers
Estrogen receptor (ER+) positive and/or progesterone receptor (PgR+) positive or ER/PgR unknown
Patients must be positive for either ER or PR or both
Unknown ER and PR status
ER &/or PR positive
Sample must be positive for ER and/or PR
Her-2 overexpression and ER and/or PgR positive
All tumors must be ER-  PR- and HER-2 negative.
Any receptor status.
Estrogen and progesterone hormone receptor status  determined before study registration.
Hormone receptor status: Any receptor status allowed
T >2 cm  N0  M0  regardless of ER or PR status
Hormone receptor status: Estrogen receptor (ER)-positive OR ER-negative
Minorities are actively recruited.
Be able to participate as an outpatient.
NOTE: This study is approved for prisoner participation.
Inclusion criteria for minors
The first patient must have an identical twin donor
The patient must be clinically stable enough for outpatient evaluation.
Study is NOT approved for prisoner participation.
All subjects will be outpatients.
Membership in a vulnerable population (eg pregnant woman  prisoner  etc.)
6 years of education or work history
Inpatient or outpatient.
We will also recruit from the outpatient memory clinic
9th grade students who agree to provide profile data
No UCLA students or staff
No inmates or prisoners
Able to participate as an outpatient
Student attending sixth through eighth grades
Classification in school as a special education student
Inpatient admittance to Western Psychiatric Institute and Clinic
Healthy endurance-trained subjects
Subjects must be willing to be treated in the inpatient setting for a minimum of three days
Ability to participate in an outpatient study.
Inclusion: All students who attend Cleveland and Rainier Beach high schools are eligible.
Be able to participate as an outpatient.
Eligibility for care in the military medical system.
Homosexual donors
Postgraduate students
Student in participating school
Less than 10 years of formal education
Discharged by the hospitalist service or other inpatient services
Patients must be inpatients who are expected to stay in the hospital for at least 5 days
No prisoners.
6th or 7th grade students
Military or veterans health care beneficiary.
All subjects will be outpatients.
Must meet same criteria as that of a volunteer blood donor.
Be able to participate as an outpatient.
Undergraduate students at Oxford University
Donor siblings must have: HLA A2+.
INCLUSION CRITERIA: Graduate students and undergraduate students who have completed two years of college.
Require inpatient hospitalization.
History of military service 1989 or earlier.
Same cell type as donor sibling.
Student in grades 1 to 9
Must have ability to set up an outpatient monitoring system.
High school students (grades 9-12) enrolled in participating schools
Healthy volunteers studied as outpatients.
Donor: Partially HLA matched family donor
Students at the excluded colleges
The patient must be clinically stable enough for outpatient evaluation.
Ability to participate in an outpatient study for at least 26 weeks.
Positive cross-match with intended donor and/or ABO incompatible with intended donor.
Patients who are inpatients
exclusion criteria: military service prior to 1989.
No prisoners or institutionalized patients
All regular education students  including students in bilingual classes
The volunteer is currently on active duty in the US military.
Minorities are encouraged to participate.
Outpatient status required
Inpatients at OSF Saint Francis Medical
Minorities: All races and ethnic backgrounds.
VA Medical Center or outpatient clinics with at least 3000 patients.
Prisoners or subjects who are compulsorily detained
Eligible veteran of United States (US) military
Prisoners or incarcerated individuals
No military service prior to 1989 or after January 2003.
No prisoners or parolees
Urban African Americans with arthritis
Caucasian
African American
Race of all 4 grandparents self-identified either as all Caucasian or all African American.
Inpatient monitoring will be provided when medically indicated.
Race of all four grandparents self-identified as either all Caucasian or all African American.
INCLUSION CRITERIA: Ethnicity: African Americans
To enroll participants must self-identify as African Americans and be born in the United States  with American born parents or be born in Africa with African born parents
In the future  we plan to expand the study to include other groups which self-identify as African Americans (ie AfroCarribeans and Hispanic blacks).
EXCLUSION CRITERIA: African American Ethnicity other than American or West African ancestry
In the future  we will expand the study to include other African American groups such as individuals of Afro-Caribbean and Hispanic blacks.
Alcohol consumption during the inpatient pharmacokinetic portion of the study.
Caucasian (at least 2 generations originating in any of the original peoples of Europe  North Africa  or the Middle East) OR
African American (at least 2 generations originating in any of the black racial groups of Africa)
African Americans are eligible if they had a non-cardioembolic ischemic stroke at lease 7 days  but no more than 90 days before entering the trial.
Although this condition is rare amongst African-Americans  every effort will be made to recruit such individuals.
African-American  Hispanic  or Caucasian Self stated  plus the same for all 4 grandparents
African American (self-identified)
Male and females African American subjects over 18 years of age.
Full Japanese  African American  and Taiwanese ancestry
Hispanics and Native Americans are oversampled  but non-Hispanic whites will be included for comparison purposes
Black/African American or White/Caucasian
Participant is of Ashkenazi Jewish ethnicity and either has had breast cancer or has 1 first-degree or 2 second-degree relatives with breast cancer (including ductal carcinoma in situ) or ovarian cancer
African-American or Hispanic
Adults of Caucasian and Japanese Ethnicity
African American
African-American or Caucasian
African Americans
Caucasian
64 African-Americans
56 Caucasians 
African-Americans: Individuals will be considered to be African-American if they self-identify as African-American and were born in the United States
Further they must describe both parents as being African-American and born in the United States.
Asians and Pacific Islanders.
Ashkenazi Jewish ethnicity and meets criteria for 1 of the following: Prior breast cancer diagnosis
The patient population is expected  however  to be predominantly minority in composition (mainly African-American and Latino  with some Asian  European and Native American patients as well) as function of demographics and genetics of these diseases
Self-identify as African American or Caucasian
African  Caucasian  or Hispanic heritage
Minority individuals  particularly African Americans and English speaking Hispanics will be included
American Indian
Patients other than African American
White and Latino patients in a safety net hospital
Male or female of African descent
Self-identifies as all or part Latino
Self-identifies as African American
Caucasian race
African American
Unable to read English  Korean  or Chinese
Self identification of Black  White or Hispanic Ethnicity
African American or Latino
African American
must be fluent in either English or Chinese (Mandarin or Cantonese)
unable to speak English or Chinese
African Americans with stage 1-2 hypertension
African American Men and Women
Asian origin.
Chinese speaking  capable to understand the study
African American
African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated
Renal Not specified
Pulmonary
Menopausal status Not specified
Hepatic Not specified
Renal Not specified
Normal lung function
Menopausal status See Disease Characteristics
Lung function normal
No nasopharyngeal primaries
Intact uterus (womb).
Adequate renal function
Adequate hepatic function
Adequate organ function and bone marrow reserve.
Palpable axillary lymph nodes
Adequate pulmonary function
No compromised pulmonary function
Adequate hepatic  renal  and cardiac function.
Normal heart and lung evaluations
Adequate organ function
Oral cavity
